



**Keystone 65 Rx HMO
Personal Choice 65SM Rx PPO
Select Option[®] Rx PDP
2021 Utilization Management
Criteria: Prior Authorization**

**PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION
ABOUT SOME OF THE DRUGS WE COVER IN THIS PLAN**

This document was updated on 12/1/2021. For more recent information or other questions, please contact our Member Help Team: Keystone 65 at 1-844-352-1699, Personal Choice 65 at 1-888-879-4293, Select Option at 1-888-678-7009 or, for TTY/TDD users, 711, seven days a week from 8 a.m. to 8 p.m. Please note that on weekends and holidays from April 1 through September 30, your call may be sent to voicemail. Or, visit www.ibxmedicare.com to use our *Formulary (List of Covered Drugs)* search tool or view a downloadable document.

When this document refers to “we,” “us,” or “our,” it means Independence Blue Cross. When it refers to “plan” or “our plan,” it means Keystone 65 Rx, Personal Choice 65 Rx, and Select Option Rx.

You must generally use network pharmacies to use your prescription drug benefit. Benefits, formulary, pharmacy network, and/or copayments/coinsurance may change on January 1, 2022, and from time to time during the year.

Independence Blue Cross offers Medicare Advantage plans with a Medicare contract. Enrollment in Independence Medicare Advantage plans depends on contract renewal.

Keystone 65: Benefits underwritten by Keystone Health Plan East, a subsidiary of Independence Blue Cross — independent licensees of the Blue Cross and Blue Shield Association.

Personal Choice 65 and Select Option: Benefits underwritten by QCC Insurance Company, a subsidiary of Independence Blue Cross — independent licensees of the Blue Cross and Blue Shield Association.

There may be restrictions to your drug coverage

Some covered drugs may have additional requirements or limits on coverage. We call this “utilization management.” These requirements and limits may include:

- **Prior Authorization (PA):** Our plan requires you or your physician to get prior authorization for certain drugs. This means that you will need to get approval from our plan before you fill your prescriptions. If you don’t get approval, our plan may not cover the drug. Drugs that require prior authorization are listed in this document.
- **Step Therapy (ST):** In some cases, our plan requires you to first try certain drugs to treat your medical condition before we will cover another drug for that condition. Drugs that require step therapy are listed in *2021 Utilization Management Criteria: Step Therapy*.
- **Quantity Limits (QL):** For certain drugs, our plan limits the amount of the drug that our plan will cover. Drugs that have quantity limits are listed in the *Keystone 65 Rx, Personal Choice 65 Rx, and Select Option Rx Formulary (List of Covered Drugs)*.

You can find out if your drug has any additional requirements or limits by looking in your plan *Formulary (List of Covered Drugs)*. You can also get more information about the restrictions applied to specific covered drugs by visiting www.ibxmedicare.com.

You can ask our plan to make an exception to these restrictions or limits, or for a list of other similar drugs that may treat your health condition. Your *Formulary (List of Covered Drugs)* and *Evidence of Coverage* will have more information about the exception request process.

How to use this document

This document, along with *2021 Utilization Management Criteria: Step Therapy*, is intended to be used with your *Formulary (List of Covered Drugs)*. If your prescription drug has the note “PA” in the “Requirements” column of the *Keystone 65 Rx, Personal Choice 65 Rx, and Select Option Rx Formulary (List of Covered Drugs)*, you can find more information on the restriction(s) in this document.

Locate your drug in the index on page 197. The restriction information includes:

- **Prior Authorization**
 - Covered uses
 - Exclusion criteria
 - Required medical information
 - Age restrictions
 - Prescriber restrictions
 - Coverage duration
 - Other criteria

Be sure to read all the information listed for your affected drug. If you have any questions or need assistance with the information contained in this document, please call our Member Help Team: Keystone 65 at 1-844-352-1699, Personal Choice 65 at 1-888-879-4293, Select Option at 1-888-678-7009.

ABILIFY MYCITE

Products Affected

- ABILIFY MYCITE

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Schizophrenia: (1) Attestation that tracking ingestion of the medication is medically necessary. Bipolar 1 Disorder (BP): (1) Attestation that tracking ingestion of the medication is medically necessary. Adjunctive Treatment for Major Depressive Disorder (MDD): (1) Attestation that medication will be used as adjunct therapy. |
| Age Restrictions | (Schizophrenia, BP, MDD): Member is 18 years of age or older |
| Prescriber Restrictions | |
| Coverage Duration | (Schizophrenia, BP, MDD): Indefinite |
| Other Criteria | (All Indications): Approve if for continuation of therapy. |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

ABUSE DETERRENT OPIOID

Products Affected

- *hydrocodone bitartrate er oral capsule extended release 12 hour*
- *hydrocodone bitartrate er oral tablet er 24 hour abuse-deterrent*
- HYSINGLA ER
- NUCYNTA ER
- OXYCONTIN ORAL TABLET ER 12 HOUR ABUSE-DETERRENT
- XTAMPZA ER

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of one of the following: (1) Prior use of TWO generic opioids OR (2) BOTH of the following: (a) there is a history of or a potential for drug abuse among the individual or a member of the individual's household AND (b) documentation of current patient-prescriber opioid treatment agreement |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Remainder of contract year |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

ACTEMRA SQ

Products Affected

- ACTEMRA ACTPEN
- ACTEMRA SUBCUTANEOUS

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | (PJIA, SJIA, RA, GCA, SSc-ILD): Concurrent therapy with any other biologic disease modifying anti-rheumatic drug (DMARD), e.g. tumor necrosis factor antagonists. |
| Required Medical Information | Polyarticular Juvenile Idiopathic Arthritis (PJIA): (1) Diagnosis of PJIA. (2) Inadequate response or inability to tolerate TWO of the following: (a) adalimumab (Humira), (b) etanercept (Enbrel), (c) Xeljanz OR documentation demonstrating that a trial may be inappropriate. Systemic Juvenile Idiopathic Arthritis (SJIA): (1) Diagnosis of SJIA. (2) Inadequate response or inability to tolerate ONE of the following: (a) Non-steroidal anti-inflammatory drug (NSAID), OR (b) Systemic glucocorticoid. Moderate to severe rheumatoid arthritis (RA): (1) Diagnosis of moderate to severe RA. (2) Inadequate response or inability to tolerate to TWO of the following: (a) Humira, (b) Enbrel, (c) Rinvoq, (d) Xeljanz/Xeljanz XR OR documentation demonstrating that a trial may be inappropriate. Giant Cell Arteritis (GCA): (1) Diagnosis of GCA. (2) Documentation of inadequate response/inability to tolerate oral corticosteroids. Systemic Sclerosis-associated Interstitial Lung Disease (SScILD): (1) Diagnosis of SSc-ILD. (2) Inadequate response/inability to tolerate a 3-month trial of ONE of the following:(a)mycophenolate mofetil OR (b) cyclophosphamide. |
| Age Restrictions | (PJIA, SJIA): Member is 2 years of age or older. (RA, GCA, SSc-ILD): Member is 18 years of age or older |
| Prescriber Restrictions | (PJIA, SJIA, RA, GCA): Prescribed by or in consultation with a Rheumatologist. (SSc-ILD): Prescribed by or in consultation with a pulmonologist or Rheumatologist |
| Coverage Duration | Indefinite |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

ACTHAR HP

Products Affected

- ACTHAR

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | (All Indications): Scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, history of or the presence of peptic ulcer, congestive heart failure, uncontrolled hypertension, primary adrenocortical insufficiency, adrenocortical hyperfunction, sensitivity to proteins or porcine origin, or where congenital infections are suspected in infants. OR Administration of live or live attenuated vaccines in patients receiving immunosuppressive doses of H.P. Acthar Gel. Concurrent primary adrenocortical insufficiency or adrenocortical hyperfunction. |
| Required Medical Information | Part D is medically necessary when ONE of the following is present: (1) Infantile Spasms (IS): (A) Diagnosis of IS. (2) Acute Exacerbation of Multiple Sclerosis (AEMS): (A) Diagnosis of an AEMS, (B) Currently receiving maintenance treatment for MS (e.g. Avonex, Betaseron, Copaxone, Tecfidera, etc.), (C) Inadequate response or inability to tolerate two systemic steroids (e.g. prednisone, methylprednisolone). (3) Acute Exacerbation of Psoriatic Arthritis (AEPsA): (A) Diagnosis of an AEPsA, (B) Currently receiving a DMARD, (C) Inadequate response or inability to tolerate two systemic steroids (e.g. prednisone, methylprednisolone). (4) Acute Exacerbation of Rheumatoid Arthritis (AERA): (A) Diagnosis of an AERA, (B) Currently receiving a DMARD, (C) Inadequate response or inability to tolerate two systemic steroids (e.g. prednisone, methylprednisolone). (5) Acute Exacerbation of Juvenile Rheumatoid Arthritis (AEJRA): (A) Diagnosis of an AEJRA, (B) Currently receiving a DMARD, (C) Inadequate response or inability to tolerate two systemic steroids (e.g. prednisone, methylprednisolone). (6) Acute Exacerbation of Ankylosing Spondylitis (AEAS): (A) Diagnosis of an AEAS, (B) Currently receiving a DMARD, (C) Inadequate response or inability to tolerate two systemic steroids (e.g. prednisone, methylprednisolone). (7) Nephrotic Syndrome (NS): (A) Diagnosis of NS, (B) Proteinuria greater than 3.5g/ 24 hours, (C) serum albumin less than 3 mg/dL, (D) Peripheral edema. (F) Inadequate response or inability to tolerate two systemic steroids (e.g. prednisone, methylprednisolone). (8) Systemic Lupus Erythematosus (SLE): (A) Diagnosis of SLE, (B) Inadequate response or inability to tolerate two systemic steroids (e.g. prednisone, methylprednisolone). |

| PA Criteria | Criteria Details |
|--------------------------------|--|
| Age Restrictions | (IS): Member is younger than 2 years of age. (MS): Member is 18 years of age and older. (All Other Indications): Member is 2 years of age and older |
| Prescriber Restrictions | (IS): Prescribed by or in consultation with a pediatric neurologist or neonatologist. (All Other Indications): Prescribed by or in consultation with a neurologist, rheumatologist, nephrologist, pulmonologist, ophthalmologist, dermatologist, allergist, immunologist. |
| Coverage Duration | (IS): 1 year (All Other Indications): 1 month |
| Other Criteria | Subject to Part B vs Part D review. (9) Systemic Dermatomyositis (SDM): (A) Diagnosis of SDM, (B) Inadequate response or inability to tolerate two systemic steroids (e.g. prednisone, methylprednisolone). (10) Severe Erythema Multiforme (SEM): (A) Diagnosis of SEM, (B) Inadequate response or inability to tolerate two systemic steroids (e.g. prednisone, methylprednisolone). (11) Stevens-Johnson Syndrome (SJS): (A) Diagnosis of SJS, (B) Inadequate response or inability to tolerate two systemic steroids (e.g. prednisone, methylprednisolone). (12) Serum Sickness (SS): (A) Diagnosis of SS, (B) Inadequate response or inability to tolerate two systemic steroids (e.g. prednisone, methylprednisolone). (13) Inflammatory Ophthalmic Disease (IOD): (A) Diagnosis of IOD, (B) Inadequate response or inability to tolerate two systemic steroids (e.g. prednisone, methylprednisolone). (14) Symptomatic Sarcoidosis (SSD): (A) Diagnosis of SSD, (B) Inadequate response or inability to tolerate two systemic steroids (e.g. prednisone, methylprednisolone). |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

ACUTE HAE AGENTS

Products Affected

- BERINERT
- FIRAZYR
- *icatibant acetate*
- RUCONEST

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Part D is medically necessary when the following inclusion criteria is met: Hereditary Angioedema (HAE): (1) Used for the treatment of acute abdominal, facial or laryngeal attacks of HAE. |
| Age Restrictions | |
| Prescriber Restrictions | (HAE): Prescribed by or in consultation with an allergist or immunologist |
| Coverage Duration | (HAE): Indefinite |
| Other Criteria | Subject to Part B vs Part D review. |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

ACUTE SEIZURE ACTIVITY AGENTS

Products Affected

- NAYZILAM
- VALTOCO 10 MG DOSE
- VALTOCO 15 MG DOSE
- VALTOCO 20 MG DOSE
- VALTOCO 5 MG DOSE

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | Prescriber is a neurologist/epilepsy specialist |
| Coverage Duration | Indefinite |
| Other Criteria | (All Indications): Approve for continuation of therapy. |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

ADEMPAS

Products Affected

- ADEMPAS

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | (PAH, CTEPH) (Initial, Reauth): Concurrent use of phosphodiesterase inhibitors, nitrates or nitric oxide donors, pregnancy |
| Required Medical Information | Pulmonary Arterial Hypertension (PAH) (initial): (1) Diagnosis of PAH WHO Group I with New York Heart Association (NYHA) Functional Class II - IV. (2) Diagnosis confirmed by catheterization (right-heart or Swan-Ganz) or echocardiography. (3) Mean pulmonary artery pressure greater than or equal to 25 mm Hg at rest or greater than 30 mm Hg with exertion. Chronic Thromboembolic Pulmonary Hypertension (CTEPH) (initial): (1) Diagnosis of persistent/recurrent CTPH (WHO Group 4) after surgical treatment or inoperable CTEPH. |
| Age Restrictions | (PAH, CTEPH) (Initial, Reauth): Member is 18 years of age or older |
| Prescriber Restrictions | (PAH, CTEPH) (initial, reauth): Prescribed by or in consultation with a pulmonologist or cardiologist |
| Coverage Duration | (PAH, CTEPH) (Initial): 6 month (PAH, CTEPH) (Reauth):12 months |
| Other Criteria | (PAH, CPTEH) (Reauth): Stabilization or improvement. |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

AFREZZA

Products Affected

- AFREZZA INHALATION POWDER 12 UNIT, 4 & 8 & 12 UNIT, 4 UNIT, 8 UNIT, 90 X 4 UNIT & 90X8 UNIT, 90 X 8 UNIT & 90X12 UNIT

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | (DM1, DM2) (Initial, Reauth): Deny for any of the following (1) Patient is currently a smoker or recently stopped smoking (past 6 months), (2) Patient has chronic lung disease such as asthma or chronic obstructive pulmonary disease (3) active lung cancer or a prior history of lung cancer |
| Required Medical Information | Type 1 Diabetes Mellitus (DM1) (Initial): (1) Diagnosis of type 1 diabetes mellitus, (2) Used in combination with a long-acting insulin (e.g., Lantus, Levemir), (3) Documented FEV1 within the last 60 days greater than or equal to 70% of expected normal as determined by the physician, (4) Spirometry (FEV1) has been completed prior to initiation of therapy to identify potential lung disease (must provide the result). Type 2 Diabetes Mellitus (DM2) (Initial): (1) Diagnosis of type 2 diabetes mellitus, (2) Documented FEV1 within the last 60 days greater than or equal to 70% of expected normal as determined by the physician, (3) Spirometry (FEV1) has been completed prior to initiation of therapy to identify potential lung disease (must provide the result). |
| Age Restrictions | (DM1, DM2) (Initial, Reauth): Member is 18 years of age or older |
| Prescriber Restrictions | |
| Coverage Duration | (DM1, DM2) (Initial): 6 months (DM1, DM2) (Reauth): Indefinite |
| Other Criteria | (DM1, DM2)(Reauth): Spirometry value (FEV1) that has not declined greater than or equal to 20% from baseline. |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

ALLERGEN SPECIFIC IMMUNOTHERAPY (SL)

Products Affected

- GRASTEK
- ODACTRA
- ORALAIR

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | (Initial, reauth): Deny with documentation of any of the following: (1) Severe, unstable or uncontrolled asthma (2) History of eosinophilic esophagitis |
| Required Medical Information | (Initial): (1) Patient has a positive skin test or in vitro test for the listed pollen-specific IgE antibody. (2) Inadequate response or inability to tolerate an intranasal corticosteroid and an antihistamine. |
| Age Restrictions | |
| Prescriber Restrictions | (Initial, reauth): Prescribed by or in consultation with an allergist or immunologist. |
| Coverage Duration | (Initial, reauth): Remainder of contract year |
| Other Criteria | (Reauth): (1) Patient has experienced improvement in the symptoms of their allergic rhinitis or a decrease in the number of medications needed to control allergy symptoms |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

AMANTIDINE ER

Products Affected

- GOCOVRI
- OSMOLEX ER ORAL TABLET ER 24 HOUR THERAPY PACK
- OSMOLEX ER ORAL TABLET EXTENDED

RELEASE 24 HOUR 129 MG, 193 MG

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | <p>Parkinson's Disease (PD): (1) BOTH of the following (a) inadequate response or inability to tolerate amantadine immediate release and (b) concurrent levodopa-based therapy. Drug-induced extrapyramidal symptoms (DIEPS): (1) BOTH of the following: (A) ONE of the following: (i) Patient has persistent extrapyramidal symptoms despite a trial of dose reduction, tapering, or discontinuation of the offending medication or (ii) Patient is not a candidate for a trial of dose reduction, tapering, or discontinuation of the offending medication. (B) Inadequate response or inability to tolerate amantadine immediate release. Dyskinesia in Parkinson's disease (DPD) [Gocovri only]: (1) Diagnosis of PD (2) Member is experiencing dyskinesia. (3) Member is receiving levodopa based therapy (4) Inadequate response or inability to tolerate amantadine immediate-release. Parkinson's Disease with OFF episodes (PD with OFF episodes) [Gocovri only]: (1) Diagnosis of Parkinson's disease. (2) concurrent use of carbidopa/levodopa containing product. (3) Member is experiencing intermittent OFF episodes. (4) member had inadequate response or inability to tolerate ONE of the following: (a) MAO-B inhibitor (e.g., rasagiline, selegiline), (b) Dopamine agonist (e.g., pramipexole, ropinirole), (c) COMT inhibitor (e.g., entacapone).</p> |
| Age Restrictions | |
| Prescriber Restrictions | (PD, DIEPS, DPD, PD with OFF episodes): Prescribed by or in consultation with a neurologist or psychiatrist |
| Coverage Duration | (PD, DIEPS, DPD, PD with OFF episodes): Indefinite |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

AMPYRA

Products Affected

- AMPYRA
- *dalfampridine er*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | MS (Initial): Deny if patient has history of seizure or moderate to severe renal impairment (CrCL less than or equal to 50 mL/min) |
| Required Medical Information | Multiple Sclerosis (MS) (Initial): (1) Diagnosis of multiple sclerosis. (2) Confirmation that patient has difficulty walking. |
| Age Restrictions | |
| Prescriber Restrictions | (MS) (Initial and Reauth): Prescribed by or in consultation with a neurologist |
| Coverage Duration | (MS)(Initial, Reauth): Remainder of contract year |
| Other Criteria | (MS) (Reauth): Improvement in walking speed |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

ARIKAYCE

Products Affected

- ARIKAYCE

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | Member is 18 years of age or older |
| Prescriber Restrictions | Prescribed by or in consultation with a pulmonologist or an infectious disease specialist |
| Coverage Duration | Indefinite |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

ARMODAFINIL/MODAFINIL

Products Affected

- *armodafinil*
- *modafinil*
- NUVIGIL
- PROVIGIL

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | NARCOLEPSY: (1) Diagnosis of Narcolepsy. OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME (OSAHS): (1) Diagnosis confirmed by a sleep study (unless prescriber provides justification confirming that a sleep study is not feasible). SHIFT WORK SLEEP DISORDER (SWSD): (1) One of the following: (a) Symptoms of excessive sleepiness or insomnia for at least 3 months, which is associated with a work period (usually night work) that occurs during the normal sleep period, OR (b) A sleep study demonstrating loss of a normal sleep-wake pattern (i.e., disturbed chronobiologic rhythmicity). (2) Documentation that the member has no medical or mental disorder accounting for the symptoms. |
| Age Restrictions | |
| Prescriber Restrictions | (Narcolepsy, SWSD, OSAHS): Prescribed by or in consultation with a neurologist or sleep specialist. |
| Coverage Duration | (Narcolepsy, SWSD, OSAHS): Indefinite |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

BENLYSTA SC

Products Affected

- BENLYSTA SUBCUTANEOUS

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Part D is medically necessary when the following are met: Systemic Lupus Erythematosus (SLE): (1) Diagnosis of active, autoantibody-positive SLE. (2) Patient is receiving concurrent treatment with at least ONE of the following: steroids, antimalarials, immunosuppressants, nonsteroidal anti-inflammatory drugs (NSAIDS). Lupus Nephritis (LN): (1) Diagnosis of active lupus nephritis confirmed by kidney biopsy. (2) Member is receiving concurrent standard therapy (e.g. corticosteroids, immunosuppressants, azathioprine). |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Indefinite |
| Other Criteria | Subject to Part B vs Part D review. |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

BRAND ORAL FENTANYL

Products Affected

- ACTIQ
- *fentanyl citrate buccal*
- FENTORA BUCCAL TABLET 100 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG
- LAZANDA NASAL SOLUTION 100 MCG/ACT, 400 MCG/ACT
- SUBSYS

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Cancer Pain (CP): (1) Pain associated with cancer, (2) long-acting pain medication regimen, (3) member is opioid tolerant as demonstrated by adherence for one week or more of any of the following regimens: (i) at least 25mcg of transdermal fentanyl hourly, (ii) 30mg of oxycodone daily, 60mg of oral morphine daily, (iii) 8mg of oral hydromorphone daily, (iv) 25mg of oral oxymorphone daily or an equianalgesic dose of another opioid, AND (4) inadequate response to a generic oral transmucosal fentanyl citrate product |
| Age Restrictions | |
| Prescriber Restrictions | (CP): Prescribed by or in consultation with one of the following: Pain specialist, Oncologist, Hematologist, Hospice care specialist, or Palliative care specialist. |
| Coverage Duration | (CP): Remainder of contract year |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

BRONCHITOL

Products Affected

- BRONCHITOL

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Cystic Fibrosis (CF)(Initial): (1) Diagnosis of CF. (2) Member has passed the Bronchitol Tolerance Test (BTT). (3) Member has inadequate response or inability to tolerate Pulmozyme therapy. |
| Age Restrictions | (CF)(Initial, Reauth): Member is 18 years of age or older. |
| Prescriber Restrictions | (CF)(Initial, Reauth): Prescribed by or in consultation with a pulmonologist OR specialist associated with a cystic fibrosis care center. |
| Coverage Duration | (Initial, Reauth): 12 months |
| Other Criteria | (CF)(Reauth): (1) Positive clinical response to therapy (e.g., improvement in lung function [forced expiratory volume in one second {FEV1}]). |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

CARBAGLU

Products Affected

- CARBAGLU

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Hyperammonemia Type III (HTIII): (1) Hyperammonemia due to the deficiency of the hepatic enzyme N-acetyl glutamate synthase (NAGS) |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | (HTIII): Indefinite |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

CAYSTON

Products Affected

- CAYSTON

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Cystic Fibrosis (CF): (1) Diagnosis of CF. (2) Pseudomonas Aeruginosa in the lungs. (3) Susceptibility results indicating that the Pseudomonas aeruginosa is sensitive to aztreonam. (4) FEV1 between 25% and 75% of predicted |
| Age Restrictions | (CF): Member is 7 years of age or older |
| Prescriber Restrictions | |
| Coverage Duration | (CF): Remainder of contract year |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

CERDELGA

Products Affected

- CERDELGA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | (GD): Patient is CYP2D6 Ultra Rapid Metabolizer (URM), concurrent use of Class 1A or Class III anti-arrhythmic, long QT syndrome, patient has pre-existing cardiac disease |
| Required Medical Information | Gaucher disease (GD): (1) Diagnosis of Type 1 Gaucher disease and member is CYP2D6 extensive metabolizer (EM), intermediate metabolizer (IM), or poor metabolizer (PM) as detected by an FDA-cleared test for determining CYP2D6 genotype. |
| Age Restrictions | (GD): Member is 18 years of age or older |
| Prescriber Restrictions | |
| Coverage Duration | (GD): Indefinite |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

CGRP ANTAGONISTS

Products Affected

- AIMOVIG
- AJOVY

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Migraines (Initial): Approved when ONE of the following inclusion criteria are met: (1) Diagnosis of episodic migraines defined as 4 to 14 headache days per month AND inadequate response or inability to tolerate a 4 week trial of TWO of the following prophylactic medications (a) topiramate (b) divalproex sodium/ valproic acid (c) beta-blocker: metoprolol, propranolol, timolol, atenolol, nadolol (d) tricyclic antidepressants: amitriptyline, nortriptyline (e)SNRI antidepressants: venlafaxine, duloxetine. OR (2) Diagnosis of chronic migraines defined as greater than or equal to 15 headache days per month AND inadequate response or inability to tolerate a 4 week trial of TWO of the following prophylactic medications (i) topiramate (ii) divalproex sodium/ valproic acid (iii) beta-blocker: metoprolol, propranolol, timolol, atenolol, nadolol (iv) tricyclic antidepressants: amitriptyline, nortriptyline (v)SNRI antidepressants: venlafaxine, duloxetine. |
| Age Restrictions | (Migraines)(Initial, Reauth): Member 18 years of age |
| Prescriber Restrictions | (Migraines)(Initial, Reauth): Prescribed by or in consultation with a neurologist or headache specialist certified by the United Council for Neurologic Subspecialties, or pain specialist |
| Coverage Duration | (Migraines)(Initial): 6 months (Migraines)(Reauth): 12 months |
| Other Criteria | (Migraines)(REAUTH): (1) Response to therapy as defined by a reduction in headache days per month (defined as at least 4 hours duration and moderate intensity). |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

CHOLBAM

Products Affected

- CHOLBAM

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | (BASD, PD)(Initial, Reauth): Deny if there is documentation of extrahepatic manifestations of bile acid synthesis disorders due to single enzyme defects or peroxisomal disorders including Zellweger spectrum disorders |
| Required Medical Information | Bile Acid Synthesis Disorder (BASD) (initial): (1) Diagnosis of bile acid synthesis disorder due to a single enzyme defect. Peroxisomal disorder (PD) (initial): (1) Diagnosis of peroxisomal disorder. (2) Used as adjunctive treatment. (3) Patient exhibits manifestations of liver disease, steatorrhea, or complications from decreased fat soluble vitamin absorption. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | (BASD, PD)(initial): 3 months. (BASD, PD)(Reauth): Indefinite |
| Other Criteria | (BASD,PD) (Reauth): Documentation of improved liver function tests from the start of treatment. |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

CIALIS

Products Affected

- CIALIS ORAL TABLET 2.5 MG, 5 MG
- *tadalafil oral tablet 2.5 mg, 5 mg*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | (BPH): Concurrent use of nitrates. |
| Required Medical Information | Benign prostatic hyperplasia (BPH): (1) Diagnosis of BPH. (2) Inadequate response or inability to tolerate an alpha blocker (e.g. tamsulosin, terazosin) or a 5-alpha reductase inhibitor (e.g., dutasteride, finasteride). |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | (BPH): Indefinite |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

CIMZIA

Products Affected

- CIMZIA PREFILLED
- CIMZIA SUBCUTANEOUS KIT 2 X 200 MG

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | (AS, PsA, PsO, RA, CD, nr-axSpA): Concurrent therapy with biological DMARDs or other tumor necrosis factor antagonists |
| Required Medical Information | Ankylosing Spondylitis (AS): (1) Diagnosis of AS. (2) Inadequate response or inability to tolerate both adalimumab (Humira) AND etanercept (Enbrel) or documentation demonstrating that a trial may be inappropriate. Psoriatic Arthritis (PsA): (1) Diagnosis of PsA. (2) Inadequate response or inability to tolerate to TWO of the following: (a) Humira, (b) Enbrel, (c) Xeljanz/Xeljanz XR OR documentation demonstrating that a trial may be inappropriate. Plaque Psoriasis (PsO): (1) Diagnosis of moderate to severe PsO. (2) Inadequate response or inability to tolerate to BOTH of the following: (a) ONE of the following: (i) Humira, (ii) Enbrel, or (iii) Skyrizi AND (b) Cosentyx OR documentation demonstrating that a trial may be inappropriate. Rheumatoid Arthritis (RA): (1) Diagnosis of moderate to severe RA. (2) Inadequate response or inability to tolerate to TWO of the following: (a) Humira, (b) Enbrel, (c) Rinvoq, (d) Xeljanz/Xeljanz XR OR documentation demonstrating that a trial may be inappropriate. Crohn's Disease (CD): (1) Diagnosis of moderate to severe CD. (2) Inadequate response or inability to tolerate adalimumab (Humira) or documentation demonstrating that a trial may be inappropriate. Non-radiographic axial Spondyloarthritis (nr-axSpA): (1) Diagnosis of nr-axSpA. (2) Inadequate response or inability to tolerate two NSAIDs OR Cosentyx OR documentation demonstrating that a trial may be inappropriate. |
| Age Restrictions | (AS, PsA, PsO, RA, CD, nr-axSpA): Member is 18 years of age or older |
| Prescriber Restrictions | (CD): Prescribed by or in consultation with a gastroenterologist. (RA, AS, nr-axSpA): Prescribed by or in consultation with a rheumatologist. (PsA): prescribed by or in consultation with a dermatologist or rheumatologist. (PsO): Prescribed by or in consultation with a dermatologist. |
| Coverage Duration | (AS, PsA, PsO, RA, CD, nr-axSpA): Indefinite |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |

| PA Criteria | Criteria Details |
|----------------|------------------|
| Off Label Uses | |

CINRYZE

Products Affected

- CINRYZE

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Part D is medically necessary when: Hereditary Angioedema (HAE): (1) Diagnosis of hereditary angioedema (HAE) (2) For prophylaxis against HAE attacks. |
| Age Restrictions | (HAE): Member is 6 years of age or older |
| Prescriber Restrictions | (HAE): Prescribed by or in consultation with an allergist or immunologist |
| Coverage Duration | (HAE): Indefinite |
| Other Criteria | Subject to Part B vs Part D review. |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

COMBINATION NSAID PRODUCTS

Products Affected

- DUEXIS
- *ibuprofen-famotidine*
- *naproxen-esomeprazole*
- VIMOVO

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | (All Indications)(Initial): An inadequate response or inability to tolerate a two-week trial of BOTH of the following: (1) Concurrent administration of each of the components of the requested product, and (2) At least ONE generic alternatives (when available) of each of the individual components of the requested product. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | (All Indication) (Initial, Reauth): 1 year |
| Other Criteria | (All Indications): Positive clinical response to therapy. |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

CORLANOR

Products Affected

- CORLANOR

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Chronic Heart Failure (CHF): (1)Diagnosis of chronic heart failure. (2) stable, symptomatic chronic heart failure (3) left ventricular ejection fraction less than or equal to 35% and (4) sinus rhythm with resting heart rate greater than or equal to 70 beats per minute. (5) Patient is clinically stable for at least 4 weeks on an optimized regimen which includes: (a) maximally tolerated doses of beta blockers or inability to tolerate beta blockers, (b) ACE inhibitors or ARBs or inability to tolerate ACE inhibitor or ARB. Chronic Heart Failure due to Dilated Cardiomyopathy in pediatric patients ages 6 months and older (CHF-DC): (1) Diagnosis of chronic heart failure due to dilated cardiomyopathy (2) Patient is in sinus rhythm with an elevated heart rate. |
| Age Restrictions | |
| Prescriber Restrictions | (CHF, CHF-DC): Prescribed by or in consultation with a cardiologist |
| Coverage Duration | (CHF, CHF-DC): Indefinite |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

COSENTYX

Products Affected

- COSENTYX (300 MG DOSE)
- COSENTYX SENSOREADY (300 MG)
- COSENTYX SUBCUTANEOUS SOLUTION
PREFILLED SYRINGE 75 MG/0.5ML

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | (PsA, PsO, AS, nr-axSpA): Concurrent therapy with biological DMARDs or other tumor necrosis factor antagonists |
| Required Medical Information | Psoriatic Arthritis (PsA): (1) Diagnosis of PsA. (2) Inadequate response or inability to tolerate to both adalimumab (Humira) AND etanercept (Enbrel) or documentation demonstrating that a trial may be inappropriate. Plaque Psoriasis (PsO): (1) Diagnosis of moderate to severe plaque psoriasis. (2) For members 6 to 17 years of age: an inadequate response or inability to tolerate Enbrel OR documentation demonstrating that a trial may be inappropriate. For members 18 years of age or older: an inadequate response or inability to tolerate to ONE of the following: (a) Humira, (b) Enbrel, (c) Skyrizi OR documentation demonstrating that a trial may be inappropriate. Ankylosing Spondylitis (AS): (1) Diagnosis of AS. (2) Inadequate response or inability to tolerate to both adalimumab (Humira) AND etanercept (Enbrel) or documentation demonstrating that a trial may be inappropriate. Non-Radiographic Axial Spondyloarthritis (nr-axSpA): (1) Diagnosis of nr-axSpA, (2) Inadequate response or inability to tolerate two NSAIDs. |
| Age Restrictions | (PsA, AS, nr-axSpA): Member is 18 years of age or older. (PsO): Member is 6 years of age or older. |
| Prescriber Restrictions | (PsO): Prescribed by or in consultation with a dermatologist. (PsA): Prescribed by or in consultation with a rheumatologist or dermatologist. (AS, nr-axSpA): Prescribed by or in consultation with a rheumatologist. |
| Coverage Duration | (PsA, PsO, AS, nr-axSpA): Indefinite |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

CRESEMBA [ORAL]

Products Affected

- CRESEMBA ORAL

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Invasive Aspergillosis (IA): (1) For use in the treatment of invasive aspergillosis after inadequate response or inability to tolerate Voriconazole (oral Vfend). Mucormycosis (MC): (1) Diagnosis of mucormycosis |
| Age Restrictions | (IA, MC): Member is 18 years of age or older |
| Prescriber Restrictions | (IA, MC): Prescribed by or in consultation with an infectious disease specialist |
| Coverage Duration | (IA, MC): Remainder of contract year |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

CYSTADROPS

Products Affected

- CYSTADROPS

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Cystinosis: (1) Diagnosis of cystinosis, (2) patient has corneal cystine crystal accumulation |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Remainder of contract year |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

CYSTARAN

Products Affected

- CYSTARAN

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Cystinosis: (1) Diagnosis of cystinosis, (2) patient has corneal cystine crystal accumulation |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | (Cystinosis): Remainder of contract year |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

DAYVIGO

Products Affected

- DAYVIGO

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Insomnia: (1) Diagnosis of insomnia. (2) Inadequate response or inability to tolerate generic ramelteon (Rozerem). |
| Age Restrictions | (Insomnia): Apply if member is greater than or equal to 65 years |
| Prescriber Restrictions | |
| Coverage Duration | (Insomnia): Remainder of contract year |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

DEFERASIROX

Products Affected

- *deferasirox granules*
- *deferasirox oral tablet*
- *deferasirox oral tablet soluble*
- EXJADE
- JADENU
- JADENU SPRINKLE

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | (NTDT, CIO-BT)(Initial, Reauth): CrCl less than 40 mL/min or serum creatinine more than 2 times the age-appropriate ULN, platelet counts less than 50,000/mL |
| Required Medical Information | Chronic Iron Overload in nontransfusion-dependent thalassemia (NTDT) (Initial): (1) Diagnosis of Chronic iron overload in nontransfusion-dependent thalassemia syndromes,(2) liver iron concentration (LIC) of at least 5 mg of iron per gram of liver dry weight (mg Fe/g dw), (3) serum ferritin greater than 300 mcg/L. (4) Serum ferritin levels consistently greater than 300 mcg/L (as demonstrated with at least two lab values within the previous two months). Chronic Iron Overload Caused by Blood Transfusions (CIO-BT)(Initial): (1) Diagnosis of chronic iron overload caused by blood transfusions (transfusional hemosiderosis) in patients 2 years and older. (2) Serum ferritin levels consistently greater than 300 mcg/L (as demonstrated with at least two lab values within the previous two months). |
| Age Restrictions | (NTDT)(Initial, Reauth): Member is 10 years of age or older. (CIO-BT) (Initial, Reauth): Member is 2 years of age or older. |
| Prescriber Restrictions | |
| Coverage Duration | (NDT, CIO-BT)(Initial):3 months. (NDT, CIO-BT)(Reauth): 6 months |
| Other Criteria | (CIO-BT)(Reauth): (1) Decreased serum ferritin level compared with the baseline level for transfusion- dependent anemia. (NTDT)(Reauth): (1) Decreased serum ferritin level compared with the baseline level or reduction in LIC (liver iron concentration). |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

DIACOMIT

Products Affected

- DIACOMIT

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | Member is 2 years of age or older |
| Prescriber Restrictions | Prescribed by or in consultation with a neurologist |
| Coverage Duration | Indefinite |
| Other Criteria | (All Indications): Approve if for continuation of therapy. |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

DICLOFENAC 3% PRODUCTS

Products Affected

- *diclofenac sodium external gel 3 %*

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Actinic Keratoses: (1) Diagnosis of Actinic Keratoses |
| Age Restrictions | Actinic Keratoses: Member is 18 years of age or older |
| Prescriber Restrictions | |
| Coverage Duration | Actinic Keratoses: 90 days |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

DICLOFENAC EPOLAMINE

Products Affected

- LICART EXTERNAL

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Previously experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Use for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery. |
| Required Medical Information | (1): Inadequate response or inability to tolerate at least 2 prescription strength topical NSAIDs (i.e. Diclofenac Gel 1%, Diclofenac Topical Solution 1.5%) |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Remainder of contract year |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

DOJOLVI

Products Affected

- DOJOLVI

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD): (1) Diagnosis of molecularly confirmed LC-FAOD, (2) Will be used as a source of calories and fatty acids. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | (LC-FAOD): Remainder of contract year |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

DOPTELET

Products Affected

- DOPTELET ORAL TABLET 20 MG

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Chronic Liver Disease (CLD): (1) Baseline platelet count less than 50,000/mcL. Chronic Immune Thrombocytopenia (CIT): (1) Baseline platelet count less than 50,000/mcL. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | (CLD): 1 month. (CIT): 12 months |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

DUPIXENT

Products Affected

- DUPIXENT SUBCUTANEOUS SOLUTION PEN-INJECTOR MG/2ML
- DUPIXENT SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 200 MG/1.14ML, 300

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Atopic Dermatitis (AD): (1) Diagnosis or moderate-severe atopic dermatitis. (2) inadequate response or inability to tolerate BOTH of the following: (a) one topical steroid (medium potency or higher) AND (b) topical tacrolimus. Asthma: (1) ONE of the following: (a) Member has oral corticosteroid-dependent asthma or (b) Member has blood eosinophil levels of at least 150 cells/mcL at baseline or at least 300 cells/mcL within the past 12 months, (2) the requested medication will be used in addition to BOTH of the following: (a) medium to high dose inhaled corticosteroid (e.g. greater than or equal to 500mcg fluticasone propionate equivalent/day) AND (b) one additional controller medication. Chronic Rhinosinusitis with Nasal Polyposis(CRSwNP): (1) Diagnosis of chronic rhinosinusitis with nasal polyposis, (2) concurrent use of intranasal corticosteroid. |
| Age Restrictions | (Asthma): Member is 12 years old or older. (AD): Member is 6 years or older. (CRSwNP): Member is 18 years of age or older |
| Prescriber Restrictions | (AD): Prescribed by or in consultation with a dermatologist, allergist, immunologist. (Asthma): Prescribed by or in consultation with an allergist, immunologist or pulmonologist. (CRSwNP): Prescribed by or in consultation with an allergist, immunologist or ENT specialist. |
| Coverage Duration | (AD, Asthma, CRSwNP): Indefinite |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

EGRIFTA

Products Affected

- EGRIFTA SV

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | (HIV-L): (1) hypothalamic-pituitary axis due to hypophysectomy, hypopituitarism, pituitary tumor/surgery, or head irradiation or trauma, (2) hypersensitivity to tesamorelin and/or mannitol, (3) malignancy, active (either newly diagnosed or recurrent) malignancies should be inactive and completely treated prior to initiating therapy, (4) pregnancy. |
| Required Medical Information | HIV-Associated Lipodystrophy (HIV-L): (1) Diagnosis of HIV-associated lipodystrophy, (2) one of the following: (a) waist-circumference of greater than or equal to 95 cm (37.4 inches) in men, OR (b) waist-circumference of greater than or equal to 94 cm (37 inches) for women, (3) one of the following: (a) Waist-to-hip ratio of greater than or equal to 0.94 for men, OR (b) waist-to-hip ratio of greater than or equal to 0.88 for women, (4) body mass index (BMI) greater than 20 kg/m ² , (5) fasting blood glucose (FBG) levels less than or equal to 150 mg/dL (8.33 mmol/L), (6) patient has been on a stable regimen of antiretrovirals (e.g., NRTIs, NNRTI, Protease Inhibitors, Integrase Inhibitors) for at least 8 weeks. |
| Age Restrictions | |
| Prescriber Restrictions | (HIV-L): Prescribed by or in consultation with HIV-infection specialist OR endocrinologist. |
| Coverage Duration | (HIV-L): Remainder of contract year |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

EMFLAZA

Products Affected

- EMFLAZA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Duchenne Muscular Dystrophy (MDM): (1) Inadequate response or inability to tolerate prednisone or prednisolone |
| Age Restrictions | (DMD): Member is 2 years of age or older |
| Prescriber Restrictions | (DMD): Prescribed by or in consultation with a neurologist |
| Coverage Duration | (DMD): Indefinite |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

EMGALITY

Products Affected

- EMGALITY
- EMGALITY (300 MG DOSE)

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Migraines (Initial): Approved when ONE of the following inclusion criteria are met: (1) Diagnosis of episodic migraines defined as 4 to 14 headache days per month AND inadequate response or inability to tolerate a 4 week trial of TWO of the following prophylactic medications (a) topiramate (b) divalproex sodium/ valproic acid (c) beta-blocker: metoprolol, propranolol, timolol, atenolol, nadolol (d) tricyclic antidepressants: amitriptyline, nortriptyline (e)SNRI antidepressants: venlafaxine, duloxetine. OR (2) Diagnosis of chronic migraines defined as greater than or equal to 15 headache days per month AND inadequate response or inability to tolerate a 4 week trial of TWO of the following prophylactic medications (i) topiramate (ii) divalproex sodium/ valproic acid (iii) beta-blocker: metoprolol, propranolol, timolol, atenolol, nadolol (iv) tricyclic antidepressants: amitriptyline, nortriptyline (v)SNRI antidepressants: venlafaxine, duloxetine. Episodic Cluster Headaches (ECH) (Initial): (1) Diagnosis of episodic cluster headache, (2) Member has experienced at least 2 cluster periods lasting 6 days to 365 days, separated by pain-free periods lasting at least three months, (3) Emgality will not be used in combination with another CGRP inhibitor. |
| Age Restrictions | (Migraine, ECH)(Initial, Reauth): Member is 18 years of age or older |
| Prescriber Restrictions | (Migraine, ECH)(Initial, Reauth): Prescribed by or in consultation with a neurologist or headache specialist certified by the United Council for Neurologic Subspecialties, pain specialist |
| Coverage Duration | (Migraine, ECH)(Initial): 3 months, (Migraine, ECH)(Reauth):12 months |
| Other Criteria | (Migraine)(REAUTH): (1) Response to therapy as defined by a reduction in headache days per month (defined as at least 4 hours duration and moderate intensity). (ECH)(REAUTH): (1) Response to therapy as defined by a reduction in weekly cluster headache attacks. |
| Indications | All Medically-accepted Indications. |

| PA Criteria | Criteria Details |
|----------------|------------------|
| Off Label Uses | |

EMSAM

Products Affected

- EMSAM

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Major depressive disorder (MDD): (1) Diagnosis of major depressive disorder. (2) Inadequate response or inability to tolerate ONE SSRI or SNRI. (3) At least 14 days has elapsed after discontinuation of antidepressants without long half-lives OR at least 5 weeks has elapsed after discontinuation with antidepressants with long half-lives e.g. Fluoxetine. |
| Age Restrictions | (MDD): Member is 18 years of age or older. |
| Prescriber Restrictions | |
| Coverage Duration | (MDD): Indefinite |
| Other Criteria | (All Indications): Approve if for continuation of therapy. |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

ENBREL

Products Affected

- ENBREL MINI
- ENBREL SUBCUTANEOUS SOLUTION 25 MG/0.5ML
- ENBREL SUBCUTANEOUS SOLUTION PREFILLED SYRINGE
- ENBREL SUBCUTANEOUS SOLUTION RECONSTITUTED
- ENBREL SURECLICK SUBCUTANEOUS SOLUTION AUTO-INJECTOR

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | (RA, PsA, PJIA, PsO, AS): Concurrent therapy with any other biologic disease modifying anti-rheumatic drug (DMARD), e.g. tumor necrosis factor antagonists |
| Required Medical Information | Rheumatoid Arthritis (RA): (1) Diagnosis of moderate to severe RA. (2) One of the following: (A) Member has a previous trial with infliximab (Remicade), OR (B) Inadequate response or inability to tolerate ONE of the following: Methotrexate, Hydroxychloroquine, Leflunomide, Azathioprine, Sulfasalazine. Psoriatic Arthritis (PsA): (1) Diagnosis of PsA. (2) One of the following: (A) Member has a previous trial with infliximab (Remicade), OR (B) Inadequate response or inability to tolerate ONE of the following: Methotrexate, Hydroxychloroquine, Leflunomide, Azathioprine, Sulfasalazine. Juvenile Idiopathic Arthritis (PJIA): (1) Diagnosis of moderate to severe PJIA, (2) One of the following: (A) Member has a previous trial with infliximab (Remicade), OR (B) Inadequate response or inability to tolerate ONE of the following: Methotrexate, Hydroxychloroquine, Leflunomide, Azathioprine, Sulfasalazine. Plaque Psoriasis (PsO): (1) Diagnosis of moderate to severe chronic PsO, (2) One of the following: (A) Member has a previous trial with infliximab (Remicade), OR (B) Inadequate response or inability to tolerate ONE of the following drugs: Topical Calcipotriene, Topical Anthralin, Topical Steroids, Topical immunomodulators (Elidel, Protopic), Topical retinoids. Ankylosing Spondylitis (AS): (1) Diagnosis of AS, (2) One of the following: (A) Member has a previous trial with infliximab (Remicade), OR (B) Inadequate response or inability to tolerate two NSAIDs. |
| Age Restrictions | (PJIA): Member is 2 years of age or older. (RA, PsA, AS): Member is 18 years of age or older. (PsO): Member is 4 years of age or older |
| Prescriber Restrictions | (RA, PJIA, AS): Prescribed by or in consultation with a rheumatologist. (PsA): Prescribed by or in consultation with a rheumatologist or dermatologist. (PsO): Prescribed by or in consultation with a dermatologist. |
| Coverage Duration | (RA, PsA, PJIA, PsO, AS): Indefinite |

| PA Criteria | Criteria Details |
|-----------------------|-------------------------------------|
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

ENDARI

Products Affected

- ENDARI

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Sickle Cell Disease (SC): (1) One of the following: (A) Member is using Endari with concurrent hydroxyurea therapy, OR (B) Member has an inadequate response or inability to tolerate hydroxyurea. (2) Member has had 2 or more painful sickle cell crises within the past 12 months. |
| Age Restrictions | |
| Prescriber Restrictions | (SC): Prescribed by or in consultation with a hematologist or oncologist |
| Coverage Duration | (SC): Indefinite |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

ENSPRYNG

Products Affected

- ENSPRYNG

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Neuromyelitis Optica Spectrum Disorder (NMOSD)(Initial): (1) Diagnosis of NMSOD, (2) Member is anti-aquaporin-4 (AQP4) antibody positive. |
| Age Restrictions | |
| Prescriber Restrictions | (NMOSD)(Initial, Reauth): Prescribed by or in consultation with a neurologist |
| Coverage Duration | (NMOSD)(Initial, Reauth): 12 months |
| Other Criteria | (NMOSD)(Reauth): Positive clinical response to therapy |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

EPIDIOLEX

Products Affected

- EPIDIOLEX

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Dravet Syndrome (DS): (1) Inadequate response or inability to tolerate ONE of the following: (a) clobazam (b) valproic acid or (c) topiramate. (2) Baseline CBC, serum transaminases and total bilirubin prior to initiating therapy. Lennox-Gastaut Syndrome (LGS): (1) Inadequate response or inability to tolerate ONE of the following: (a) clobazam (b) valproic acid, or (c) topiramate. (2) Baseline CBC, serum transaminases and total bilirubin prior to initiating therapy. Tuberous Sclerosis Complex (TSC): (1) Concurrent use with additional anti-epileptic(s). (2) Baseline CBC, serum transaminases and total bilirubin prior to initiating therapy. |
| Age Restrictions | (DS, LGS, TCS): Member is 1 year of age or older |
| Prescriber Restrictions | (DS, LGS, TCS): Prescribed by or in consultation with a neurologist |
| Coverage Duration | (DS, LGS, TCS): Indefinite |
| Other Criteria | (All Indications): Approve if for continuation of therapy. |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

EUCRISA

Products Affected

- EUCRISA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Atopic Dermatitis (AD): (1) Inadequate response or inability to tolerate at least ONE of the following: (a) topical tacrolimus OR topical pimecrolimus , OR (b) generic, prescription medium potency or higher topical steroid. |
| Age Restrictions | (AD): Member is 3 months of age or older |
| Prescriber Restrictions | |
| Coverage Duration | (AD): Indefinite |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

EVEKEO

Products Affected

- *amphetamine sulfate*
- EVEKEO
- EVEKEO ODT

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Attention Deficit Hyperactivity Disorder (ADHD): (1) Diagnosis of ADHD. Narcolepsy: (1) Diagnosis of narcolepsy. |
| Age Restrictions | (ADHD): Member is 3 years of age or older. (Narcolepsy): Member is 6 years of age or older. |
| Prescriber Restrictions | |
| Coverage Duration | (ADHD, Narcolepsy): Remainder of Contract Year |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

EVENITY

Products Affected

- EVENITY

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Post Menopausal Osteoporosis (PMO): (1) Diagnosis of PMO. (2) Member has severe osteoporosis or is at a very high risk for fracture as defined by ONE of the following: (a) T-score of the individual's bone mineral density (BMD) is at least -3.5 standard deviations below the young adult mean, (b) Member has a history of multiple vertebral fractures, (c) BOTH of the following: (i) T-score of the individual's bone mineral density (BMD) is at least -2.5 standard deviations below the young adult mean AND (ii) Member has a history of osteoporotic fracture (i.e. hip, spine, etc.). (3) Inadequate response or inability to tolerate ONE of the following: (a) bisphosphonates, (b) hormone replacement therapy, (c) selective-estrogen receptor modulators (SERMs), OR (d) Denosumab (Prolia). (3) Cumulative lifetime therapy does not exceed 12 months. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | (PMO): 12 months |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

EVRYSDI

Products Affected

- EVRYSDI

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Spinal Muscular Atrophy (SMA)(Initial): (1) Diagnose of SMA, (2) Member has confirmed mutations in chromosome 5q that leads to SMN protein deficiency. |
| Age Restrictions | (SMA)(Initial, Reauth): Member is 2 months of age or older |
| Prescriber Restrictions | (SMA)(Initial, Reauth): Prescribed by or in consultation with a neurologist |
| Coverage Duration | (SMA)(Initial)(Reauth):12 months |
| Other Criteria | (SMA)(Reauth): (1) Positive clinical response to therapy (e.g. improvement in ability to sit without support, survive without permanent ventilation) |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

EXTENDED RELEASE METFORMIN

Products Affected

- GLUMETZA
- *metformin hcl er (mod)*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | (DM2)(Initial, Reauth): (1) Serum creatinine levels greater than or equal to 1.5 mg/dL in males, or serum creatinine levels greater than or equal to 1.4 mg/dL in females. (2) Hepatic impairment. (3) Metabolic acidosis, including diabetic ketoacidosis. (4) Used for preventing weight gain. |
| Required Medical Information | Diabetes Mellitus Type 2 (DM2)(Initial): (1) Diagnosis of DM2. (2) Member has an HgbA1C greater than 7.0%. All Indications: (1) Inadequate response or inability to tolerate both of the following: (a) Immediate release metformin, and (b) Extended-release metformin (generic Glucophage XR). |
| Age Restrictions | (DM2 for tablets) (Initial, Reauth): Member is 18 years of age or older |
| Prescriber Restrictions | |
| Coverage Duration | (DM2)(Initial, Reauth): End of contract year. |
| Other Criteria | (DM2)(Reauth): Member has had a positive clinical response to therapy. |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

EYSUVIS

Products Affected

- EYSUVIS

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Dry Eye Disease (DED)(Initial): (1) Diagnosis of DED |
| Age Restrictions | |
| Prescriber Restrictions | (DED)(Initial, Reauth): Prescribed by or in consultation with an ophthalmologist |
| Coverage Duration | (Initial, Reauth): 14 days |
| Other Criteria | (DED)(Reauth): (1) Positive clinical response to therapy (e.g., improvement in dry eye symptoms). |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

FASENRA

Products Affected

- FASENRA
- FASENRA PEN

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Part D is medically necessary when there is a documentation of the following: Severe Asthma (SA): (1) Diagnosis of severe asthma with eosinophilic phenotype as defined by ONE of the following at initiation of therapy (a) blood eosinophil levels are at least 150 cells/microliter if dependent on daily oral corticosteroids for at least 6 continuous months or (b) blood eosinophil levels are at least 300 cells/microliter AND, (2) ONE of the following: (a) Patient has had at least one asthma exacerbation requiring systemic corticosteroids within the past 12 months, or (b) Any prior intubation for asthma exacerbation, or (c) prior asthma-related hospitalization within the past 12 months, AND (3) Patient is currently treated with ONE of the following unless there is a contraindication or intolerance to these medications: (a) high-dose inhaled corticosteroids (ICS) (e.g., greater than or equal to 500 mcg fluticasone propionate equivalent/day) AND an additional asthma controller medication (e.g., leukotriene receptor antagonist, long-acting beta-2 agonist (LABA), theophylline) OR (b) one maximally-dosed combination ICS/LABA product). |
| Age Restrictions | (SA): Member is 12 years of age or older |
| Prescriber Restrictions | (SA): Prescribed by or in consultation with pulmonologist or allergy/immunology specialist |
| Coverage Duration | (SA): Indefinite |
| Other Criteria | Subject to Part B vs Part D review |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

FENTANYL CITRATE LOZENGE

Products Affected

- *fentanyl citrate buccal*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of all of the following: (1) pain associated with cancer, (2) long acting medication regimen AND (3) member is opioid tolerant as demonstrated by adherence to one of the following regimens for at least one week: at least 25mcg of transdermal fentanyl hourly, 30mg of oxycodone daily, 60mg of oral morphine daily, 8mg of oral hydromorphone daily, 25mg of oral oxymorphone daily or an equianalgesic dose of another opioid |
| Age Restrictions | |
| Prescriber Restrictions | Prescribed by or in consultation with one of the following: Pain specialist, Oncologist, Hematologist, Hospice care specialist, or Palliative care specialist. |
| Coverage Duration | Remainder of contract year |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

FERRIPROX

Products Affected

- *deferiprone*
- FERRIPROX

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Transfusional Iron Overload (TIO): (1) Diagnosis of transfusional iron overload due to one of the following: (a) Thalassemia syndromes, (b) sickle cell disease, (c) other transfusion-dependent anemias. (2) Inadequate response or inability to tolerate current chelation therapy. |
| Age Restrictions | (TIO): Member is 3 years of age or older |
| Prescriber Restrictions | |
| Coverage Duration | (TIO): Remainder of contract year |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

FINTEPLA

Products Affected

- FINTEPLA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Dravet Syndrome (DS): Inadequate response or inability to tolerate ONE of the following: (a) clobazam, (b) valproic acid, (c) divalproex sodium, (d) topiramate, or (e) levetiracetam |
| Age Restrictions | (DS): Member is 2 years of age or older. |
| Prescriber Restrictions | (DS): Prescribed by or in consultation with a neurologist. |
| Coverage Duration | (DS): Indefinite. |
| Other Criteria | (All Indications): Approve if for continuation of therapy. |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

FIRDAPSE

Products Affected

- FIRDAPSE

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | (LEMS)(Initial, Continuation): history of seizures |
| Required Medical Information | Lambert-Eaton myasthenic syndrome (LEMS)(Initial): (1) Diagnosis of LEMS. (2) Neurological symptoms persist after treatment of malignancy, when malignancy is present. |
| Age Restrictions | (LEMS)(Initial, Continuation): Member is 18 years of age or older |
| Prescriber Restrictions | (LEMS)(Initial, Continuation): Prescribed by or in consultation with a neurologist. |
| Coverage Duration | (LEMS)(Initial):90 Days, (LEMS)(Continuation): Indefinite |
| Other Criteria | (LEMS)(CONTINUATION): Attestation member has had a positive clinical response to therapy |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

FLECTOR

Products Affected

- *diclofenac epolamine external*
- FLECTOR EXTERNAL

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Previously experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Use for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery. |
| Required Medical Information | (1): Inadequate response or inability to tolerate at least 2 prescription strength topical NSAIDs (i.e. Diclofenac Gel 1%, Diclofenac Topical Solution 1.5%) |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Remainder of contract year |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

GALAFOLD

Products Affected

- GALAFOLD

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Fabry's Disease (FD)(Initial): (1) Member has amenable galactosidase alpha gene (GLA) variant per FDA labeling information |
| Age Restrictions | (FD)(Initial, Reauth): Member is 16 years of age or older |
| Prescriber Restrictions | (FD)(Initial, Reauth): Prescribed by or in consultation with a clinical genetics specialist OR a nephrologist |
| Coverage Duration | (FD)(Initial): 6 months, (FD)(Reauth): Indefinite |
| Other Criteria | (FD)(Reauth): Attestation member has had a response to therapy |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

GATTEX

Products Affected

- GATTEX

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Short Bowel Syndrome (SBS)(Initial): (1) Diagnosis of Short Bowel Syndrome, (2) individual receives parenteral support at least three times per week for at least 12 months. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | (SBS)(Initial, Reauth): 6 months |
| Other Criteria | (SBS)(REAUTH): (1)Reduction in parenteral support from baseline (prior to initiation of Gattex therapy) |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

GRALISE

Products Affected

- GRALISE ORAL TABLET

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Post Herpetic Neuralgia (PHN): (1) Diagnosis of post herpetic neuralgia, (2) Inadequate response to gabapentin. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | (PHN): Indefinite |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

GROWTH HORMONES

Products Affected

- GENOTROPIN
- GENOTROPIN MINIQUICK
- HUMATROPE INJECTION SOLUTION RECONSTITUTED 12 MG, 24 MG, 6 MG
- NORDITROPIN FLEXPRO SUBCUTANEOUS SOLUTION PEN-INJECTOR
- NUTROPIN AQ NUSPIN 10 SUBCUTANEOUS SOLUTION PEN-INJECTOR
- NUTROPIN AQ NUSPIN 20 SUBCUTANEOUS SOLUTION PEN-INJECTOR
- NUTROPIN AQ NUSPIN 5 SUBCUTANEOUS SOLUTION PEN-INJECTOR
- OMNITROPE SUBCUTANEOUS SOLUTION CARTRIDGE
- OMNITROPE SUBCUTANEOUS SOLUTION RECONSTITUTED
- SAIZEN
- SAIZENPREP
- ZOMACTON

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | One of the following: (1) Growth Failure in Children (GFC)(Initial): (A) Diagnosis of growth hormone deficiency, (B) subnormal serum insulin-like growth factor-1 (IGF-1), (C) growth velocity less than or equal to 5 cm/year after 2 years of age, (D) documentation of bone age, (E) abnormal response from provocative testing, such as insulin-induced hypoglycemia test, levodopa, or clonidine. (2) Small for Gestational Age (SGA)(Initial): (A) Diagnosis of SGA, (B) Clinical documentation of no catch-up growth by 2 to 4 years of age. (3) Growth Failure Associated with Chronic Kidney Disease (GF-CKD) (Initial), (4) Growth failure associated with Noonan Syndrome, Prader-Willi Syndrome, Turner Syndrome or short stature homeobox-containing gene (SHOX) deficiency (Initial), (5) Diagnostically confirmed Growth Hormone Deficiency in adults (GHDA)(Initial), OR (6) Idiopathic Short Stature (ISS)(Initial): (A) Diagnosis of ISS defined by height standard deviation score (SDS) less than or equal to 2.25, (B) Documentation of growth velocity less than 25th percentile for bone age. |
| Age Restrictions | |
| Prescriber Restrictions | (All Indications)(Initial): Prescribed by or in consultation with an endocrinologist or nephrologist |
| Coverage Duration | (All Indications) (Initial, Continuation): 12 months |

| PA Criteria | Criteria Details |
|-----------------------|---|
| Other Criteria | (All Indications) (Continuation): (1) Annual clinical re-evaluation by the treating endocrinologist, (2) expected adult height not attained, and (3) documentation of expected adult height goal. (GFC, GHDA)(Continuation): (1) Normalization of IGF-1. (SGA, ISS)(Continuation): (1) Increase in growth velocity from baseline. (GF-CKD)(Continuation): (1) No history of renal transplant. |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

HAEGARDA

Products Affected

- HAEGARDA

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Hereditary Angioedema(HAE): (1) Diagnosis of hereditary angioedema (HAE), (2) For prophylaxis against HAE attacks. |
| Age Restrictions | |
| Prescriber Restrictions | (HAE): Prescribed by or in consultation with an allergist or immunologist |
| Coverage Duration | (HAE): Indefinite |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

HETLIOZ

Products Affected

- HETLIOZ

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Non-24 Hour Sleep-Wake Cycle (Non-24): (1) Diagnosis of a circadian period greater than 24 hours (also known as non-24-hour sleep-wake disorder), (2) Member is totally blind (has no light perception). Nighttime Sleep Disturbances in Smith-Magenis Syndrome (SMS): (1) Diagnosis of SMS, (2) Member is experiencing sleep disturbances. |
| Age Restrictions | (SMS): Member is 16 years of age or older |
| Prescriber Restrictions | (Non-24, SMS): Prescribed by a sleep specialist or neurologist |
| Coverage Duration | Remainder of contract year |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

HETLIOZ LQ

Products Affected

- HETLIOZ LQ

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Nighttime sleep disturbances in Smith-Magenis Syndrome (SMS): (1) Diagnosis of SMS, (2) Member is experiencing sleep disturbances |
| Age Restrictions | (SMS): Member is 3 to 15 years of age |
| Prescriber Restrictions | (SMS): Prescribed by a sleep specialist or neurologist |
| Coverage Duration | Remainder of contract year |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

HIGH DOSE OPIOIDS

Products Affected

- BELBUCA BUCCAL FILM 300 MCG, 450 MCG, 600 MCG, 750 MCG, 900 MCG
- DILAUDID ORAL TABLET 4 MG, 8 MG
- *fentanyl transdermal patch 72 hour 100 mcg/hr, 25 mcg/hr, 37.5 mcg/hr, 50 mcg/hr, 62.5 mcg/hr, 75 mcg/hr, 87.5 mcg/hr*
- *hydrocodone bitartrate er oral tablet er 24 hour abuse-deterrent*
- *hydromorphone hcl er oral tablet extended release 24 hour*
- *hydromorphone hcl oral tablet 4 mg, 8 mg*
- HYSINGLA ER
- *levorphanol tartrate oral tablet 3 mg*
- *methadone hcl oral solution*
- *methadone hcl oral tablet*
- *morphine sulfate er beads oral capsule extended release 24 hour 120 mg*
- *morphine sulfate er oral capsule extended release 24 hour 100 mg, 60 mg, 80 mg*
- *morphine sulfate er oral tablet extended release 100 mg, 200 mg, 60 mg*
- MS CONTIN ORAL TABLET EXTENDED RELEASE 100 MG, 200 MG, 60 MG
- NUCYNTA ER
- NUCYNTA ORAL TABLET 100 MG, 75 MG
- *oxycodone hcl er oral tablet er 12 hour abuse-deterrent 30 mg, 60 mg, 80 mg*
- *oxycodone hcl er oral tablet er 12 hour abuse-deterrent 40 mg*
- *oxycodone hcl oral tablet 30 mg*
- OXYCONTIN ORAL TABLET ER 12 HOUR ABUSE-DETERRENT
- *oxymorphone hcl er oral tablet extended release 12 hour 20 mg, 30 mg*
- *oxymorphone hcl er oral tablet extended release 12 hour 40 mg*
- *oxymorphone hcl oral tablet 10 mg*
- ROXICODONE ORAL TABLET 30 MG
- XTAMPZA ER

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | NEW TO HIGH DOSE OPIOID THERAPY : ONE of the following (A) pain associated with cancer, (B) chronic non-cancer pain and BOTH of the following (1) member is opioid tolerant (e.g. at least one week where total daily dose is at least one of the following: 30mg of oxycodone, 60mg of oral morphine, 8mg of oral hydromorphone, 25mg of oral oxymorphone or an equianalgesic dose of another opioid) AND (2) the member has been evaluated for non-opioid prescription pharmacologic treatment prior to initiation of high dose opioid therapy. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Remainder of contract year |

| PA Criteria | Criteria Details |
|-----------------------|--|
| Other Criteria | CONTINUING HIGH DOSE OPIOID THERAPY (morphine equivalent dose 90mg per day or greater): ONE of the following (1) pain associated with cancer OR (2) chronic non-cancer pain and ALL (a) member's pain has been assessed within the last 6 months AND (b) member has clinically meaningful improvement in pain and functioning that outweighs risks to patient safety AND (c) member is not being treated for substance abuse |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA AGENTS

Products Affected

- JUXTAPID ORAL CAPSULE 10 MG, 20 MG, 30 MG, 5 MG

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | (HoFH)(Initial, Reauth): Moderate-severe liver impairment, active liver disease, unexplained LFT abnormalities. Juxtapid: Pregnancy, concomitant use with strong or moderate CYP3A4 inhibitors. |
| Required Medical Information | Homozygous Familial Hypercholesterolemia (HoFH): (1) Diagnosis of HoFH with ONE of the following: (a) Genetic confirmation of 2 mutant alleles at the LDL receptor, Apo B, PCSK9, or ARH adaptor protein gene locus (b) Untreated LDL-C greater than 500 mg/dL or treated LDL cholesterol greater than or equal to 300 mg/dL or treated non-HDL cholesterol greater than or equal to 330 mg/dL together with either of the following: (i) Tendinous xanthoma prior to 10 years of age (ii) Elevated LDL cholesterol prior to lipid-lowering therapy consistent with HeFH in both parents AND (2) Inadequate response or inability to tolerate the combination of BOTH of the following: (a) Either ezetimibe or a Bile Acid Sequestrant (e.g. cholestyramine) AND (b) ONE of the following: (i) ONE high potency statin at the maximally tolerated dose (e.g., atorvastatin, rosuvastatin) OR (ii) Inability to tolerate statin therapy as determined by one of the following: (A) member had rhabdomyolysis or symptoms with creatine kinase (CK) exceeding 10 times the upper limit of normal (ULN) or (B) either of the following with TWO statins: myalgia (no CK elevation) or myositis (CK less than 10 times ULN or (C) hepatotoxicity from statin use (increased AST/ALT exceeding 3 times ULN) or (D) liver disease documented by Child Pugh A or worse OR AST/ALT exceeding 3 times ULN for at least 6 weeks. |
| Age Restrictions | |
| Prescriber Restrictions | (HoFH)(Initial, Reauth): Prescribed by or in consultation with a cardiologist, endocrinologist, or lipid specialist. |
| Coverage Duration | (HoFH)(Initial, Reauth): 6 months |
| Other Criteria | (HoFH)(REAUTH): (1) Documentation of reduction in LDL level since initiation of therapy with respective drug |

| PA Criteria | Criteria Details |
|-----------------------|-------------------------------------|
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

HORIZANT

Products Affected

- HORIZANT ORAL TABLET EXTENDED RELEASE

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Postherpetic neuralgia (PHN): (1) Diagnosis of PHN and (2) Inadequate response or inability to tolerate gabapentin. Restless legs syndrome (RLS): (1) Diagnosis of RLS and (2) Inadequate response or inability to tolerate pramipexole or ropinirole. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | (PHN, RLS): Indefinite |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

HRM

Products Affected

- ALLZITAL
- ASCOMP-CODEINE
- BUPAP ORAL TABLET 50-300 MG
- *butalbital-acetaminophen*
- *butalbital-apap-caff-cod*
- *butalbital-apap-caffeine oral capsule*
- *butalbital-apap-caffeine oral tablet 50-325-40 mg*
- *butalbital-asa-caff-codeine*
- *butalbital-aspirin-caffeine oral capsule*
- *carbinoxamine maleate oral solution*
- *carbinoxamine maleate oral tablet 4 mg*
- *chlordiazepoxide hcl*
- *chlordiazepoxide-clidinium*
- *chlorzoxazone oral tablet 375 mg, 500 mg, 750 mg*
- *clemastine fumarate oral syrup*
- *clemastine fumarate oral tablet 2.68 mg*
- DEMEROL INJECTION SOLUTION 25 MG/ML, 50 MG/ML
- *dipyridamole oral*
- ESGIC ORAL TABLET
- FIORICET ORAL CAPSULE
- FIORICET/CODEINE ORAL CAPSULE 50-300-40-30 MG
- *flurazepam hcl*
- INDOCIN ORAL
- INDOCIN RECTAL
- LIBRAX
- LORZONE
- *meperidine hcl injection solution 100 mg/ml, 25 mg/ml, 50 mg/ml*
- *meperidine hcl oral solution*
- *meperidine hcl oral tablet 50 mg*
- *meprobamate*
- *metaxalone*
- *methocarbamol oral*
- *norgesic forte*
- *orphenadrine citrate er*
- *pentazocine-naloxone hcl*
- *promethazine hcl oral syrup*
- *promethazine hcl oral tablet*
- *promethazine hcl rectal suppository 12.5 mg, 25 mg*
- *promethazine-phenylephrine*
- PROMETHEGAN RECTAL SUPPOSITORY 25 MG, 50 MG
- RYVENT
- SKELAXIN
- TENCON ORAL TABLET 50-325 MG
- VTOL LQ
- ZEBUTAL ORAL CAPSULE 50-325-40 MG

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Risk versus benefit has been assessed for this request of a high risk medication (HRM) in elderly |
| Age Restrictions | Apply if member is greater than or equal to 65 years |
| Prescriber Restrictions | |
| Coverage Duration | 2 years |

| PA Criteria | Criteria Details |
|-----------------------|-------------------------------------|
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

HRM ESTROGENS

Products Affected

- ACTIVELLA ORAL TABLET 1-0.5 MG
- AMABELZ
- ANGELIQ
- BIJUVA
- CLIMARA
- CLIMARA PRO
- COMBIPATCH
- DIVIGEL TRANSDERMAL GEL 1 MG/GM
- DOTTI
- ELESTRIN
- ESTRACE ORAL
- *estradiol oral*
- *estradiol transdermal*
- *estradiol-norethindrone acet*
- ESTROGEL
- EVAMIST
- FEMHRT
- FYAVOLV
- JINTELI
- LYLLANA
- MENOSTAR
- MIMVEY
- MINIVELLE
- *norethindrone-eth estradiol*
- PREFEST
- PREMARIN ORAL
- VIVELLE-DOT

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | ONE of the following: (1) Inadequate response or inability to tolerate vaginal estrogen preparations (e.g. vaginal tablets, rings, or cream, etc.) OR (2) Risk versus benefit has been assessed for this request of a high risk medication (HRM) in elderly |
| Age Restrictions | Apply if member is greater than or equal to 65 years |
| Prescriber Restrictions | |
| Coverage Duration | 2 years |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

HRM KETOROLAC

Products Affected

- *ketorolac tromethamine nasal*
- *ketorolac tromethamine oral*
- SPRIX

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | ONE of the following: (1) Inadequate response or inability to tolerate TWO alternative NSAIDs such as meloxicam, naproxen, celecoxib, ibuprofen, etc. OR (2) Risk versus benefit has been assessed for this request of a high risk medication (HRM) in elderly |
| Age Restrictions | Apply if member is greater than or equal to 65 years |
| Prescriber Restrictions | |
| Coverage Duration | One Month |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

HRM NON BENZODIAZEPINE HYPNOTICS

Products Affected

- AMBIEN CR ORAL TABLET EXTENDED RELEASE 12.5 MG
- AMBIEN ORAL TABLET 10 MG
- EDLUAR SUBLINGUAL TABLET SUBLINGUAL 10 MG
- *eszopiclone oral tablet 3 mg*
- LUNESTA ORAL TABLET 3 MG
- *zolpidem tartrate er oral tablet extended release 12.5 mg*
- *zolpidem tartrate oral tablet 10 mg*
- *zolpidem tartrate sublingual tablet sublingual 3.5 mg*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | (Initial): Risk versus benefit has been assessed for this request of a high risk medication (HRM) in elderly |
| Age Restrictions | (Initial, Reauth): Apply if member is greater than or equal to 65 years |
| Prescriber Restrictions | |
| Coverage Duration | (Initial): 3 months. (Reauth): 2 years |
| Other Criteria | (REAUTH): Prescriber is aware of the risk versus benefit of using the medication chronically (greater than 90 days) |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

HRM SHORT TERM SKELETAL MUSCLE RELAXANTS

Products Affected

- AMRIX
- *carisoprodol oral*
- *carisoprodol-aspirin-codeine*
- *cyclobenzaprine hcl er*
- *cyclobenzaprine hcl oral*
- FEXMID
- SOMA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Acute Muscle Spasms (AMS): Prescriber attestation that drug will be used only for short periods (up to 2 or 3 weeks). All Indications: Risk versus benefit has been assessed for this request of a high risk medication (HRM) in elderly. |
| Age Restrictions | Apply if member is greater than or equal to 65 years |
| Prescriber Restrictions | |
| Coverage Duration | (AMS)= 1 year, All other indications= 2 years |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

HUMIRA

Products Affected

- HUMIRA PEDIATRIC CROHNS START SUBCUTANEOUS PREFILLED SYRINGE KIT 80 MG/0.8ML, 80 MG/0.8ML & 40MG/0.4ML
- HUMIRA PEN SUBCUTANEOUS PEN-INJECTOR KIT
- HUMIRA PEN-CD/UC/HS STARTER
- HUMIRA PEN-PEDIATRIC UC START
- HUMIRA PEN-PS/UV/ADOL HS START SUBCUTANEOUS PEN-INJECTOR KIT 40 MG/0.8ML
- HUMIRA PEN-PSOR/UVEIT STARTER
- HUMIRA SUBCUTANEOUS PREFILLED SYRINGE KIT 10 MG/0.1ML, 20 MG/0.2ML, 40 MG/0.4ML, 40 MG/0.8ML

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | (RA, AS, JIA, PsA, PsO, CD, UC, HS, UV): Concurrent therapy with any other biologic disease modifying anti-rheumatic drug (DMARD), e.g. tumor necrosis factor antagonists |
| Required Medical Information | Rheumatoid Arthritis (RA): (1)Diagnosis of moderate to severe RA. (2) One of the following: (A) Member has previous trial with infliximab (Remicade), OR (B) Inadequate response or inability to tolerate one of the following: methotrexate, hydroxychloroquine, leflunomide, azathioprine, sulfasalazine. Ankylosing Spondylitis (AS): (1) Diagnosis of AS. (2) One of the following: (A) Member has previous trial with infliximab (Remicade), OR (B) Inadequate response or inability to tolerate one of the following: methotrexate, hydroxychloroquine, leflunomide, azathioprine, sulfasalazine. Juvenile Idiopathic Arthritis (JIA): (1) Diagnosis of moderate to severe JIA. (2) One of the following: (A) Member has previous trial with infliximab (Remicade), OR (B) Inadequate response or inability to tolerate one of the following: methotrexate, hydroxychloroquine, leflunomide, azathioprine, sulfasalazine. Psoriatic Arthritis (PsA): (1) Diagnosis of PsA. (2) One of the following: (A) Member has previous trial with infliximab (Remicade), OR (B) Inadequate response or inability to tolerate one of the following: methotrexate, hydroxychloroquine, leflunomide, azathioprine, sulfasalazine. Plaque Psoriasis (PsO): (1) Diagnosis of moderate to severe PsO. (2) One of the following: (A) Member has previous trial with infliximab (Remicade), OR (B) Inadequate response or inability to tolerate ONE of the following drugs: topical calcipotriene containing products, topical anthralin, topical steroids, topical immunomodulators (Elidel, Protopic), topical retinoids. |
| Age Restrictions | (JIA, UV): Member is 2 years of age or older. (CD): Member is 6 years of age or older. (HS): Member is 12 years of age or older. (RA, AS, PsA, PsO): Member is 18 years of age or older. (UC): Member is 5 years of age or older. |

| PA Criteria | Criteria Details |
|--------------------------------|--|
| Prescriber Restrictions | (RA, JIA, AS): Prescribed by or in consultation with a rheumatologist. (PsA): Prescribed by or in consultation with a dermatologist or rheumatologist. (PsO, HS): Prescribed by or in consultation with a dermatologist. (CD, UC): Prescribed by or in consultation with a gastroenterologist. (UV): Prescribed by or in consultation with a rheumatologist or ophthalmologist. |
| Coverage Duration | (RA, AS, JIA, PsA, PsO, CD, UC, HS, UV): Indefinite |
| Other Criteria | Crohn's Disease (CD): (1) Diagnosis of CD. (2) One of the following: (A) Member has previous trial with infliximab (Remicade), OR (B) Inadequate response or inability to tolerate ONE of the following: corticosteroid, Aminosalicylate, or Immunomodulators (ex. azathioprine or 6-mercaptopurine). Ulcerative Colitis (UC): (1) Diagnosis of UC. (2) One of the following: (A) Member has previous trial with infliximab (Remicade), OR (B) Inadequate response or inability to tolerate ONE of the following: corticosteroid, Aminosalicylate, or Immunomodulators (ex. azathioprine or 6-mercaptopurine). Hidradenitis Suppurativa (HS): (1) Diagnosis of HS. Uveitis (UV): (1) Diagnosis of non-infectious intermediate, posterior, or pan- uveitis. (2) One of the following: (A) Member has previous trial with infliximab (Remicade), OR (B) Inadequate response or inability to tolerate BOTH of the following one topical ophthalmic steroid and one oral corticosteroid. |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

HUMULIN U500

Products Affected

- HUMULIN R U-500 (CONCENTRATED)
- HUMULIN R U-500 KWIKPEN SUBCUTANEOUS SOLUTION PEN-INJECTOR

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Type 1 Diabetes (T1DM): (1) Diagnosis of type 1 diabetes mellitus (2) Insulin requirement exceeding 200 units per day. Type 2 Diabetes (T1DM): (1) Diagnosis of Type 2 diabetes mellitus (2) Insulin requirement exceeding 200 units per day. |
| Age Restrictions | |
| Prescriber Restrictions | (T1DM, T1DM2): Prescribed by or in consultation with an endocrinologist |
| Coverage Duration | (T1DM, T1DM2): Indefinite |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

ILUMYA

Products Affected

- ILUMYA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | (PsO): Concurrent therapy with biological DMARDs or other tumor necrosis factor antagonists |
| Required Medical Information | Plaque Psoriasis (PsO): (1) Diagnosis of moderate to severe PsO. (2) Inadequate response or inability to tolerate TWO of the following: (a) adalimumab (Humira), (b) etanercept (Enbrel), (c) Skyrizi OR documentation demonstrating that a trial may be inappropriate. |
| Age Restrictions | (PsO): Member is 18 years of age or older. |
| Prescriber Restrictions | (PsO): Prescribed by or in consultation with a dermatologist |
| Coverage Duration | (PsO): Indefinite |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

INCRELEX

Products Affected

- INCRELEX

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | (GHGD, PIGF-1D) (Initial and Continuation): Known or suspected malignancy, closed epiphyses, concurrent GH therapy |
| Required Medical Information | Growth Hormone Gene Deletion (GHGD): (Initial) (1) Diagnosis of growth hormone gene deletion who have developed neutralizing antibodies to growth hormone. Severe Primary IGF-1 Deficiency (PIGF-1D): (Initial) (1) Diagnosis of Severe primary IGF-1 deficiency (2) height standard deviation score less than or equal to -3.0 (3) basal IGF-1 standard deviation score less than or equal to -3.0 AND normal or elevated growth hormone. |
| Age Restrictions | (GHGD, PIGF-1D) (Initial and Continuation): Member is 2 years of age or older |
| Prescriber Restrictions | (GHGD, PIGF-1D) (Initial and Continuation) Prescribed by or in consultation with a pediatric endocrinologist |
| Coverage Duration | (Initial and continuation): 12 months |
| Other Criteria | (GHGD, PIGF-1D)(CONTINUATION): (1) Documentation of increase in growth velocity from baseline AND (2) Annual clinical re-evaluation by a pediatric endocrinologist |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

INGREZZA

Products Affected

- INGREZZA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Tardive Dyskinesia (TD) (Initial): (1) Diagnosis of moderate to severe tardive dyskinesia (2) documentation of baseline AIMS and (3) one of the following: (a) persistent symptoms of tardive dyskinesia despite a trial of dose reduction, tapering, or discontinuation of the offending medication, or (b) member is not a candidate for a trial of dose reduction, tapering, or discontinuation of the offending medication. |
| Age Restrictions | |
| Prescriber Restrictions | (TD) (Initial, Reauth): Prescribed by or in consultation with a neurologist or a psychiatrist |
| Coverage Duration | (TD) (Initial): 3 months (TD)(Reauth): indefinite |
| Other Criteria | (TD) (Reauthorization criteria): Valbenazine (Ingrezza) is reapproved with documentation of positive clinical response, as demonstrated by improvement in AIMS, to Ingrezza therapy |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

INHALED TOBRAMYCIN

Products Affected

- TOBI PODHALER

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Cystic Fibrosis (CF): (1) Diagnosis of cystic fibrosis AND (2) evidence of P. aeruginosa in the lungs |
| Age Restrictions | (CF): Member is 6 years of age or older |
| Prescriber Restrictions | (CF): Prescribed by or in consultation with a pulmonologist OR infectious disease specialist. |
| Coverage Duration | (CF): Indefinite |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

INJECTABLE METHOTREXATE

Products Affected

- OTREXUP SUBCUTANEOUS SOLUTION AUTO-INJECTOR 10 MG/0.4ML, 12.5 MG/0.4ML, 15 MG/0.4ML, 17.5 MG/0.4ML, 20 MG/0.4ML, 22.5 MG/0.4ML, 25 MG/0.4ML
- RASUVO SUBCUTANEOUS SOLUTION AUTO-INJECTOR 10 MG/0.2ML, 12.5 MG/0.25ML, 15 MG/0.3ML, 17.5 MG/0.35ML, 20 MG/0.4ML, 22.5 MG/0.45ML, 25 MG/0.5ML, 30 MG/0.6ML, 7.5 MG/0.15ML
- REDITREX

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Rheumatoid arthritis (RA): (1) Diagnosis of severe, active rheumatoid arthritis (RA), (2) Inadequate response or inability to tolerate oral methotrexate. Psoriatic Arthritis (PsA): (1) Diagnosis of PsA, (2) Inadequate response or inability to tolerate oral methotrexate. Polyarticular juvenile idiopathic arthritis (pJIA): (1) Diagnosis of pJIA, (2) Inadequate response or inability to tolerate oral methotrexate. Psoriasis: (1) Diagnosis of severe psoriasis, (2) Inadequate response to BOTH of the following: (a) oral methotrexate AND (b) topical steroids (e.g. clobetasol propionate cream/ointment, betamethasone cream/ointment, etc.). |
| Age Restrictions | (Psoriasis): Member is 18 years of age or older |
| Prescriber Restrictions | (RA, pJIA, PsA): Recommended by rheumatologist. (Psoriasis): Recommended by dermatologist |
| Coverage Duration | (RA, pJIA, PsA, Psoriasis): Indefinite |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

INTRAVENOUS IMMUNE GLOBULIN (IVIG)

Products Affected

- BIVIGAM INTRAVENOUS SOLUTION 5 GM/50ML GM/100ML, 10 GM/200ML, 20 GM/200ML, 5 GM/50ML
- FLEBOGAMMA DIF INTRAVENOUS SOLUTION 5 GM/50ML
- GAMMAGARD INJECTION SOLUTION 2.5 GM/25ML
- GAMMAGARD S/D LESS IGA
- GAMMAKED INJECTION SOLUTION 1 GM/10ML
- GAMMAPLEX INTRAVENOUS SOLUTION 10 GM/100ML, 10 GM/200ML, 20 GM/200ML, 5 GM/50ML
- GAMMUNEX-C INJECTION SOLUTION 1 GM/10ML
- OCTAGAM INTRAVENOUS SOLUTION 1 GM/20ML, 2 GM/20ML
- PANZYGA
- PRIVIGEN INTRAVENOUS SOLUTION 20 GM/200ML

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Part D is medically necessary when ONE of the following is present: (1) Autoimmune mucocutaneous blistering disease pemphigus vulgaris, pemphigus foliaceus, bullous pemphigoid, mucous membrane (cicatrical) pemphigoid , benign mucous membrane pemphigoid, epidermolysis bullosa acquisita and ONE of the following: (a) inadequate response or inability to tolerate conventional therapy (i.e. steroids, immunosuppressants) OR (b) rapidly progressive disease in conjunction with conventional therapy (i.e. steroids, immunosuppressants). (2) Acute Idiopathic Thrombocytopenia Purpura (ITP) and ONE of the following (a) management of acute bleeding (b) used to increase platelet count prior to surgical procedures) (c) severe thrombocytopenia (platelets less than 20, 000 per uL) or (d) high risk for intracerebral hemorrhage. (3) Chronic ITP and ALL of the following (a) inadequate response or inability to tolerate corticosteroids (b) duration of illness greater than 6 months (c) platelets persistently less than 20,000/ uL. (4) Chronic B-cell lymphocytic leukemia with IgG less than 600mg/dL and recurrent, serious bacterial infections requiring antibiotic therapy. (5) Hematopoietic stem cell transplant and IgG less than 400mg/dL. (6) HIV and all of the following (a) less than 14 years of age (b) evidence of qualitative or quantitative humoral immunologic defects and (c) current bacterial infection despite antimicrobial prophylaxis. (7) Solid organ transplant. (8) Chronic Inflammatory Demyelinating Polyneuritis confirmed by electrodiagnostic testing or nerve biopsy and an inadequate response or inability to tolerate corticosteroids. |
| Age Restrictions | |
| Prescriber Restrictions | |

| PA Criteria | Criteria Details |
|--------------------------|---|
| Coverage Duration | (All Indications): 6 months |
| Other Criteria | <p>Subject to Part B vs Part D review. (9) Dermatomyositis or Polymyositis diagnosed by laboratory testing (antinuclear or myositis specific antibodies), biopsy, EMG, or MRI) and inadequate response or inability to tolerate steroids or immunosuppressants. (10) Guillain Barre syndrome with impaired function (i.e. unable to stand or walk without aid). (11) Lambert Eaton myasthenic syndrome refractory to steroids, immunosuppressants, or cholinesterase inhibitors. (12) Multifocal motor neuropathy diagnosed by electrodiagnostic studies. (13) Acute exacerbations of MS unresponsive to steroids. (14) Myasthenia gravis refractory to at least 8 weeks of standard therapy (steroids, immunosuppressants, cholinesterase inhibitors). (15) Myasthenic crisis. (16) Stiff person syndrome refractory to standard therapy (muscle relaxants, benzodiazepines, gabapentin). (17) Severe, active SLE unresponsive to steroids. (18) Kawasaki disease. (All Indications)(CONTINUATION): (1) Documentation of clinical improvement as appropriate to the diagnosis such as, but not limited to, Rankin score and Activities of Daily Living (ADL) scores.</p> |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

ISTURISA

Products Affected

- ISTURISA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Cushing's disease (CD): (1) Diagnosis of (pituitary) Cushing's disease. (2) Pituitary surgery is not an option or has not been curative (3) Member has inadequate response or inability to tolerate Signifor [LAR]. |
| Age Restrictions | (CD): Member is 18 years of age or older |
| Prescriber Restrictions | (CD): Prescribed by or in consultation with an endocrinologist |
| Coverage Duration | (CD): Remainder of contract year |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

JYNARQUE

Products Affected

- JYNARQUE

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | (Initial): Baseline serum transaminases and bilirubin prior to initiation of therapy |
| Age Restrictions | (Initial and Reauth): Member is 18 years of age or older |
| Prescriber Restrictions | (Initial and Reauth): Prescribed by or in consultation with a nephrologist or kidney transplant specialist |
| Coverage Duration | (Initial): 3 months. (Reauth): 12 months. |
| Other Criteria | (REAUTH): (1) ONE of the following (a) decline in kidney function has slowed or (b) kidney pain has improved and (2) serum transaminase less than 3 times the upper limit of normal and (3) bilirubin less than 2 times upper limit of normal |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

KALYDECO

Products Affected

- KALYDECO

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Cystic Fibrosis (CF): (1) Diagnosis of Cystic Fibrosis with documentation of one mutation in the CFTR gene that is responsive to ivacaftor based on clinical and/or in vitro assay data, (2) Mutation was documented by an FDA-cleared CF to detect the presence of the CFTR mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions. |
| Age Restrictions | (CF): Member is 4 months of age or older for granules. Member is 6 years of age or older for tablets |
| Prescriber Restrictions | (CF): Prescribed by or in consultation with is a pulmonologist |
| Coverage Duration | (CF): Indefinite |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

KEVEYIS

Products Affected

- KEVEYIS

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | (Initial, Reauth): Concomitant use of high dose Aspirin, severe pulmonary disease and hepatic insufficiency |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | (Initial, Reauth): Prescribed by or in consultation with a neurologist |
| Coverage Duration | (Initial): 3 months (Reauth): Indefinite |
| Other Criteria | (Reauth): Member has had a positive clinical response to therapy |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

KEVZARA

Products Affected

- KEVZARA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | (RA): Concurrent therapy with any other biologic disease modifying anti-rheumatic drug (DMARD), e.g. tumor necrosis factor antagonists |
| Required Medical Information | Rheumatoid arthritis (RA): (1) Diagnosis of RA. (2) Inadequate response or inability to tolerate TWO of the following: (a) adalimumab (Humira), (b) etanercept (Enbrel), (c) Rinvoq, (d) Xeljanz/Xeljanz XR OR documentation demonstrating that a trial may be inappropriate. |
| Age Restrictions | (RA): Member is 18 years of age or older |
| Prescriber Restrictions | (RA): Prescribed by or in consultation with a rheumatologist |
| Coverage Duration | (RA): Indefinite |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

KINERET

Products Affected

- KINERET SUBCUTANEOUS SOLUTION
PREFILLED SYRINGE

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | (RA, JIA, NOMID, DIRA): Concurrent therapy with any other biologic disease modifying anti-rheumatic drug (DMARD), e.g. tumor necrosis factor antagonists |
| Required Medical Information | Rheumatoid Arthritis (RA): (1) Diagnosis of RA. (2) Inadequate response or inability to tolerate TWO of the following: (a) adalimumab (Humira), (b) etanercept (Enbrel), (c) Rinvoq, (d) Xeljanz/Xeljanz XR OR documentation demonstrating that a trial may be inappropriate. Juvenile Idiopathic Arthritis (JIA): (1) Diagnosis of JIA. (2) Inadequate response or inability to tolerate to both adalimumab (Humira) AND etanercept (Enbrel). Neonatal-Onset Multisystem Inflammatory Disease (NOMID): (1) Diagnosis of NOMID. (2) Diagnosis has been confirmed by one of the following: (a) NLRP-3 (nucleotide-binding domain, leucine rich family (NLR), pyrin domain containing 3] gene (also known as Cold-Induced Auto-inflammatory Syndrome-1 [CIAS1]) mutation (b) Evidence of active inflammation including both of the following: (i) clinical symptoms (e.g., rash, fever, arthralgia) (ii) elevated acute phase reactants (e.g., ESR, CRP). Deficiency of Interleukin-1 Receptor Antagonist (DIRA): (1) Diagnosis of DIRA. |
| Age Restrictions | |
| Prescriber Restrictions | (RA, JIA, NOMID, DIRA): Prescribed by or in consultation with a rheumatologist or pediatric specialist. |
| Coverage Duration | Indefinite |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

KLISYRI

Products Affected

- KLISYRI

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Actinic Keratoses: (1) Diagnosis of Actinic Keratoses. (2) Inadequate response or inability to tolerate one of the following: (a) fluorouracil, (b) imiquimod, or (c) diclofenac 3% gel. |
| Age Restrictions | Actinic Keratosis: Member is 18 years of age or older |
| Prescriber Restrictions | |
| Coverage Duration | 30 days |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

KORLYM

Products Affected

- KORLYM

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | (HCS): Pregnancy |
| Required Medical Information | Hyperglycemia in Patients with Cushing Syndrome (HCS): (1) Hyperglycemia secondary to hypercortisolism in adult patient with endogenous Cushing syndrome, (2) patient has type 2 diabetes mellitus or glucose intolerance, (3) patient has failed surgery or is not a candidate for surgery. |
| Age Restrictions | |
| Prescriber Restrictions | (HCS): Prescribed by or in consultation with an endocrinologist |
| Coverage Duration | (HCS): Indefinite |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

KYNMOBI

Products Affected

- KYNMOBI

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | (PD): Member not using medication with any 5-HT3 antagonist (e.g., ondansetron, granisetron, dolasetron, palonosetron, alosetron) |
| Required Medical Information | Parkinson's Disease (PD): (1) Diagnosis of Parkinson's disease, (2) Member is experiencing intermittent OFF Episodes, (3) Concomitant use of medication with other medications for the treatment of Parkinson's disease (e.g., carbidopa/levodopa, pramipexole, ropinirole, etc.) |
| Age Restrictions | |
| Prescriber Restrictions | (PD): Prescribed by or in consultation with a neurologist |
| Coverage Duration | (PD): Indefinite |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

LIDOCAINE TRANSDERMAL PATCH

Products Affected

- *lidocaine external patch 5 %*
- LIDODERM

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Post-Herpetic Neuralgia (PHN): (1) Diagnosis of post-herpetic neuralgia. Diabetic Peripheral Neuropathy (DPN): (1) Diagnosis of diabetic peripheral neuropathy. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | (PHN, DPN): Indefinite |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

LUPKYNIS

Products Affected

- LUPKYNIS

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Lupus Nephritis (LN): (1) Diagnosis of active lupus nephritis. (2) Used in combination with mycophenolate mofetil and corticosteroids. |
| Age Restrictions | (LN): Member is 18 years of age or older |
| Prescriber Restrictions | (LN): Prescribed by or in consultation with nephrologist or rheumatologist |
| Coverage Duration | Indefinite |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

LYRICA CR

Products Affected

- LYRICA CR
- *pregabalin er*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Neuropathic Pain Associated with Diabetic Peripheral Neuropathy (DPN): (1) Diagnosis of neuropathic pain associated with diabetic peripheral neuropathy, (2) inadequate response or inability to tolerate gabapentin or generic pregabalin. Post-Herpetic Neuralgia (PHN): (1) Diagnosis of post-herpetic neuralgia (2) inadequate response or inability to tolerate gabapentin or generic pregabalin. |
| Age Restrictions | (DPN, PHN): Member is 18 years of age or older |
| Prescriber Restrictions | |
| Coverage Duration | (DPN, PHN): Indefinite |
| Other Criteria | (All Indications): Approve if for continuation of therapy. |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

MULPLETA

Products Affected

- MULPLETA

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of baseline platelet count less than 50,000/mcL |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 1 month |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

MYALEPT

Products Affected

- MYALEPT

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Generalized Lipodystrophy (GL): (1) Diagnosis of congenital or acquired generalized lipodystrophy. |
| Age Restrictions | |
| Prescriber Restrictions | (GL): Prescribed by or in consultation with an endocrinologist |
| Coverage Duration | (GL): Indefinite |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

MYCAPSSA

Products Affected

- MYCAPSSA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | (Acromegaly)(Initial): (1) One of the following: (a) Inadequate response to surgical resection and/or pituitary irradiation, (b) member is not a candidate for surgical resection or pituitary irradiation (2) Inadequate response or inability to tolerate a dopamine agonist (e.g., bromocriptine or cabergoline) at maximally tolerated doses (3) Member has responded to and tolerated treatment with octreotide or lanreotide. |
| Age Restrictions | (Acromegaly): Member is 18 years of age or older |
| Prescriber Restrictions | |
| Coverage Duration | (Acromegaly)(Initial, Reauth): 12 months |
| Other Criteria | (Acromegaly) (Reauth): Positive clinical response to therapy (e.g., reduction or normalization of IGF-1/GH level for same age and sex) |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

MYFEMBREE

Products Affected

- MYFEMBREE

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Uterine Leiomyomas (UL)(Initial): (1) Diagnosis of heavy menstrual bleeding associated with uterine leiomyomas (fibroids), (2) Member is premenopausal, (3) ONE of the following: (a) Inadequate response or inability to tolerate one of the following for at least 3 months: combination (estrogen/progestin) contraceptive, progestins, tranexamic acid, OR (b) Member has had a previous interventional therapy to reduce bleeding (e.g., uterine-artery embolization and magnetic resonance-guided focused ultrasonography), (4) Treatment duration of therapy has not exceeded a total of 24 months. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | (Initial, Reauth): 12 months |
| Other Criteria | (UL) (Reauth): (1) Member has improvement in bleeding associated with uterine leiomyomas (fibroids) (e.g., significant/sustained reduction in menstrual blood loss per cycle, improved quality of life, etc.), (2) Treatment duration of therapy has not exceeded a total of 24 months. |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

MYTESI

Products Affected

- MYTESI

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Noninfectious Diarrhea associated with HIV/AIDS (NID): (1) Diagnosis of HIV/AIDS and patient is on antiretroviral therapy. (2) Patient requires symptomatic relief of non-infectious diarrhea. (3) Inadequate response or inability to tolerate at least one anti-diarrheal medication (e.g., loperamide, atropine/diphenoxylate, etc.). (4) Infectious diarrhea (e.g., cryptosporidiosis, C. Difficile, etc.) has been ruled out. |
| Age Restrictions | (NID): Member is 18 years of age or older |
| Prescriber Restrictions | |
| Coverage Duration | (NID): Remainder of contract year |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

NATPARA

Products Affected

- NATPARA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Hypocalcemia Due to Chronic Hypoparathyroidism (H-CH)(Initial): (1) Diagnosis of H-CH. (2) Patient has a documented parathyroid hormone concentration that is inappropriately low for the level of calcium, recorded on at least two occasions within the previous 12 months. (3) Patient has normal thyroid-stimulating hormone concentrations if not on thyroid hormone replacement therapy (or if on therapy, the dose had to have been stable for greater than or equal to 3 months). (4) Patient has normal magnesium and serum 25-hydroxyvitamin D concentrations. (5) NATPARA will be used as an adjunct treatment. |
| Age Restrictions | (H-CH)(Initial, Reauth): Member is 18 years of age or older |
| Prescriber Restrictions | (H-CH)(Initial, Reauth): Prescribed by or in consultation with an endocrinologist |
| Coverage Duration | (H-CH)(Initial): 6 month, (H-CH)(Reauth): Until the end of the contract year |
| Other Criteria | (H-CH)(Reauth): One of the following: (1) Patient has achieved and maintained serum calcium levels in the ideal range (7.5 - 10.6 mg/dL), OR (2) Patient has experienced a 50% or greater reduction in oral calcium intake, OR (3) Patient has experienced a 50% or greater reduction in oral vitamin D intake. |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

NEXLETOL/NEXLIZET

Products Affected

- NEXLETOL
- NEXLIZET

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Heterozygous Familial Hypercholesterolemia (HeFH) OR Atherosclerotic Cardiovascular Disease (ASCVD) (Initial): (1) One of the following: (A) Diagnosis of HeFH, OR (B) Diagnosis of ASCVD as diagnosed by either stress test, angiography, atherosclerotic event (e.g. MI, angina, stroke, claudication, carotid stenosis) or arterial intervention for atherosclerotic disease (e.g. coronary, peripheral, carotid). (2) ONE of the following: (A) LDL-C 70 mg/dL or greater after at least 8 weeks of one low, moderate or high-intensity statin therapy and member will continue to receive statin therapy at maximally tolerate dose OR (B) Inability to tolerate statin therapy as documented by one of the following: (i) member had rhabdomyolysis or symptoms with creatine kinase (CK) exceeding 10 times the upper limit of normal (ULN) or (ii) either of the following with TWO statins: myalgia (no CK elevation) or myositis (CK less than 10 times ULN or (iii) hepatotoxicity from statin use (increased AST/ALT exceeding 3 times ULN) or (iv) liver disease documented by Child Pugh A or worse OR AST/ALT exceeding 3 times ULN for at least 6 weeks. (3) One of the following: (A) Member has been receiving at least 8 weeks of ezetimibe (Zetia) therapy as adjunct to maximally tolerated statin therapy OR (B) Member has contraindication or intolerance to ezetimibe (Zetia). |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | (HeFH, ASCVD) (Initial): 6 months. (HeFH, ASCVD) (Continuation): 12 months |
| Other Criteria | (HeFH, ASCVD) (Continuation): (1) Positive Clinical response to therapy (e.g., reduction in LDL-C levels). (2) One of the following: (A) Member continues to receive other lipid-lowering therapy (e.g., statins, ezetimibe) at the maximally tolerated dose OR (B) Member has inability to tolerate other lipid-lowering therapy (e.g., statins, ezetimibe) |
| Indications | All Medically-accepted Indications. |

| PA Criteria | Criteria Details |
|----------------|------------------|
| Off Label Uses | |

NON ORAL PAH AGENTS

Products Affected

- VENTAVIS

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Part D is medically necessary when ALL of the following are met: Pulmonary Arterial Hypertension(PAH) (Initial): (1)Diagnosis of pulmonary arterial hypertension (PAH) WHO Group I with New York Heart Association (NYHA) Functional Class II to IV. (2) Diagnosis confirmed by catheterization (right-heart or Swan-Ganz) or echocardiography. (3) Mean pulmonary artery pressure greater than or equal to 25 mm Hg at rest or greater than 30 mm Hg with exertion. |
| Age Restrictions | |
| Prescriber Restrictions | (PAH)(PH-ILD)(Initial): Prescribed by or in consultation with a Cardiologist or Pulmonologist |
| Coverage Duration | (PAH)(Initial): 6 months. (PAH) (Continuation): 12 months. |
| Other Criteria | Subject to Part B vs Part D review. (PAH)(CONTINUATION): Stabilization or improvement as evaluated by a cardiologist or pulmonologist. |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

NON-ORAL ANTIBIOTICS

Products Affected

- NUZYRA
- SIVEXTRO
- VABOMERE
- ZEMDRI
- ZERBAXA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | (Initial): Part D is medically necessary when documentation of a current bacterial infection and an inadequate response or inability to tolerate at least TWO drugs to which the organism is susceptible OR the requested agent is the only antibiotic to which the organism is susceptible. |
| Age Restrictions | |
| Prescriber Restrictions | (Initial, Reauth): One of the following: (1) Prescribed by an infectious disease (ID) specialist or prescribed with ID consultation (telephone consultation is acceptable) including name of the ID specialist and date of the consultation within the last 60 days OR (2) Prescribed as part of chemotherapy prophylaxis protocol. |
| Coverage Duration | (Initial, Reauth): 1 month |
| Other Criteria | Subject to Part B vs Part D review. (REAUTH): Prescriber attests that an infectious disease consult determines that a longer duration of therapy is required. |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

NON-ORAL CHEMO AGENTS

Products Affected

- SYNRIBO
- TRELSTAR MIXJECT

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Part D is medically necessary when ANY of the following inclusion criteria is met: (1) Drug is FDA approved for indication and regimen requested, (2) The indication and regimen is classified as Category 1 or 2A by National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium, (3) narrative text in The American Hospital Formulary Service-Drug Information (AHFS-DI) or Clinical Pharmacology Compendium is supportive for the specific condition(s) requested, (4) The Micromedex Compendium and the strength of recommendation is listed as Class I, Class IIa, or Class IIb for the specific condition(s) requested, (5) Indication is listed in Lexi-Drugs as "off label" with evidence level A, (6) supported by Peer-Reviewed Medical Literature as defined in Chapter 15 Section 50.4.5 of the Medicare Benefit Policy Manual, (7) Documentation of continuous therapy with the medication requested. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Indefinite |
| Other Criteria | Subject to Part B vs Part D review. |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

NON-PREFERRED HEPATITIS C AGENTS

Products Affected

- SOVALDI ORAL PACKET
- SOVALDI ORAL TABLET 400 MG
- VIEKIRA PAK
- VOSEVI
- ZEPATIER

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | (1) Documentation of member's Hepatitis C genotype. (2) Prescribed regimen is consistent with the current AASLD/ IDSA guidance. (3) Inability to tolerate ONE of the following when appropriate per the current AASLD/IDSA guidance: Harvoni, Epclusa, or Mavyret. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Duration will be applied consistent with AASLD/ IDSA guidance |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

NOXAFIL

Products Affected

- NOXAFIL ORAL
- *posaconazole*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | <p>Prophylaxis of Invasive Aspergillus Infections (AI): (1) For use in prophylaxis of invasive Aspergillus infection due to being severely immunocompromised after inadequate response or inability to tolerate voriconazole (Vfend).</p> <p>Prophylaxis of Invasive Candida Infections(CI): (1) For use in prophylaxis of invasive Candida infection due to being severely immunocompromised after inadequate response or inability to tolerate voriconazole (Vfend).</p> <p>Oropharyngeal Candidiasis (OC): (1) Diagnosis of oropharyngeal candidiasis after inadequate response or inability to tolerate both itraconazole and fluconazole.</p> |
| Age Restrictions | (AI, OC, CI): Member is 13 years of age or older |
| Prescriber Restrictions | (AI, OC, CI): Prescribed by or in consultation with an infectious disease specialist or as part of chemotherapy prophylaxis protocol |
| Coverage Duration | (AI, OC, CI): Remainder of contract year |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

NUCALA

Products Affected

- NUCALA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | <p>Part D is medically necessary when there is documentation of ONE of the following: Severe Asthma with Eosinophilic Phenotype (SA) (Initial): (1) Diagnosis of severe asthma with eosinophilic phenotype as defined by one of the following: a) blood eosinophil levels are at least 150 cells/microliter at initiation of therapy (measured within 6 weeks of dosing), or b) blood eosinophil levels at least 300 cells/microliter within the past 12 months. (2) Patient has had at least two or more asthma exacerbations requiring systemic corticosteroids within the past 12 months OR patient has had any prior intubation for an asthma exacerbation OR Patient has had a prior asthma-related hospitalization within the past 12 months, AND (3) Patient is currently treated with high-dose inhaled corticosteroids (ICS) (e.g., greater than or equal to 500 mcg fluticasone propionate equivalent/day) AND an additional controller medication (e.g., long-acting beta agonist such as salmeterol or formoterol, leukotriene inhibitor such as montelukast, theophylline), unless the individual is intolerant of or has a contraindication to two of the additional controller agents. Eosinophilic Granulomatosis with Polyangiitis (EGPA) (Initial): (1) Diagnosis of Eosinophilic Granulomatosis with Polyangiitis (EGPA), (2) Member's disease has relapsed or is refractory to standard of care therapy (i.e., corticosteroid treatment with or without immunosuppressive therapy), and (3) Member is currently receiving corticosteroid therapy (e.g., prednisolone, prednisone).</p> |
| Age Restrictions | (SA, EGPA) (Initial, Reauth): Member is 6 years of age or older. (HES) (Initial, Reauth): Member is 12 years of age or older. |
| Prescriber Restrictions | (SA): Prescribed by or in consultation with pulmonologist or allergy/immunology specialist. (EGPA): Prescribed by or in consultation with a rheumatologist. (HES): Prescribed by or in consultation with either allergist/immunologist or hematologist. |
| Coverage Duration | (SA, EGPA, HES) (Initial): 12 months. (SA, EGPA, HES) (Reauth): 12 months. |

| PA Criteria | Criteria Details |
|-----------------------|---|
| Other Criteria | <p>Subject to Part B vs Part D review. Hypereosinophilic Syndrome (HES) (Initial): (1) Diagnosis of HES. (2) All of the following: (a) Member has been diagnosed for at least 6 months, (b) Verification that other non-hematologic secondary causes have been ruled out (e.g., drug hypersensitivity, parasitic helminth infection, HIV infection, non-hematologic malignancy), (c) member is FIP1-like1-platelet derived growth factor receptor alpha kinase (FIP1L1-PDGFR kinase)-negative. (3) member has uncontrolled HES defined by both of the following: (a) Pre-treatment blood eosinophil count greater than or equal to 1000 cells/microliter, (b) Member has experienced 2 or more flares within the past 12 months. (4) Inadequate response or inability to tolerate one of the following: (a) corticosteroid therapy (e.g., prednisone), (b) cytotoxic/immunosuppressive therapy (e.g., hydroxyurea, cyclosporine, imatinib). (SA)(Reauth): (1) Patient is currently treated with high-dose inhaled corticosteroids (ICS) (e.g., greater than or equal to 500mcg fluticasone propionate equivalent/day) AND an additional controller medication (e.g., long-acting beta agonist such as salmeterol or formoterol, leukotriene inhibitor such as montelukast, theophylline), unless the individual is intolerant of or has a contraindication to two of the additional controller agents. (EGPA) (Reauth): (1) Positive clinical response to therapy (e.g., increase in remission time). (HES) (Reauth): (1) Positive clinical response (e.g., reduction in corticosteroid use, reduction of blood eosinophil count, reduction in flares).</p> |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

NUEDEXTA

Products Affected

- NUEDEXTA

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Pseudobulbar Affect (PBA): Diagnosis of Pseudobulbar affect |
| Age Restrictions | (PBA): Member is 18 years of age or older |
| Prescriber Restrictions | |
| Coverage Duration | (PBA): Indefinite |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

NUPLAZID

Products Affected

- NUPLAZID ORAL CAPSULE
- NUPLAZID ORAL TABLET 10 MG

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Parkinson disease psychosis (PDP): Documentation of inadequate response or inability to tolerate ONE of the following (1) quetiapine or (2) clozapine. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | (PDP): Indefinite |
| Other Criteria | (All Indications): Approve if for continuation of therapy. |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

OCALIVA

Products Affected

- OCALIVA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Primary biliary cholangitis (PBC): (1) Used in combination with ursodeoxycholic acid (e.g., Urso, Urso Forte, ursodiol), OR (2) inability to tolerate ursodeoxycholic acid. |
| Age Restrictions | |
| Prescriber Restrictions | (PBC) (Initial, Reauth): Prescribed by or in consultation with a hepatologist or gastroenterologist |
| Coverage Duration | (PBC) (Initial): 6 months. (PBC) (Reauth): Indefinite |
| Other Criteria | (PCB)(Reauth): Positive clinical response to Ocaliva therapy |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

OLUMIANT

Products Affected

- OLUMIANT

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | (RA): Concurrent therapy with any other biologic disease modifying anti-rheumatic drug (DMARD), e.g. tumor necrosis factor antagonists JAK inhibitors, or potent immunosuppressants such as azathioprine, cyclosporine |
| Required Medical Information | Rheumatoid arthritis (RA): (1) Diagnosis of RA. (2) Inadequate response or inability to tolerate to BOTH of the following: (a) ONE of the following: Humira or Enbrel, AND (b) ONE of the following: Rinvoq or Xeljanz/Xeljanz XR OR documentation demonstrating that a trial may be inappropriate. |
| Age Restrictions | (RA): Member is 18 years of age or older |
| Prescriber Restrictions | (RA): Prescribed by or in consultation with a rheumatologist |
| Coverage Duration | (RA): Indefinite |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

ORAL ANTIBIOTICS

Products Affected

- NUZYRA
- SIVEXTRO
- XENLETA ORAL

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | (Initial): Documentation of a current bacterial infection and an inadequate response or inability to tolerate TWO antibiotics to which the organism is susceptible OR the requested medication is the only antibiotic to which the organism is susceptible. |
| Age Restrictions | |
| Prescriber Restrictions | (Initial, Reauth): One of the following: (1) Prescribed by an infectious disease (ID) specialist or prescribed with ID consultation (telephone consultation is acceptable) including name of the ID specialist and date of the consultation within the last 60 days OR (2) Prescribed as part of chemotherapy prophylaxis protocol. |
| Coverage Duration | (Initial, Reauth): 1 month |
| Other Criteria | (REAUTH): Prescriber attests that an infectious disease consult determines that a longer duration of therapy is required. |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

ORAL CHEMO AGENTS

Products Affected

- *abiraterone acetate*
- AFINITOR
- AFINITOR DISPERZ
- ALECENSA
- ALUNBRIG
- AYWAKIT
- BALVERSA
- *bexarotene*
- BOSULIF
- BRAFTOVI ORAL CAPSULE 75 MG
- BRUKINSA
- CABOMETYX
- CALQUENCE
- CAPRELSA
- COMETRIQ (100 MG DAILY DOSE) ORAL KIT 80 & 20 MG
- COMETRIQ (140 MG DAILY DOSE) ORAL KIT 3 X 20 MG & 80 MG
- COMETRIQ (60 MG DAILY DOSE)
- COPIKTRA
- COTELLIC
- DAURISMO
- ERIVEDGE
- ERLEADA
- *erlotinib hcl*
- *everolimus oral tablet 2.5 mg, 5 mg, 7.5 mg*
- FARYDAK
- FOTIVDA
- GAVRETO
- GILOTRIF
- GLEEVEC
- IBRANCE
- ICLUSIG
- IDHIFA
- *imatinib mesylate*
- IMBRUVICA
- INLYTA
- INQOVI
- INREBIC
- IRESSA
- JAKAFI
- KISQALI (200 MG DOSE)
- KISQALI (400 MG DOSE)
- KISQALI (600 MG DOSE)
- KISQALI FEMARA (400 MG DOSE)
- KISQALI FEMARA (600 MG DOSE)
- KISQALI FEMARA(200 MG DOSE)
- KOSELUGO
- *lapatinib ditosylate*
- LENVIMA (10 MG DAILY DOSE)
- LENVIMA (12 MG DAILY DOSE)
- LENVIMA (14 MG DAILY DOSE)
- LENVIMA (18 MG DAILY DOSE)
- LENVIMA (20 MG DAILY DOSE)
- LENVIMA (24 MG DAILY DOSE)
- LENVIMA (4 MG DAILY DOSE)
- LENVIMA (8 MG DAILY DOSE)
- LONSURF
- LORBRENA
- LUMAKRAS
- LYNPARZA ORAL TABLET
- MEKINIST
- MEKTOVI
- NERLYNX
- NEXAVAR
- NINLARO
- NUBEQA
- ODOMZO
- ONUREG
- ORGOVYX
- PEMAZYRE
- PIQRAY (200 MG DAILY DOSE)
- PIQRAY (250 MG DAILY DOSE)
- PIQRAY (300 MG DAILY DOSE)
- POMALYST
- QINLOCK
- RETEVMO
- REVLIMID
- ROZLYTREK
- RUBRACA
- RYDAPT
- SPRYCEL
- STIVARGA
- *sunitinib malate*
- SUTENT
- TABRECTA

- TAFINLAR
- TAGRISSO
- TALZENNA
- TARCEVA
- TARGRETIN
- TASIGNA
- TAZVERIK
- TEPMETKO
- THALOMID
- TIBSOVO
- TRUSELTIQ (100MG DAILY DOSE)
- TRUSELTIQ (125MG DAILY DOSE)
- TRUSELTIQ (50MG DAILY DOSE)
- TRUSELTIQ (75MG DAILY DOSE)
- TUKYSA
- TURALIO
- TYKERB
- UKONIQ
- VENCLEXTA
- VENCLEXTA STARTING PACK
- VERZENIO
- VITRAKVI
- VIZIMPRO
- VOTRIENT
- WELIREG
- XALKORI
- XOSPATA
- XPOVIO (100 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 50 MG
- XPOVIO (40 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 40 MG
- XPOVIO (40 MG TWICE WEEKLY) ORAL TABLET THERAPY PACK 40 MG
- XPOVIO (60 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 60 MG
- XPOVIO (60 MG TWICE WEEKLY)
- XPOVIO (80 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 40 MG
- XPOVIO (80 MG TWICE WEEKLY)
- XTANDI
- YONSA
- ZEJULA
- ZELBORAF
- ZOLINZA
- ZYDELIG
- ZYKADIA ORAL TABLET
- ZYTIGA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Approved when ANY of the following inclusion criteria is met: (1) Drug is FDA approved for indication and regimen requested, (2) The indication and regimen is classified as Category 1 or 2A by National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium, (3) narrative text in The American Hospital Formulary Service-Drug Information (AHFS-DI) or Clinical Pharmacology Compendium is supportive for the specific condition(s) requested, (4) The Micromedex Compendium and the strength of recommendation is listed as Class I, Class IIa, or Class IIb for the specific condition(s) requested, (5) Indication is listed in Lexi-Drugs as "off label" with evidence level A, (6) supported by Peer-Reviewed Medical Literature as defined in Chapter 15 Section 50.4.5 of the Medicare Benefit Policy Manual, (7) Documentation of continuous therapy with the medication requested. |
| Age Restrictions | |
| Prescriber Restrictions | |

| PA Criteria | Criteria Details |
|--------------------------|-------------------------------------|
| Coverage Duration | Indefinite |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

ORAL PAH AGENTS

Products Affected

- *ambrisentan*
- *bosentan*
- LETAIRIS
- OPSUMIT
- ORENITRAM
- TRACLEER

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Pulmonary Arterial Hypertension (PAH) (Initial): (1) Documentation of a diagnosis of pulmonary arterial hypertension (PAH) WHO Group I with New York Heart Association (NYHA) Functional Class II to IV. (2) Diagnosis confirmed by catheterization (right-heart or Swan-Ganz) or echocardiography. (3) Documentation of mean pulmonary artery pressure greater than or equal to 25 mm Hg at rest or greater than 30 mm Hg with exertion. |
| Age Restrictions | |
| Prescriber Restrictions | (PAH) (Initial): Prescribed by or in consultation with a Cardiologist or Pulmonologist |
| Coverage Duration | (PAH) (Initial): 6 month. (PAH) (Continuation):12 months. |
| Other Criteria | (PAH)(Continuation): Stabilization or improvement as evaluated by a cardiologist or pulmonologist. |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

ORENCIA SQ

Products Affected

- ORENCIA CLICKJECT
- ORENCIA SUBCUTANEOUS SOLUTION
PREFILLED SYRINGE

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | (RA, PsA, JIA): Concurrent therapy with biological DMARDs or other tumor necrosis factor antagonists |
| Required Medical Information | Rheumatoid arthritis (RA): (1) Diagnosis of RA. (2) Inadequate response or inability to tolerate to TWO of the following: (a) Humira, (b) Enbrel, (c) Rinvoq, (d) Xeljanz/Xeljanz XR OR documentation demonstrating that a trial may be inappropriate. Psoriatic arthritis (PsA): (1) Diagnosis of PsA. (2) Inadequate response or inability to tolerate to TWO of the following: (a) Humira, (b) Enbrel, (c) Xeljanz/Xeljanz XR OR documentation demonstrating that a trial may be inappropriate. Juvenile idiopathic arthritis (JIA): (1) Diagnosis of JIA. (2) Inadequate response or inability to tolerate TWO of the following: (a) adalimumab (Humira), (b) etanercept (Enbrel), (c) Xeljanz OR documentation demonstrating that a trial may be inappropriate. |
| Age Restrictions | (RA, PsA, JIA): Member is 2 years of age or older. |
| Prescriber Restrictions | (RA, JIA): Prescribed by or in consultation with a rheumatologist. (PsA): Prescribed by or in consultation with a dermatologist or rheumatologist. |
| Coverage Duration | (RA, JIA, PsA): Indefinite |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

ORIAHNN

Products Affected

- ORIAHNN

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Uterine Leiomyomas (UL)(Initial): (1) Diagnosis of heavy menstrual bleeding associated with uterine leiomyomas (fibroids), (2) Member is premenopausal, (3) ONE of the following: (a) Inadequate response or inability to tolerate one of the following for at least 3 months: combination (estrogen/progesterone) oral contraceptive, progestins, tranexamic acid, OR (b) Member has had a previous interventional therapy to reduce bleeding (e.g., uterine-artery embolization and magnetic resonance-guided focused ultrasonography), (4) Treatment duration of therapy has not exceeded a total of 24 months. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | (UL)(Initial, Reauth): 12 months |
| Other Criteria | (UL)(Reauth): (1) Member has improvement in bleeding associated with uterine leiomyomas (fibroids) (e.g., significant/sustained reduction in menstrual blood loss per cycle, improved quality of life, etc.), (2) Treatment duration of therapy has not exceeded a total of 24 months. |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

ORILISSA

Products Affected

- ORILISSA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Pain Associated with Endometriosis (PAE): (1) Documentation of ONE of the following, (a) Inadequate response or inability to tolerate BOTH of the following (i) one nonsteroidal anti-inflammatory drug AND (ii) (a) one contraceptive OR (b) Member has had surgical ablation to prevent recurrence. (2) Treatment duration does not exceed 24 months (150mg tablet) or 6 months (200mg tablet). |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | (PAE): 24 months for 150mg tablet, 6 months for 200mg tablet |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

ORKAMBI

Products Affected

- ORKAMBI

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | (CF): Diagnosis of CF other than those homozygous for the F508del mutation |
| Required Medical Information | Cystic Fibrosis (CF): (1) Diagnosis of CF, (2) Patient is homozygous for the F508del mutation in the CFTR gene (3) If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of the F508del mutation on both alleles of the CFTR gene |
| Age Restrictions | (CF): Member is 2 years of age or older |
| Prescriber Restrictions | (CF): Prescribed by or in consultation with pulmonologist |
| Coverage Duration | (CF): Indefinite |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

ORLADEYO

Products Affected

- ORLADEYO

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Hereditary Angioedema (HAE): (1) Diagnosis of HAE, (2) For prophylaxis against HAE attacks. |
| Age Restrictions | (HAE): Member is 12 years of age or older |
| Prescriber Restrictions | (HAE): Prescribed by or in consultation with an immunologist, allergist or pulmonologist |
| Coverage Duration | Indefinite |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

OTEZLA

Products Affected

- OTEZLA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | <p>Oral Ulcers Associated with Bechet's Disease (OU-BD): (1) Diagnosis of OU-BD. (2) Inadequate response or inability to tolerate ONE topical corticosteroid (e.g. triamcinolone acetonide dental paste) AND ONE systemic corticosteroid.</p> <p>Psoriatic arthritis (PsA): (1) Diagnosis of PsA. (2) Inadequate response or inability to tolerate TWO of the following: (a) Humira, (b) Enbrel, (c) Xeljanz/Xeljanz XR OR documentation demonstrating that a trial may be inappropriate.</p> <p>Plaque psoriasis (PsO): (1) Diagnosis of moderate to severe PsO. (2) Inadequate response or inability to tolerate BOTH of the following: (a) ONE of the following: (i) Humira, (ii) Enbrel, or (iii) Skyrizi AND (b) Cosentyx OR documentation demonstrating that a trial may be inappropriate.</p> |
| Age Restrictions | (PsA, PsO, OU-BD): Member is 18 years of age or older |
| Prescriber Restrictions | (PsA, PsO, OU-BD): Prescribed by or in consultation with a Rheumatologist or Dermatologist. |
| Coverage Duration | (PsA, PsO, OU-BD): Indefinite |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

OXBRYTA

Products Affected

- OXBRYTA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | (SCD)(Initial, Reauth): Concurrent therapy with Adakveo (crizanlizumab-tmca) |
| Required Medical Information | Sickle Cell Disease (SCD) (Initial): (1) Diagnosis of sickle cell disease, (2) Patient had at least 1 vaso-occlusive crisis (VOC) event within the past 12 months (e.g., acute painful crisis, acute chest syndrome,) (3) Hemoglobin level that is between 5.5 g/dL and 10.5 g/dL prior to therapy initiation (4) Inadequate response or inability to tolerate hydroxyurea (i.e., Siklos, Droxia). |
| Age Restrictions | (SCD)(Initial, Reauth): Member is 12 years of age or greater |
| Prescriber Restrictions | (SCD)(Initial, Reauth): Prescribed by or in consultation with a hematologist |
| Coverage Duration | (SCD)(Initial, Reauth): 12 months |
| Other Criteria | (SCD)(Reauth): Member has had a positive clinical response to Oxbryta therapy (e.g., an increase in hemoglobin level of greater than or equal to 1 g/dL from baseline, decreased annualized incidence rate of VOCs) |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

OXERVATE

Products Affected

- OXERVATE

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | Prescribed by or in consultation with an ophthalmologist |
| Coverage Duration | 8 weeks |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

PALYNZIQ

Products Affected

- PALYNZIQ

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Phenylketonuria (PK)(Initial): (1) Patient has uncontrolled blood phenylalanine concentrations greater than 600 micromol/L on existing management |
| Age Restrictions | (PK)(Initial, Continuation): Member is 18 years of age or older |
| Prescriber Restrictions | |
| Coverage Duration | (PK)(Initial): 6 months, (PK)(Continuation): Indefinite |
| Other Criteria | (PK)(CONTINUATION): (1) A positive clinical response to Palynziq therapy defined by at least a 20% reduction in blood phenylalanine concentrations from pre-treatment baseline OR blood phenylalanine concentrations less than or equal to 600 micromol/L |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

PARKINSON'S DISEASE AGENTS

Products Affected

- INBRIJA
- NOURIANZ
- ONGENTYS

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Parkinson's Disease (PD): (1) Diagnosis of Parkinson's disease. (2) concurrent use of carbidopa/levodopa containing product, (3) Member is experiencing intermittent OFF episodes, (4) member had inadequate response or inability to tolerate ONE of the following: (a) MAO-B inhibitor (e.g., rasagiline, selegiline), (b) Dopamine agonist (e.g., pramipexole, ropinirole), (c) COMT inhibitor (e.g., entacapone) |
| Age Restrictions | |
| Prescriber Restrictions | (PD): Prescribed by or in consultation with a neurologist |
| Coverage Duration | (PD): Indefinite |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

PART D VS EXCLUDED

Products Affected

- AURYXIA
- CRINONE
- IMVEXXY MAINTENANCE PACK
- IMVEXXY STARTER PACK
- INTRAROSA
- OSPHENA
- ZTLIDO

| PA Criteria | Criteria Details |
|------------------------------|-------------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Indefinite |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

PDE INHIBITOR AGENTS FOR PAH

Products Affected

- ADCIRCA
- ALYQ
- REVATIO ORAL
- *tadalafil (pah)*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Pulmonary Arterial Hypertension (PAH)(Initial): (1) Diagnosis of PAH WHO Group I with New York Heart Association (NYHA) Functional Class II to IV, (2) Diagnosis confirmed by catheterization (right-heart or Swan-Ganz) or echocardiography, (3) Mean pulmonary artery pressure greater than or equal to 25 mm Hg at rest or greater than 30 mm Hg with exertion, (4) inadequate response or inability to tolerate generic tadalafil (Applies to Brand Adcira only) |
| Age Restrictions | |
| Prescriber Restrictions | (PAH)(Initial): Prescribed by or in consultation with Cardiologist or Pulmonologist |
| Coverage Duration | (PAH)(Initial): 6 months (PAH)(Reauth): 12 months |
| Other Criteria | (PAH)(Reauth): (1) Stabilization or improvement as evaluated by a cardiologist or pulmonologist. |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

PRALUENT

Products Affected

- PRALUENT SUBCUTANEOUS SOLUTION AUTO-INJECTOR

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | <p>Hyperlipidemia (HLA) (Initial): (1) Diagnosis of hyperlipidemia, (2) ONE of the following: (A) LDL-C 70 mg/dL or greater after a minimum 8-week trial of at least moderate-intensity statin therapy OR (B) Inability to tolerate statin therapy as documented by one of the following: (i) member had rhabdomyolysis or symptoms with creatine kinase (CK) exceeding 10 times the upper limit of normal (ULN) or (ii) either of the following with TWO statins: myalgia (no CK elevation) or myositis (CK less than 10 times ULN or (iii) hepatotoxicity from statin use (increased AST/ALT exceeding 3 times ULN) or (iv) liver disease documented by Child Pugh A or worse OR AST/ALT exceeding 3 times ULN for at least 6 weeks</p> <p>Atherosclerotic cardiovascular disease (ASCVD) (Initial): (1) Diagnosis of atherosclerotic cardiovascular disease (ASCVD) as diagnosed by either stress test, angiography, atherosclerotic event (e.g. MI, angina, stroke, claudication, carotid stenosis) or arterial intervention for atherosclerotic disease (e.g. coronary, peripheral, carotid), (2) ONE of the following: (A) LDL-C 70 mg/dL or greater after a minimum 8-week trial of at least moderate-intensity statin therapy OR (B) Inability to tolerate statin therapy as documented by one of the following: (i) member had rhabdomyolysis or symptoms with creatine kinase (CK) exceeding 10 times the upper limit of normal (ULN) or (ii) either of the following with TWO statins: myalgia (no CK elevation) or myositis (CK less than 10 times ULN or (iii) hepatotoxicity from statin use (increased AST/ALT exceeding 3 times ULN) or (iv) liver disease documented by Child Pugh A or worse OR AST/ALT exceeding 3 times ULN for at least 6 weeks</p> |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | (Initial): 6 months (Continuation): 12 months |

| PA Criteria | Criteria Details |
|-----------------------|--|
| Other Criteria | <p>Homozygous Familial Hypercholesterolemia (HoFH)(Initial): (1) Diagnosis of HoFH. (2) One of the following: (a) Untreated LDL-C greater than 500 mg/dL or (b) Treated LDL-C greater than 300mg/dL. (3) Member is receiving other lipid-lowering therapy or inability to tolerate statin therapy as documented by one of the following: (a) member had rhabdomyolysis or symptoms with creatine kinase (CK) exceeding 10 times the upper limit of normal (ULN), or (b) either of the following with TWO statins: myalgia (no CK elevation) or myositis (CK less than 10 times ULN), or (c) hepatotoxicity from statin use (increased AST/ALT exceeding 3 times ULN), or (d) liver disease documented by Child Pugh A or worse OR AST/ALT exceeding 3 times ULN for at least 6 weeks. (4) Not used in combination with Juxtapid (lomitapide). (HLA, ASVCD)(CONTINUATION): (1) Positive Clinical response to therapy (e.g., reduction in LDL-C levels). (HoFH)(Continuation) (1) Positive Clinical response to therapy (e.g., reduction in LDL-C levels). (2) Member continues to receive other lipid-lowering therapy or inability to tolerate statin therapy as documented by one of the following: (a) member had rhabdomyolysis or symptoms with creatine kinase (CK) exceeding 10 times the upper limit of normal (ULN), or (b) either of the following with TWO statins: myalgia (no CK elevation) or myositis (CK less than 10 times ULN), or (c) hepatotoxicity from statin use (increased AST/ALT exceeding 3 times ULN), or (d) liver disease documented by Child Pugh A or worse OR AST/ALT exceeding 3 times ULN for at least 6 weeks (3) Not used in combination with Juxtapid (lomitapide).</p> |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

PREFERRED HEPATITIS C AGENTS

Products Affected

- EPCLUSA ORAL TABLET
- HARVONI ORAL PACKET
- HARVONI ORAL TABLET 90-400 MG
- *ledipasvir-sofosbuvir*
- MAVYRET ORAL TABLET
- *sofosbuvir-velpatasvir*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | (1) Documentation of patient's Hepatitis C Genotype. (2) Prescribed regimen is consistent with the current AASLD/IDSA guidance. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Duration will be applied consistent with AASLD/ IDSA guidance |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

PRETOMANID

Products Affected

- *pretomanid*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Multidrug Resistant Tuberculosis (MDRTB): (1) Diagnosis of pulmonary extensively drug resistant (XDR), treatment-intolerant or nonresponsive MDRTB. (2) Medication will be used as part of a combination regimen with bedaquiline (Sirturo) and linezolid. |
| Age Restrictions | (MDRTB): Member is 18 years of age or older |
| Prescriber Restrictions | |
| Coverage Duration | (MDRTB): 26 weeks |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

PROCYSBI

Products Affected

- PROCYSBI ORAL PACKET

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | (NC) (Initial, Reauth): Hypersensitivity to penicillamine |
| Required Medical Information | Nephrotic Cystinosis (NC) (Initial): (1) Diagnosis of nephrotic cystinosis, (2) inadequate response or titration from cysteamine bitartrate immediate-release capsules (Cystagon), (3) documentation of baseline WBC and alkaline phosphatase levels. |
| Age Restrictions | |
| Prescriber Restrictions | (NC)(Initial, Reauth): Prescribed by or in consultation with a nephrologist. |
| Coverage Duration | (NC) (Initial): 3 months. (NC) (Reauth): 6 months. |
| Other Criteria | (NCB)(REAUTH): The prescriber has evaluated all of the following since the initiation of treatment: (1) ONE of the following: (a) WBC cysteine level or (b) plasma cysteamine level, (2) WBC count, AND (3) alkaline phosphatase level. |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

PROLIA

Products Affected

- PROLIA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | <p>Part D is medically necessary for: Osteoporosis (OS) (Initial): (1) Diagnosis of osteoporosis. (2) ONE of the following: (a) T-score less than or equal to -2.5 (b) history of osteoporotic fracture (e.g., vertebral, hip, non-vertebral) or (c) multiple risk factors for fracture. (3) ONE of the following: (a) inadequate response or inability to tolerate at least one other osteoporosis medicine (e.g., oral bisphosphonates, calcitonin, estrogens, selective estrogen receptor modulator (SERMs)) or (b) severely deteriorated condition indicating that the osteoporosis is so significant that a trial of oral bisphosphonates is not medically warranted. Osteopenia (OPN) (Initial): (1) Diagnosis of osteopenia (T-score less than -1.0, but greater than -2.5). (2) One of the following: (a) Member is receiving adjuvant aromatase inhibitor therapy for breast cancer (b) member is receiving androgen deprivation therapy for non-metastatic prostate cancer. Prophylaxis of Postmenopausal Osteoporosis (PO) (Initial): (1) For prevention of postmenopausal osteoporosis. (2) BMD T score less than -1.0 and greater than -2.5. (3) Inadequate response or inability to tolerate an oral bisphosphonates or a selective estrogen receptor modulator (SERMs). Glucocorticoid Induced Osteoporosis (GCO)(Initial): (1) Diagnosis of CGO in men or women. (2) Daily dose of prednisone is greater than or equal to 5mg for at least 3 months. (3) Inadequate response or inability to tolerate ONE of the following: (a) bisphosphonates, (b) hormone replacement therapy, or (iii) selective-estrogen receptor modulators (SERMs).</p> |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | (PO, OS, OPN): Indefinite |
| Other Criteria | Subject to Part B vs Part D review. |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

PULMONARY FIBROSIS AGENTS

Products Affected

- ESBRIET
- OFEV

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Idiopathic Pulmonary Fibrosis (IPF): (1) Diagnosis of IPF confirmed by high resolution CT scan or biopsy. Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): (1) Diagnosis of SSc-ILD confirmed by a high resolution CT scan or biopsy. Chronic Fibrosing Interstitial Lung Disease (ILDs) with progressive phenotype (Initial): (1) Confirmed by high resolution CT scan (HRCT) showing at least 10% of lung volume with fibrotic features, (2) Disease has a progressive phenotype as observed by one of the following: (a) decline of forced vital capacity (FVC), (b) worsening of respiratory symptoms, (c) increased extent of fibrosis seen on imaging. |
| Age Restrictions | |
| Prescriber Restrictions | (IPF, SSc-ILD, ILDs): Prescribed by or in consultation a pulmonologist or lung transplant specialist. |
| Coverage Duration | (IPF, SSc-ILD, ILDs)(Initial, Reauth): 12 months |
| Other Criteria | (REAUTH) (IPF, ILDs, SSc-ILD): BOTH of the following (1) stabilization from baseline or a less than 10% decline in forced vital capacity AND (2) no elevations in AST or ALT greater than 5 times upper limit of normal or greater than 3 times upper limit of normal with signs or symptoms of severe liver damage |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

QBREXZA

Products Affected

- QBREXZA

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Hyperhidrosis: (1) Hyperhidrosis Disease Severity Scale grade 3 or 4 |
| Age Restrictions | (Hyperhidrosis): Member is 9 years of age or older |
| Prescriber Restrictions | (Hyperhidrosis): Prescribed by or in consultation with a dermatologist, primary care physician, internist, or pediatrician. |
| Coverage Duration | (Hyperhidrosis): Indefinite |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

QUALAQUIN

Products Affected

- QUALAQUIN
- *quinine sulfate oral*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Uncomplicated Malaria: (1) Diagnosis of uncomplicated malaria due to (a) plasmodium falciparum malaria or (b) plasmodium vivax . Babesiosis: (1) Diagnosis of babesiosis. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Babesiosis: 7 days Uncomplicated Malaria: 14 Days |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

RAVICTI

Products Affected

- RAVICTI

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | (UCD): Acute hyperammonemia. N-acetylglutamate synthase (NAGS) deficiency |
| Required Medical Information | Urea Cycle Disorder (UCD): (1) Diagnosis of urea cycle disorder involving deficiencies of carbamoyl phosphate synthetase (CPS), ornithine transcarbamoylase (OTC), or argininosuccinic acid synthetase (AAS) confirmed via enzymatic, biochemical, or genetic testing. (2) Inadequate response or inability to tolerate sodium phenylbutyrate. |
| Age Restrictions | (UCD): Member is 2 months of age or older |
| Prescriber Restrictions | |
| Coverage Duration | (UCD): Remainder of contract year |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

REPATHA

Products Affected

- REPATHA
- REPATHA PUSHTRONEX SYSTEM
- REPATHA SURECLICK

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Hyperlipidemia (HLA) (Initial): (1) Diagnosis of hyperlipidemia. Homozygous Familial Hypercholesterolemia (HoH)(Initial): (1) Diagnosis of HoH. Atherosclerotic cardiovascular disease (ASCVD)(Initial): (1) Diagnosis of ASCVD confirmed by either stress test, angiography, atherosclerotic event (e.g. MI, angina, stroke, claudication, carotid stenosis) or arterial intervention for atherosclerotic disease (e.g. coronary, peripheral, carotid). (All Indications) (Initial): ONE of the following: (A) LDL-C 70 mg/dL or greater after a minimum 8-week trial of at least moderate-intensity statin therapy OR (B) Inability to tolerate statin therapy as documented by one of the following: (i) member had rhabdomyolysis or symptoms with creatine kinase (CK) exceeding 10 times the upper limit of normal (ULN) or (ii) either of the following with TWO statins: myalgia (no CK elevation) or myositis (CK less than 10 times ULN or (iii) hepatotoxicity from statin use (increased AST/ALT exceeding 3 times ULN) or (iv) liver disease documented by Child Pugh A or worse OR AST/ALT exceeding 3 times ULN for at least 6 weeks. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | (All Indications)(Initial): 6 months. (All Indications)(Continuation): 12 months. |
| Other Criteria | (HLA, HoH, ASCVD): CONTINUATION OF REPATHA: (1) Positive Clinical response to therapy (e.g., reduction in LDL-C levels). |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

RESPIRATORY ENZYMES

Products Affected

- ARALAST NP INTRAVENOUS SOLUTION RECONSTITUTED 1000 MG
- GLASSIA
- PROLASTIN-C INTRAVENOUS SOLUTION
- RECONSTITUTED ZEMAIRA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | (ATT): (1) IgA deficiency with known anti-IgA antibody. |
| Required Medical Information | Part D is medically necessary when ALL of the following are met: Congenital Alpha-1 Antitrypsin Deficiency (ATT): (1) Diagnosis of congenital alpha1-antitrypsin deficiency confirmed by one of the following: (a) PiZZ, PiZ(null) or Pi(null)(null) protein phenotypes (homozygous) or (b) Other rare AAT disease-causing alleles associated with serum alpha1-antitrypsin (AAT) level less than 11?mol/L. (2) Low serum concentration of alpha-1 antitrypsin defined as less than 35 percent of normal (less than 80 mg/dL or less than 11 uM/L or less than 0.8 g/L). (2) the member has progressive panacinar emphysema with a documented rate of decline in forced expiratory volume in 1 second (FEV 1) |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | (ATT): Indefinite |
| Other Criteria | Subject to Part B vs Part D review. |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

RINVOQ

Products Affected

- RINVOQ

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | (RA): Concurrent use with any other biologic disease modifying anti-rheumatic drug (DMARD), other JAK inhibitors, or potent immunosuppressants. |
| Required Medical Information | Rheumatoid Arthritis (RA): (1) Diagnosis of moderate to severely active RA. (2) Member has inadequate response or inability to tolerate methotrexate. |
| Age Restrictions | (RA): Member is 18 years of age or older |
| Prescriber Restrictions | (RA): Prescribed by or in consultation with a rheumatologist |
| Coverage Duration | (RA): Indefinite |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

RUZURGI

Products Affected

- RUZURGI

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Lambert-Eaton Myasthenic Syndrome (LES)(Initial): (1) Neurological symptoms persist after treatment of malignancy, when malignancy is present. |
| Age Restrictions | (LES)(Initial, Continuation): Member is 6 to less than 17 years of age |
| Prescriber Restrictions | (LES)(Initial, Continuation): Prescribed by or in consultation with a neurologist |
| Coverage Duration | (LES)(Initial): 90 days. (LES)(Continuation): Indefinite |
| Other Criteria | (LES)(CONTINUATION): Positive clinical response to therapy. |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

SAMSCA

Products Affected

- SAMSCA
- *tolvaptan*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Hyponatremia: (1) patients who are unable to sense or appropriately respond to thirst, hypovolemic hyponatremia, (2) concomitant use of strong CYP3A inhibitors |
| Required Medical Information | Hyponatremia: (1) Diagnosis of clinically significant hypervolemic or euvolemic hyponatremia. |
| Age Restrictions | Hyponatremia: Member is 18 years of age or older. |
| Prescriber Restrictions | Hyponatremia: Prescribed by or in consultation with a cardiologist, endocrinologist or nephrologist |
| Coverage Duration | Hyponatremia: Indefinite |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

SEROSTIM

Products Affected

- SEROSTIM SUBCUTANEOUS SOLUTION
RECONSTITUTED 4 MG, 5 MG, 6 MG

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Wasting or Cachexia Associated with HIV (WC-HIV): (1) Diagnosis of wasting or cachexia associated with HIV. |
| Age Restrictions | |
| Prescriber Restrictions | (WC-HIV): Prescribed by or in consultation with a HIV specialist or infectious disease specialist |
| Coverage Duration | (WC-HIV): 48 weeks |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

SIGNIFOR

Products Affected

- SIGNIFOR

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Cushing's disease (CD): (1) Diagnosis of (pituitary) Cushing's disease. (2) Pituitary surgery is not an option or has not been curative |
| Age Restrictions | (CD): Member is 18 years of age or older |
| Prescriber Restrictions | (CD): Prescribed by or in consultation with an endocrinologist |
| Coverage Duration | (CD): Remainder of contract year |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

SILDENAFIL

Products Affected

- *sildenafil citrate oral suspension reconstituted*
- *sildenafil citrate oral tablet 20 mg*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | (PAH, RP): Documentation of concomitant nitrate use |
| Required Medical Information | Pulmonary Arterial Hypertension (PAH): (1) Diagnosis of PAH WHO Group I with New York Heart Association (NYHA) Functional Class II to IV (2) Diagnosis confirmed by catheterization (right-heart or Swan-Ganz) or echocardiography (3) Mean pulmonary artery pressure greater than or equal 25 mm Hg at rest or greater than 30 mm Hg with exertion. Raynaud's Phenomenon (RP): (1) Diagnosis of secondary Raynaud's phenomenon. (2) Inadequate response or inability to tolerate a calcium channel blocker. |
| Age Restrictions | |
| Prescriber Restrictions | (PAH, RP): Prescribed by or in consultation with a Cardiologist or Pulmonologist |
| Coverage Duration | (PAH, RP): Indefinite |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

SILIQ

Products Affected

- SILIQ

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | (PsO)(Initial, Reauth): Concurrent therapy with biological DMARDs or other tumor necrosis factor antagonists |
| Required Medical Information | Plaque psoriasis (PsO)(Initial): (1) Diagnosis of moderate to severe PsO. (2) Inadequate response or inability to tolerate TWO of the following: (a) adalimumab (Humira), (b) etanercept (Enbrel), (c) Skyrizi OR documentation demonstrating that a trial may be inappropriate. (3) Member has been evaluated for depression and suicidal ideations using the PHQ-9. |
| Age Restrictions | (PsO)(Initial, Reauth): Member is 18 years of age or older |
| Prescriber Restrictions | (PsO)(Initial, Reauth): Prescribed by or in consultation with a dermatologist |
| Coverage Duration | (PsO) (Initial): 16 weeks (PsO) (Reauth) 1 year |
| Other Criteria | (PsO) (Reauth): (1) Member has positive response to therapy, (2) Member has been evaluated for depression and suicidal ideations using the PHQ-9 |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

SIMPONI

Products Affected

- SIMPONI SUBCUTANEOUS SOLUTION AUTO-INJECTOR
- SIMPONI SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | (AS, PsA, RA, UC): Concurrent therapy with any other biologic disease modifying anti-rheumatic drug (DMARD), e.g. tumor necrosis factor antagonists |
| Required Medical Information | Ankylosing Spondylitis (AS): (1) Diagnosis of AS. (2) Inadequate response or inability to tolerate to both adalimumab (Humira) AND etanercept (Enbrel) or documentation demonstrating that a trial may be inappropriate. Psoriatic Arthritis (PsA): (1) Diagnosis of moderate to severe PsA. (2) Inadequate response or inability to tolerate to TWO of the following: (a) Humira, (b) Enbrel, (c) Xeljanz/Xeljanz XR OR documentation demonstrating that a trial may be inappropriate. Rheumatoid arthritis (RA): (1) Diagnosis of moderate to severe RA. (2) Inadequate response or inability to tolerate to TWO of the following: (a) Humira, (b) Enbrel, (c) Rinvoq, (d) Xeljanz/Xeljanz XR OR documentation demonstrating that a trial may be inappropriate. Ulcerative Colitis (UC): (1) Diagnosis of moderate to severe UC. (2) Inadequate response or inability to tolerate BOTH Humira and Xeljanz/Xeljanz XR OR documentation demonstrating that a trial may be inappropriate. |
| Age Restrictions | (AS, PsA, RA, UC): Member is 18 years of age or older |
| Prescriber Restrictions | (RA, AS): Prescribed by or in consultation with a rheumatologist. (PsA): Prescribed by or in consultation with a rheumatologist or dermatologist. (UC): Prescribed by or in consultation with a gastroenterologist. |
| Coverage Duration | (AS, PsA, RA, UC): Indefinite |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

SIRTURO

Products Affected

- SIRTURO

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB): (1) Diagnosis of MDR-TB. (2) Member weighs at least 15kg (applies to members 5 to less than 18 years of age). (3) One of the following: (a) Medication will be used in combination with at least 3 other drugs to which the patient's MDR-TB isolate has been shown to be susceptible in vitro OR (b) If in vitro testing results are unavailable, treatment will be initiated in combination with at least 4 other drugs to which the patient's MDR-TB isolate is likely to be susceptible. (4) Sirturo (bedaquiline) will be administered by directly observed therapy (DOT). |
| Age Restrictions | (MDR-TB): Member is 5 years of age or older. |
| Prescriber Restrictions | (MDR-TB): Prescribed by or in consultation with infectious disease specialist or pulmonologist |
| Coverage Duration | (MDR-TB): 24 weeks |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

SKYRIZI

Products Affected

- SKYRIZI
- SKYRIZI (150 MG DOSE)
- SKYRIZI PEN

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | (PsO): Concurrent therapy with biological DMARDs or other tumor necrosis factor antagonists |
| Required Medical Information | Plaque psoriasis (PsO): (1) Diagnosis of moderate to severe PsO. (2) Inadequate response or inability to tolerate ONE of the following drugs: topical calcipotriene containing products, topical anthralin, topical steroids, topical immunomodulators (Elidel, Protopic), topical retinoids. |
| Age Restrictions | (PsO): Member is 18 years of age or older |
| Prescriber Restrictions | (PsO): Prescribed by or in consultation a dermatologist |
| Coverage Duration | (PsO): Indefinite |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

STELARA

Products Affected

- STELARA SUBCUTANEOUS SOLUTION 45 MG/0.5ML
- STELARA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Part D is medically necessary when: Plaque psoriasis (PsO): (1) Diagnosis of moderate to severe PsO. (2) One of the following: (A) For members 6 to 17 years of age: Inadequate response or inability to tolerate etanercept (Enbrel) or documentation demonstrating that a trial may be inappropriate, OR (B) For members 18 years of age and older: inadequate response or inability to tolerate to BOTH of the following: (a) ONE of the following: (i) Humira, (ii) Enbrel, or (iii) Skyrizi AND (b) Cosentyx OR documentation demonstrating that a trial may be inappropriate. Psoriatic arthritis (PsA): (1) Diagnosis of PsA. (2) Inadequate response or inability to tolerate to both adalimumab (Humira) AND etanercept (Enbrel) or documentation demonstrating that a trial may be inappropriate. Crohn's Disease (CD): (1) Diagnosis of moderate to severe CD. (2) Inadequate response or inability to tolerate adalimumab (Humira) or documentation demonstrating that a trial may be inappropriate. Ulcerative Colitis (UC): (1) Diagnosis of moderate to severe UC. (2) Inadequate response or inability to tolerate BOTH of the following: adalimumab (Humira) and Xeljanz/Xeljanz XR or documentation demonstrating that a trial may be inappropriate. |
| Age Restrictions | (CD, UC, PsA): Member is 18 years of age or older. (PsO): Member is 6 years of age or older. |
| Prescriber Restrictions | (CD, UC): prescribed by or in consultation with a Gastroenterologist. (PsO): prescribed by or in consultation with a Dermatologist. (PsA): prescribed by or in consultation with a Dermatologist or Rheumatologist |
| Coverage Duration | (PsO, PsA, CD, UC): Indefinite |
| Other Criteria | Subject to Part B vs Part D review. |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

SUNOSI

Products Affected

- SUNOSI

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | NARCOLEPSY: (1) Confirmed by Polysomnography (PSG) or Multiple sleep latency test (MSLT), (2) Inadequate response or inability to tolerate modafinil or armodafinil. OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME (OSAHS): (1) Diagnosis confirmed by a sleep study (unless prescriber provides justification confirming that a sleep study is not feasible), (2) documentation that the medication is being used as an adjunct treatment for the underlying obstruction, (3) inadequate response or inability to tolerate modafinil or armodafinil. |
| Age Restrictions | |
| Prescriber Restrictions | (Narcolepsy, OSAHS): Prescribed by or in consultation with a neurologist or sleep specialist |
| Coverage Duration | (Narcolepsy, OSAHS):Indefinite |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

SYMDEKO

Products Affected

- SYMDEKO

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Cystic Fibrosis (CF): (1) Diagnosis of Cystic Fibrosis. (2) One of the following: a) Member is homozygous for the F508del mutation, or b) Member has at least one tezacaftor/ivacaftor responsive mutation in the CFTR gene. (3) If the patient's genotype is unknown, an FDA-cleared test must be used to detect the presence of CFTR mutation followed by verification with bi-directional sequencing when recommended by the mutation test |
| Age Restrictions | (CF): Member is 6 years of age or older |
| Prescriber Restrictions | (CF): Prescribed by or in consultation with a pulmonologist |
| Coverage Duration | (CF): Indefinite |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

SYMLIN

Products Affected

- SYMLINPEN 120 SUBCUTANEOUS SOLUTION
PEN-INJECTOR
- SYMLINPEN 60 SUBCUTANEOUS SOLUTION
PEN-INJECTOR

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | (DM): Gastroparesis. |
| Required Medical Information | Diabetes Mellitus (DM): (1) Diagnosis of diabetes (Type 1 or Type 2). (2) inadequate response to optimal insulin monotherapy. (3) concurrent use of mealtime insulin. |
| Age Restrictions | (DM): Member is 18 years of age or older |
| Prescriber Restrictions | |
| Coverage Duration | (DM): Indefinite |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

TAFAMIDIS

Products Affected

- VYNDAMAX
- VYNDAQEL

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM)(Initial): (1) Diagnosis of ATTR-CM confirmed by one of the following: (a) patient has a transthyretin (TTR) mutation (e.g., V122I), (b) cardiac or noncardiac tissue biopsy demonstrating histologic confirmation of TTR amyloid deposits, or (c) all of the following: echocardiogram or cardiac magnetic resonance image suggestive of amyloidosis, scintigraphy scan suggestive of cardiac TTR amyloidosis, and absence of light-chain amyloidosis, (2) One of the following: (a) History of heart failure (HF), with at least one prior hospitalization for HF, or (b) presence of clinical signs and symptoms of HF (e.g., dyspnea, edema), (c) Patient has New York Heart Association (NYHA) Functional Class I, II, or III heart failure |
| Age Restrictions | (ATTR-CM) (Initial, Reauth): Member is 18 years of age or older |
| Prescriber Restrictions | (ATTR-CM) (Initial, Reauth): Prescribed by or in consultation with a cardiologist |
| Coverage Duration | (ATTR-CM) (Initial, Reauth): 12 months |
| Other Criteria | (ATTR-CM)(Reauth): (1) Positive clinical response to therapy, (2) Patient continues to have NYHA Functional Class I, II, or III heart failure. |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

TAKHZYRO

Products Affected

- TAKHZYRO

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Part D is medically necessary when: Hereditary Angioedema (HAE): (1) Diagnosis of HAE. (2) For prophylaxis against HAE attacks. |
| Age Restrictions | |
| Prescriber Restrictions | (HAE): Prescribed by or in consultation with an allergist or immunologist |
| Coverage Duration | (HAE): Indefinite |
| Other Criteria | Subject to Part B vs Part D review. |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

TALTZ

Products Affected

- TALTZ

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | (PsO, PsA, AS, nr-axSpA): Concurrent therapy with biological DMARDs or other tumor necrosis factor antagonists |
| Required Medical Information | Plaque Psoriasis (PsO): (1) Diagnosis of moderate to severe PsO. (2) ONE of the following: (A) For members 6 to 17 years of age: an inadequate response or inability to tolerate Enbrel or documentation demonstrating that a trial may be inappropriate, OR (B) For members 18 years of age or older: an inadequate response or inability to tolerate Cosentyx or documentation demonstrating that a trial may be inappropriate. Psoriatic arthritis (PsA): (1) Diagnosis of PsA. (2) Inadequate response or inability to tolerate Cosentyx OR documentation demonstrating that a trial may be inappropriate. Ankylosing spondylitis (AS): (1) Diagnosis of AS. (2) Inadequate response or inability to tolerate Cosentyx OR documentation demonstrating that a trial may be inappropriate. Non-Radiographic Axial Spondyloarthritis (nr-axSpA): (1) Diagnosis of nr-axSpA. (2) Inadequate response or inability to tolerate Cosentyx OR documentation demonstrating that a trial may be inappropriate. |
| Age Restrictions | (PsA, AS, nr-axSpA): Member is 18 years of age or older. (PsO): Member is 6 years of age or older. |
| Prescriber Restrictions | (PsO): Prescribed by or in consultation with a dermatologist. (PsA): Prescribed by or in consultation with a dermatologist or rheumatologist. (AS, nr-axSpA): Prescribed by or in consultation with a rheumatologist. |
| Coverage Duration | (PsO, PsA, AS, nr-axSpA): Indefinite |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

TAVALISSE

Products Affected

- TAVALISSE

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Chronic Immune Thrombocytopenia (ITP)(Initial): (1) Documentation of baseline platelet count less than 30,000/mcL, (2) Inadequate response or inability to tolerate ONE of the following: (a) Corticosteroids, (b) Immunoglobulins, (c) Splenectomy, (d) Thrombopoietin receptor agonists (e.g., Nplate, Promacta), or (e) rituximab (Rituxan). |
| Age Restrictions | (ITP)(Initial, Continuation): Member is 18 years of age or older |
| Prescriber Restrictions | (ITP)(Initial, Continuation): Prescribed by or in consultation with hematologist/oncologist |
| Coverage Duration | (ITP)(Initial, Continuation): 12 months |
| Other Criteria | (ITP)(Continuation): (1) Positive clinical response to Tavalisse therapy as evidenced by an increase in platelet count to a level sufficient to avoid clinically important bleeding. |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

TEGSEDI

Products Affected

- TEGSEDI

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis)(Initial): (1) Diagnosis of hATTR amyloidosis with polyneuropathy confirmed by molecular genetic testing that reveals pathogenic variation(s) in the TTR gene (e.g. variation of V30M). (2) ONE of the following baseline ambulation parameters in either the Familial Amyloid Polyneuropathy (FAP) Stage or Polyneuropathy Disability (PND) Score (a) Stage 1 (unimpaired ambulation) or 2 (assisted ambulation) on the Familial Amyloid Polyneuropathy (FAP) staging tool, or (b) Score I, II, IIIa, or IIIb on the Polyneuropathy Disability (PND) scoring tool. (3) Documented presence of cardiac or renal manifestations, or motor, sensory, or autonomic neuropathy related to the hATTR amyloidosis with polyneuropathy (e.g., neuropathic pain, muscle weakness that affects daily living, orthostatic hypotension, diarrhea, nausea, vomiting, heart failure, arrhythmias, proteinuria, renal failure, vision disorders, such as vitreous opacity, dry eyes, glaucoma, or pupils with an irregular or scalloped appearance) |
| Age Restrictions | |
| Prescriber Restrictions | (hATTR Amyloidosis)(Initial, Continuation): Prescribed by or in consultation with a neurologist |
| Coverage Duration | (hATTR Amyloidosis)(Initial): 16 months. (hATTR Amyloidosis)(Continuation): Indefinite |
| Other Criteria | (hATTR Amyloidosis)(Continuation): (1) Documented improvement or stability in the signs and symptoms hATTR amyloidosis with polyneuropathy (e.g., neuropathic pain, muscle weakness that affects daily living, orthostatic hypotension, diarrhea, nausea, vomiting, heart failure, arrhythmias, proteinuria, renal failure, vision disorders, such as vitreous opacity, dry eyes, glaucoma, or pupils with an irregular or scalloped appearance), based on objective or standard evaluation scales, and (2) ONE of the following: (a) Stage 1 (unimpaired ambulation) or 2 (assisted ambulation) on the Familial Amyloid Polyneuropathy (FAP) staging tool, or (b) Score I, II, IIIa, or IIIb on the Polyneuropathy Disability (PND) scoring tool |

| PA Criteria | Criteria Details |
|-----------------------|-------------------------------------|
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

TERIPARATIDE

Products Affected

- FORTEO SUBCUTANEOUS SOLUTION PEN-INJECTOR 620 MCG/2.48ML
- *teriparatide (recombinant)*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | <p>Primary or Hypogonadal Osteoporosis (HGO)(Initial): (1) Diagnosis of HGO in men. (2) Member has severe osteoporosis or is at a high to very high risk for fracture as defined by ONE of the following: (a) Member has a history of multiple vertebral fractures, (b) T-score of the individual's bone mineral density (BMD) is at least -2.5 standard deviations below the young adult mean OR (c) history of osteoporotic fracture (i.e. hip, spine, etc.). (3) Inadequate response or inability to tolerate (a) bisphosphonates or (b) hormone replacement therapy. Postmenopausal Osteoporosis (PMO) (Initial): (1) Diagnosis of PMO. (2) Member has severe osteoporosis or is at a high to very high risk for fracture as defined by ONE of the following: (a) Member has a history of multiple vertebral fractures, (b) T score of the individual's bone mineral density (BMD) is at least -2.5 standard deviations below the young adult mean OR (c) history of osteoporotic fracture (i.e. hip, spine, etc.). (3) Inadequate response or inability to tolerate ONE of the following: (a) bisphosphonates, (b) hormone replacement therapy, (c) selective-estrogen receptor modulators (SERMs), OR (d) Denosumab (Prolia). Glucocorticoid Induced Osteoporosis (GCO)(Initial): (1) Diagnosis of CGO in men or women. (2) Daily dose of prednisone is greater than or equal to 5mg for at least 3 months. (3) Inadequate response or inability to tolerate ONE of the following: (a) bisphosphonates, (b) hormone replacement therapy, (iii) selective-estrogen receptor modulators (SERMs), or (c) Denosumab (Prolia).</p> |
| Age Restrictions | (HGO, PMO, GCO) (Initial and Reauth): Member is 18 years of age or older |
| Prescriber Restrictions | |
| Coverage Duration | (HGO, PMO, GCO) (Initial and Reauth): Remainder of contract year |
| Other Criteria | (HGO, PMO, GCO) (Reauth): One of the following: (1) Cumulative lifetime therapy does not exceed 2 years [applies to Teriparatide and Forteo], OR (2) member remains at or has returned to having a high risk for fracture despite a total of 24 months of use of parathyroid hormones [applies to Forteo only]. |

| PA Criteria | Criteria Details |
|-----------------------|-------------------------------------|
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

TESTOSTERONE PRODUCTS

Products Affected

- AVEED
- DEPO-TESTOSTERONE INTRAMUSCULAR SOLUTION
- JATENZO
- *testosterone cypionate intramuscular solution 100 mg/ml, 200 mg/ml*
- *testosterone enanthate intramuscular solution*
- *testosterone transdermal gel 10 mg/act (2%), 12.5 mg/act (1%), 20.25 mg/1.25gm (1.62%), 20.25 mg/act (1.62%), 25 mg/2.5gm (1%), 40.5 mg/2.5gm (1.62%), 50 mg/5gm (1%)*
- *testosterone transdermal solution*
- XYOSTED

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Delayed Puberty (DP): (1) Diagnosis of delayed puberty in male patients (Applies to Testosterone Enanthate only). Breast Cancer (BC): (1) Diagnosis of inoperable breast cancer in female patients (Applies to Testosterone Enanthate only). Hypogonadism (HG)(New starts only): (1) Attestation that diagnosis was initially confirmed by ALL of the following: (A) Two early morning total testosterone levels below 300 ng/dL measured on separate occasions, (B) Normal Prolactin Level, and (C) Physical or cognitive symptoms of testosterone deficiency (e.g. physical: fatigue, sleep disturbances, decreased activity, cognitive: depressive symptoms, cognitive dysfunction, loss of concentration, poor memory, irritability), (2) ONE of the following (A) negative history of prostate and breast cancer OR (B) Both of the following (i) history of prostate cancer with stable PSA less than or equal to 4ng/dL for 2 years and (ii) documentation that the risk versus benefit has been assessed. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | (DP, BC): Indefinite (HG)(New Starts, Continuation): Indefinite |
| Other Criteria | (HG)(Continuation): ONE of the following (1) negative history of prostate and breast cancer OR (2) Both of the following (a) history of prostate cancer with stable PSA less than or equal to 4ng/dL for 2 years and (b) documentation that the risk versus benefit has been assessed. |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

TOPICAL CHEMO AGENTS

Products Affected

- TARGRETIN

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Approved when ANY of the following inclusion criteria is met: (1) Drug is FDA approved for indication and regimen requested, (2) The indication and regimen is classified as Category 1 or 2A by National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium, (3) narrative text in The American Hospital Formulary Service-Drug Information (AHFS-DI) or Clinical Pharmacology Compendium is supportive for the specific condition(s) requested, (4) The Micromedex Compendium and the strength of recommendation is listed as Class I, Class IIa, or Class IIb for the specific condition(s) requested, (5) Indication is listed in Lexi-Drugs as "off label" with evidence level A, (6) supported by Peer-Reviewed Medical Literature as defined in Chapter 15 Section 50.4.5 of the Medicare Benefit Policy Manual, (7) Documentation of continuous therapy with the medication requested. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Indefinite |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

TOPICAL RETINOID PRODUCTS

Products Affected

- *adapalene external cream*
- *adapalene external gel*
- *adapalene external pad*
- *adapalene external solution*
- *adapalene-benzoyl peroxide external gel*
- AKLIEF
- ALTRENO
- ATRALIN
- AVITA
- *clindamycin-tretinoin*
- DIFFERIN EXTERNAL CREAM
- DIFFERIN EXTERNAL GEL 0.3 %
- DIFFERIN EXTERNAL LOTION
- EPIDUO
- EPIDUO FORTE
- RETIN-A
- RETIN-A MICRO
- RETIN-A MICRO PUMP EXTERNAL GEL 0.06 %, 0.08 %
- *tretinoin external*
- *tretinoin microsphere*
- VELTIN
- ZIANA

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------------|
| Exclusion Criteria | Cosmetic use |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Remainder of contract year |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

TREMFYA

Products Affected

- TREMFYA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | (PsO, PsA): Concurrent therapy with biological DMARDs or other tumor necrosis factor antagonists |
| Required Medical Information | Plaque psoriasis (PsO): (1) Diagnosis or moderate to severe PsO. (2) Inadequate response or inability to tolerate Cosentyx OR documentation demonstrating that a trial may be inappropriate. Psoriatic arthritis (PsA): (1) Diagnosis of PsA, (2) Inadequate response or inability to tolerate Cosentyx or documentation demonstrating that a trial may be inappropriate. |
| Age Restrictions | (PsO, PsA): Member is 18 years of age or older |
| Prescriber Restrictions | (PsO): Prescribed by or in consultation with a dermatologist. (PsA): Prescribed by or in consultation with a rheumatologist. |
| Coverage Duration | (PsO, PsA): Indefinite |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

TRIKAFTA

Products Affected

- TRIKAFTA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Cystic Fibrosis (CF): (1) Member has at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene as detected by a FDA-cleared cystic fibrosis mutation test OR a mutation in the CFTR gene that is responsive based on in vitro data. |
| Age Restrictions | (CF): Member is 6 years of age or older |
| Prescriber Restrictions | (CF): Prescribed by or in consultation with a pulmonologist |
| Coverage Duration | (CF): Indefinite |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

TYMLOS

Products Affected

- TYMLOS

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Postmenopausal Osteoporosis (PMO) (Initial): (1) Diagnosis of PMO. (2) Member has severe osteoporosis or is at a high to very high risk for fracture as defined by ONE of the following: (a) Member has a history of multiple vertebral fractures, (b) T score of the individual's bone mineral density (BMD) is at least -2.5 standard deviations below the young adult mean OR (c) history of osteoporotic fracture (i.e. hip, spine, etc.). (3) Inadequate response or inability to tolerate ONE of the following: (a) bisphosphonates, (b) hormone replacement therapy, (c) selective-estrogen receptor modulators (SERMs), OR (d) Denosumab (Prolia). |
| Age Restrictions | (PMO) (Initial and Reauth): Member is 18 years of age or older |
| Prescriber Restrictions | |
| Coverage Duration | (PMO) (Initial and Reauth): Remainder of contract year |
| Other Criteria | (PMO)(Reauth): Cumulative lifetime therapy does not exceed 2 years |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

UPTRAVI

Products Affected

- UPTRAVI ORAL

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | (PAH)(Initial, Reauth): Not taken in combination with a prostanoid/prostacyclin analogue (e.g. epoprostenol, iloprost, treprostinil) |
| Required Medical Information | Pulmonary Arterial Hypertension (PAH)(Initial): (1) Diagnosis of pulmonary arterial hypertension (PAH) WHO Group I with New York Heart Association (NYHA) Functional Class II to IV AND (2) Diagnosis confirmed by catheterization (right-heart or Swan-Ganz) or echocardiography AND (3) Documentation of mean pulmonary artery pressure greater than or equal to 25 mm Hg at rest or greater than 30 mm Hg with exertion AND (4) inadequate response or inability to tolerate TWO of the following (a) an endothelin receptor antagonist (Tracleer if naive to the class) (b) a phosphodiesterase inhibitor (sildenafil if naive to the class) (c) riociguat (Adempas). |
| Age Restrictions | |
| Prescriber Restrictions | (PAH)(Initial): Prescribed by or in consultation with a Cardiologist or Pulmonologist |
| Coverage Duration | (PAH)(Initial): 6 month. (PAH) (Reauth): 12 months. |
| Other Criteria | (PAH)(REAUTH): Stabilization or improvement as evaluated by a cardiologist or pulmonologist. |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

VALCHLOR

Products Affected

- VALCHLOR

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Mycosis Fungoides-Type Cutaneous T-Cell Lymphoma (MFTCL): One of the following: (1) (a) Diagnosis of Stage 1A and 1B mycosis fungoides-type cutaneous T-cell lymphoma. (b) Patient has received prior skin-directed therapy. |
| Age Restrictions | |
| Prescriber Restrictions | (MFTCL): Prescribed by or in consultation with an Oncologist or Dermatologist |
| Coverage Duration | (MFTCL): 12 months |
| Other Criteria | (All Indications): Approve if for continuation of therapy. |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

VECAMEYL

Products Affected

- VECAMEYL

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | (EHTN, MHTN): Uremia, glaucoma, organic pyloric stenosis, coronary insufficiency, recent myocardial infarction |
| Required Medical Information | Essential Hypertension (EHTN): (1) Diagnosis of moderately severe to severe essential hypertension or malignant hypertension, (2) an inadequate response or inability to tolerate at least two antihypertensive medications in different classes. Malignant Hypertension (MHTN): (1) Diagnosis of malignant hypertension, (2) An inadequate response or inability to tolerate at least two antihypertensive medications in different classes. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | (EHTN, MHTN): Indefinite |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

VERQUVO

Products Affected

- VERQUVO

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Heart Failure (HF): (1) Diagnosis of chronic heart failure. (2) Member has an ejection fraction of less than 45 percent. (3) Member has New York Heart Association (NYHA) Class II, III or IV symptoms. (4) One of the following: (a) member was hospitalized for heart failure within the last 6 months, or (b) member used outpatient intravenous diuretics (e.g., bumetanide, furosemide) for heart failure within the last 3 months. (5) Inadequate response or inability to tolerate BOTH of the following at a maximally tolerated dose: (a) One of the following: (i) ACE inhibitor (e.g., captopril, enalapril), (ii) ARB (e.g., candesartan, valsartan), (iii) ARNI (e.g., Entresto (sacubitril and valsartan), AND (b) beta blocker (e.g., bisoprolol, carvedilol) |
| Age Restrictions | |
| Prescriber Restrictions | (HF): prescribed by or in consultation with a cardiologist |
| Coverage Duration | Indefinite |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

VYVANSE

Products Affected

- VYVANSE

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Attention Deficit Hyperactivity Disorder (ADHD): (1) Diagnosis of ADHD (2) inadequate response or inability to tolerate one of the following: immediate release formulations of amphetamine, dextroamphetamine, or methylphenidate Binge Eating Disorder (BED): (1)Diagnosis of BED. (2) Member has BED for 3 months or longer. |
| Age Restrictions | (ADHD, BED): PA applies to members 19 years of age or older |
| Prescriber Restrictions | |
| Coverage Duration | (ADHD, BED): Indefinite |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

WAKIX

Products Affected

- WAKIX

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Narcolepsy: (1) Diagnosis of narcolepsy. (2) Both of the following: (A) Confirmed by Polysomnography (PSG) or Multiple sleep latency test (MSLT), and (B) Inadequate response or inability to tolerate modafinil or armodafinil. |
| Age Restrictions | |
| Prescriber Restrictions | (Narcolepsy): Prescribed by a neurologist or sleep specialist |
| Coverage Duration | (Narcolepsy): Indefinite |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

XELJANZ

Products Affected

- XELJANZ
- XELJANZ XR

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | (RA, PsA, UC, PJIA): Concurrent therapy with any other biologic disease modifying anti-rheumatic drug (DMARD), e.g. tumor necrosis factor antagonists or potent immunosuppressants such as azathioprine or cyclosporine |
| Required Medical Information | Rheumatoid arthritis (RA) [applies to Xeljanz/Xeljanz XR tablets]: (1) Diagnosis of moderate to severe RA. (2) Inadequate response or inability to tolerate one of the following: methotrexate, hydroxychloroquine, leflunomide, azathioprine, sulfasalazine. Psoriatic Arthritis (PsA) [applies to Xeljanz/Xeljanz XR tablets]: (1) Diagnosis of PsA. (2) Inadequate response or inability to tolerate adalimumab (Humira) OR etanercept (Enbrel) or documentation demonstrating that a trial may be inappropriate. Ulcerative Colitis (UC) [applies to Xeljanz/Xeljanz XR tablets]: (1) Diagnosis of moderate to severe UC. (2) Inadequate response or inability to tolerate adalimumab (Humira) or documentation demonstrating that a trial may be inappropriate. Polyarticular Juvenile Idiopathic Arthritis (PJIA) [applies to Xeljanz tablets/oral solution]: (1) Diagnosis of PJIA, (2) Inadequate response or inability to tolerate adalimumab (Humira) or etanercept (Enbrel) OR documentation demonstrating that a trial may be inappropriate. |
| Age Restrictions | (RA, PsA, UC): Member is 18 years of age or older. (PJIA): Member is 2 years of age or older. |
| Prescriber Restrictions | (RA, PJIA): Prescribed by or in consultation with a rheumatologist. (PsA): Prescribed by or in consultation with a dermatologist or rheumatologist. (UC): Prescribed by or in consultation with a gastroenterologist. |
| Coverage Duration | Indefinite |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

XENAZINE/AUSTEDO

Products Affected

- AUSTEDO
- *tetrabenazine*
- XENAZINE

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Tardive Dyskinesia (TD)(Initial): (1) Diagnosis of TD, (2) Documentation is provided of ONE of the following: (a) Persistent symptoms of tardive dyskinesia despite a trial of dose reduction, tapering or discontinuation of the offending medication, or (b) Member is not a candidate for a trial of dose reduction, tapering, or discontinuation of the offending medication. Tourette's Syndrome (TS): (1) Diagnosis of TS, (2) Patient has tics associated with Tourette's syndrome, (3) Inadequate response or inability to tolerate haloperidol or risperidone. Chorea- Huntington's Disease (CHD): (1) Diagnosis of chorea associated with Huntington's disease |
| Age Restrictions | |
| Prescriber Restrictions | (TS, CHD): Prescribed by or in consultation with a neurologist or a psychiatrist. (TD)(Initial, Continuation): Prescribed by or in consultation with a neurologist or a psychiatrist. |
| Coverage Duration | (TD)(Initial): 3 month. (TD)(Continuation): Indefinite. (TS, CHD): Indefinite. |
| Other Criteria | (TD)(Continuation): Positive clinical response to therapy. |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

XERMELO

Products Affected

- XERMELO

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Carcinoid Syndrome Diarrhea (CSD)(Initial): (1) Diagnosis of carcinoid syndrome diarrhea, (2) Diarrhea is inadequately controlled by a stable dose of somatostatin analog (SSA) therapy (e.g., octreotide [Sandostatin, Sandostatin LAR], lanreotide [Somatuline Depot]) for at least 3 months, (3) Used in combination with SSA therapy |
| Age Restrictions | (CSD)(Initial, Reauth): Member is 18 years of age or older |
| Prescriber Restrictions | (CSD)(Initial, Reauth): Prescribed by or in consultation with an Oncologist, Endocrinologist, or Gastroenterologist |
| Coverage Duration | (CSD)(Initial): 12 months (CSD)(Reauth): Indefinite |
| Other Criteria | (CSD)(Reauth): (1) Positive clinical response to Xermelo therapy, (2) Xermelo will continue to be used in combination with SSA therapy |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

XGEVA

Products Affected

- XGEVA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Part D is medically necessary when: Prevention of Skeletal Related Events in Multiple Myeloma or Bone Metastases from Solid Tumors (MM-BMST) : (1) For prevention of skeletal related events in multiple myeloma or bone metastases from solid tumors. Giant Cell Tumor of the Bone (GCTB): (1) Diagnosis of GCTB. (2) Member is (a) adult or (b) adolescent that is skeletally mature. (3) Tumor is unresectable or surgical resection is likely to result in severe morbidity. Hypercalcemia of Malignancy Refractory to Bisphosphonates (HCMRB): (1) Diagnosis of HCMRB. |
| Age Restrictions | |
| Prescriber Restrictions | (MM-BMT, GCTB, HCMRB): Prescribed by or in consultation with an oncologist or hematologist |
| Coverage Duration | (MM-BMT, GCTB, HCMRB): Indefinite |
| Other Criteria | Subject to Part B vs Part D review. (All Indications): Approve if for continuation of therapy. |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

XIFAXAN

Products Affected

- XIFAXAN ORAL TABLET 550 MG

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Prophylaxis for Hepatic Encephalopathy (HE): (1) Diagnosis of hepatic disease with risk for hepatic encephalopathy (ie previous episode of hepatic encephalopathy, advanced liver disease, hepatocellular carcinoma), (2) Inadequate response or inability to tolerate lactulose. Irritable Bowel Syndrome (IBS)(Initial): (1) Diagnosis of irritable bowels syndrome- diarrhea, (2) Inadequate response or inability to tolerate BOTH of the following: (A) ONE of the following: (i) ONE Tricyclic antidepressant or (ii)selective serotonin reuptake inhibitor and (B) dicyclomine (3): BOTH of the following: (1) Member does not exceed 3 total courses (42 days in total) of therapy, (2) Member experiences irritable bowel syndrome with diarrhea (IBS-D) symptom recurrence. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | (HE): Indefinite. (IBS)(Initial, Reauth): 2 weeks |
| Other Criteria | (IBS)(REAUTH): BOTH of the following: (1) Member does not exceed 3 total courses (42 days in total) of therapy, (2) Member experiences irritable bowel syndrome with diarrhea (IBS-D) symptom recurrence. |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

XOLAIR

Products Affected

- XOLAIR

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Subject to Part B vs Part D review. Part D is medically necessary for: Moderate to Severe Persistent Allergic Asthma (PAA): (1) DIAGNOSIS OF MODERATE TO SEVERE PERSISTENT ALLERGIC ASTHMA, (2) The individual has a positive skin test or in vitro reactivity to a perennial aeroallergen, (3) The individual has a baseline serum IgE level of between 30 IU/mL and 1300 IU/mL, (4) Inadequate response or inability to tolerate a combination of high-dose inhaled corticosteroids (ICS) with a long-acting beta-agonist (LABA). Chronic Urticaria (CU): (1) DIAGNOSIS OF CHRONIC URTICARIA, (2) an inadequate response, contraindication or inability to tolerate ONE second-generation H1 antihistamine at the maximally tolerated dose in addition to ANY of the following: (a) leukotriene receptor antagonist (e.g., montelukast) (b) histamine H2-receptor antagonist (e.g. ranitidine, cimetidine, famotidine), (c) substituting to a different second-generation antihistamine, (d) systemic glucocorticosteroids or (e) cyclosporine, (3) will be used concurrently with an h1 antihistamine, unless there is contraindication or intolerance to H1 antihistamines. Nasal Polyps (NP): (1) Diagnosis of nasal polyps. (2) Member will use concurrently with nasal corticosteroid. (3) Member had inadequate response or inability to tolerate an intranasal corticosteroid. |
| Age Restrictions | (PAA): Member is 6 years of age or older (CU): Member is 12 years of age and older (NP): Member is 18 years of age and older |
| Prescriber Restrictions | (PAA, CU): Prescribed by or in consultation with an Allergist, Dermatologist, Immunologist, or Pulmonologist. (NP): Prescribed by or in consultation with an allergist, immunologist or ENT specialist. |
| Coverage Duration | Indefinite |
| Other Criteria | Subject to Part B vs Part D review. |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

XYREM

Products Affected

- XYREM
- XYWAV

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Cataplexy in Narcolepsy (CN)(Initial): (1) Diagnosis of cataplexy in narcolepsy. Excessive Daytime Sleepiness in Narcolepsy (EDSN)(Initial): (1) Diagnosis of EDSN (Narcolepsy Type 2), (2) Inadequate response or inability to modafinil. |
| Age Restrictions | |
| Prescriber Restrictions | (CN, EDSN)(Initial, Reauth): Prescribed by or in consultation with a neurologist or sleep specialist |
| Coverage Duration | (CN, EDSN)(Initial, Reauth): 12 months |
| Other Criteria | (CN, EDSN)(Reauth): (1) Documentation to support the efficacy associated with the current regimen (including but not limited to reduction in the frequency of cataplexy attacks or an improvement in the Epworth sleepiness scale), (2) Member is re-evaluated every 12 months. |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

ZAVESCA

Products Affected

- *miglustat*
- ZAVESCA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Type 1 Gaucher's Disease (T1GD): (1) Diagnosis of mild to moderate T1GD, (2) enzyme replacement therapy is not a therapeutic option (e.g. because of allergy, hypersensitivity, or poor venous access). |
| Age Restrictions | (T1GD): Member is 18 years of age or older |
| Prescriber Restrictions | |
| Coverage Duration | (T1GD): Remainder of contract year |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

ZORBTIVE

Products Affected

- ZORBTIVE

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Short Bowel Syndrome (SBS): (1) Used in conjunction with optimal management for short bowel syndrome, including specialized nutrition support |
| Age Restrictions | |
| Prescriber Restrictions | (SBS): Prescribed by or in consultation with gastroenterologist |
| Coverage Duration | (SBS): 6 weeks |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

Index

| | | | |
|--|-----|---|-----|
| ABILIFY MYCITE..... | 3 | AYVAKIT..... | 126 |
| <i>abiraterone acetate</i> | 126 | BALVERSA..... | 126 |
| ACTEMRA ACTPEN..... | 5 | BELBUCA BUCCAL FILM 300 MCG, 450 MCG, 600 MCG, 750 MCG, 900 MCG..... | 73 |
| ACTEMRA SUBCUTANEOUS..... | 5 | BENLYSTA SUBCUTANEOUS..... | 17 |
| ACTHAR..... | 6 | BERINERT..... | 8 |
| ACTIQ..... | 18 | <i>bexarotene</i> | 126 |
| ACTIVELLA ORAL TABLET 1-0.5 MG..... | 80 | BIJUVA..... | 80 |
| <i>adapalene external cream</i> | 178 | BIVIGAM INTRAVENOUS SOLUTION 5 GM/50ML..... | 92 |
| <i>adapalene external gel</i> | 178 | <i>bosentan</i> | 129 |
| <i>adapalene external pad</i> | 178 | BOSULIF..... | 126 |
| <i>adapalene external solution</i> | 178 | BRAFTOVI ORAL CAPSULE 75 MG..... | 126 |
| <i>adapalene-benzoyl peroxide external gel</i> | 178 | BRONCHITOL..... | 19 |
| ADCIRCA..... | 141 | BRUKINSA..... | 126 |
| ADEMPAS..... | 10 | BUPAP ORAL TABLET 50-300 MG..... | 78 |
| AFINITOR..... | 126 | <i>butalbital-acetaminophen</i> | 78 |
| AFINITOR DISPERZ..... | 126 | <i>butalbital-apap-caff-cod</i> | 78 |
| AFREZZA INHALATION POWDER 12 UNIT, 4 & 8 & 12 UNIT, 4 UNIT, 8 UNIT, 90 X 4 UNIT & 90X8 UNIT, 90 X 8 UNIT & 90X12 UNIT..... | 11 | <i>butalbital-apap-caffeine oral capsule</i> | 78 |
| AIMOVIG..... | 23 | <i>butalbital-apap-caffeine oral tablet 50-325- 40 mg</i> | 78 |
| AJOVY..... | 23 | <i>butalbital-asa-caff-codeine</i> | 78 |
| AKLIEF..... | 178 | <i>butalbital-aspirin-caffeine oral capsule</i> | 78 |
| ALECENSA..... | 126 | CABOMETYX..... | 126 |
| ALLZITAL..... | 78 | CALQUENCE..... | 126 |
| ALTRENO..... | 178 | CAPRELSA..... | 126 |
| ALUNBRIG..... | 126 | CARBAGLU..... | 20 |
| ALYQ..... | 141 | <i>carbinoxamine maleate oral solution</i> | 78 |
| AMABELZ..... | 80 | <i>carbinoxamine maleate oral tablet 4 mg</i> | 78 |
| AMBIEN CR ORAL TABLET EXTENDED RELEASE 12.5 MG..... | 82 | <i>carisoprodol oral</i> | 83 |
| AMBIEN ORAL TABLET 10 MG..... | 82 | <i>carisoprodol-aspirin-codeine</i> | 83 |
| <i>ambrisentan</i> | 129 | CAYSTON..... | 21 |
| <i>amphetamine sulfate</i> | 54 | CERDELGA..... | 22 |
| AMPYRA..... | 14 | <i>chlordiazepoxide hcl</i> | 78 |
| AMRIX..... | 83 | <i>chlordiazepoxide-clidinium</i> | 78 |
| ANGELIQ..... | 80 | <i>chlorzoxazone oral tablet 375 mg, 500 mg, 750 mg</i> | 78 |
| ARALAST NP INTRAVENOUS SOLUTION RECONSTITUTED 1000 MG..... | 153 | CHOLBAM..... | 24 |
| ARIKAYCE..... | 15 | CIALIS ORAL TABLET 2.5 MG, 5 MG..... | 25 |
| <i>armodafinil</i> | 16 | CIMZIA PREFILLED..... | 26 |
| ASCOMP-CODEINE..... | 78 | CIMZIA SUBCUTANEOUS KIT 2 X 200 MG..... | 26 |
| ATRALIN..... | 178 | CINRYZE..... | 28 |
| AURYXIA..... | 140 | <i>clemastine fumarate oral syrup</i> | 78 |
| AUSTEDO..... | 189 | <i>clemastine fumarate oral tablet 2.68 mg</i> | 78 |
| AVEED..... | 176 | CLIMARA..... | 80 |
| AVITA..... | 178 | CLIMARA PRO..... | 80 |

| | | | |
|---|-----|--|-----|
| <i>clindamycin-tretinoin</i> | 178 | DUPIXENT SUBCUTANEOUS SOLUTION | |
| COMBIPATCH..... | 80 | PREFILLED SYRINGE 200 MG/1.14ML, 300 | |
| COMETRIQ (100 MG DAILY DOSE) ORAL KIT | | MG/2ML..... | 42 |
| 80 & 20 MG..... | 126 | EDLUAR SUBLINGUAL TABLET SUBLINGUAL | |
| COMETRIQ (140 MG DAILY DOSE) ORAL KIT 3 | | 10 MG..... | 82 |
| X 20 MG & 80 MG..... | 126 | EGRIFTA SV..... | 43 |
| COMETRIQ (60 MG DAILY DOSE)..... | 126 | ELESTRIN..... | 80 |
| COPIKTRA..... | 126 | EMFLAZA..... | 44 |
| CORLANOR..... | 30 | EMGALITY..... | 45 |
| COSENTYX (300 MG DOSE)..... | 31 | EMGALITY (300 MG DOSE)..... | 45 |
| COSENTYX SENSOREADY (300 MG)..... | 31 | EMSAM..... | 47 |
| COSENTYX SUBCUTANEOUS SOLUTION | | ENBREL MINI..... | 48 |
| PREFILLED SYRINGE 75 MG/0.5ML..... | 31 | ENBREL SUBCUTANEOUS SOLUTION 25 | |
| COTELLIC..... | 126 | MG/0.5ML..... | 48 |
| CRESEMBA ORAL..... | 32 | ENBREL SUBCUTANEOUS SOLUTION | |
| CRINONE..... | 140 | PREFILLED SYRINGE..... | 48 |
| <i>cyclobenzaprine hcl er</i> | 83 | ENBREL SUBCUTANEOUS SOLUTION | |
| <i>cyclobenzaprine hcl oral</i> | 83 | RECONSTITUTED..... | 48 |
| CYSTADROPS..... | 33 | ENBREL SURECLICK SUBCUTANEOUS | |
| CYSTARAN..... | 34 | SOLUTION AUTO-INJECTOR..... | 48 |
| <i>dalfampridine er</i> | 14 | ENDARI..... | 50 |
| DAURISMO..... | 126 | ENSPRYNG..... | 51 |
| DAYVIGO..... | 35 | EPCLUSA ORAL TABLET..... | 144 |
| <i>deferasirox granules</i> | 36 | EPIDIOLEX..... | 52 |
| <i>deferasirox oral tablet</i> | 36 | EPIDUO..... | 178 |
| <i>deferasirox oral tablet soluble</i> | 36 | EPIDUO FORTE..... | 178 |
| <i>deferiprone</i> | 61 | ERIVEDGE..... | 126 |
| DEMEROL INJECTION SOLUTION 25 MG/ML, | | ERLEADA..... | 126 |
| 50 MG/ML..... | 78 | <i>erlotinib hcl</i> | 126 |
| DEPO-TESTOSTERONE INTRAMUSCULAR | | ESBRIET..... | 148 |
| SOLUTION..... | 176 | ESGIC ORAL TABLET..... | 78 |
| DIACOMIT..... | 37 | ESTRACE ORAL..... | 80 |
| <i>diclofenac epolamine external</i> | 64 | <i>estradiol oral</i> | 80 |
| <i>diclofenac sodium external gel 3 %</i> | 38 | <i>estradiol transdermal</i> | 80 |
| DIFFERIN EXTERNAL CREAM..... | 178 | <i>estradiol-norethindrone acet</i> | 80 |
| DIFFERIN EXTERNAL GEL 0.3 %..... | 178 | ESTROGEL..... | 80 |
| DIFFERIN EXTERNAL LOTION..... | 178 | <i>eszopiclone oral tablet 3 mg</i> | 82 |
| DILAUDID ORAL TABLET 4 MG, 8 MG..... | 73 | EUCRISA..... | 53 |
| <i>dipyridamole oral</i> | 78 | EVAMIST..... | 80 |
| DIVIGEL TRANSDERMAL GEL 1 MG/GM..... | 80 | EVEKEO..... | 54 |
| DOJOLVI..... | 40 | EVEKEO ODT..... | 54 |
| DOPTELET ORAL TABLET 20 MG..... | 41 | EVENITY..... | 55 |
| DOTTI..... | 80 | <i>everolimus oral tablet 2.5 mg, 5 mg, 7.5 mg</i> | 126 |
| DUEXIS..... | 29 | EVRYSDI..... | 56 |
| DUPIXENT SUBCUTANEOUS SOLUTION PEN- | | EXJADE..... | 36 |
| INJECTOR..... | 42 | EYSUVIS..... | 58 |
| | | FARYDAK..... | 126 |

| | | | |
|--|--------|--|-------|
| FASENRA | 59 | HAEGARDA | 70 |
| FASENRA PEN | 59 | HARVONI ORAL PACKET | 144 |
| FEMHRT | 80 | HARVONI ORAL TABLET 90-400 MG | 144 |
| <i>fentanyl citrate buccal</i> | 18, 60 | HETLIOZ | 71 |
| <i>fentanyl transdermal patch 72 hour 100</i> <i>mcg/hr, 25 mcg/hr, 37.5 mcg/hr, 50 mcg/hr,</i> <i>62.5 mcg/hr, 75 mcg/hr, 87.5 mcg/hr</i> | 73 | HETLIOZ LQ | 72 |
| FENTORA BUCCAL TABLET 100 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG | 18 | HORIZANT ORAL TABLET EXTENDED RELEASE | 77 |
| FERRIPROX | 61 | HUMATROPE INJECTION SOLUTION RECONSTITUTED 12 MG, 24 MG, 6 MG | 68 |
| FEXMID | 83 | HUMIRA PEDIATRIC CROHNS START SUBCUTANEOUS PREFILLED SYRINGE KIT 80 MG/0.8ML, 80 MG/0.8ML & 40MG/0.4ML | 84 |
| FINTEPLA | 62 | HUMIRA PEN SUBCUTANEOUS PEN- INJECTOR KIT | 84 |
| FIORICET ORAL CAPSULE | 78 | HUMIRA PEN-CD/UC/HS STARTER | 84 |
| FIORICET/CODEINE ORAL CAPSULE 50-300- 40-30 MG | 78 | HUMIRA PEN-PEDIATRIC UC START | 84 |
| FIRAZYR | 8 | HUMIRA PEN-PS/UV/ADOL HS START SUBCUTANEOUS PEN-INJECTOR KIT 40 MG/0.8ML | 84 |
| FIRDAPSE | 63 | HUMIRA PEN-PSOR/UEIT STARTER | 84 |
| FLEBOGAMMA DIF INTRAVENOUS SOLUTION 5 GM/50ML | 92 | HUMIRA SUBCUTANEOUS PREFILLED SYRINGE KIT 10 MG/0.1ML, 20 MG/0.2ML, 40 MG/0.4ML, 40 MG/0.8ML | 84 |
| FLECTOR EXTERNAL | 64 | HUMULIN R U-500 (CONCENTRATED) | 86 |
| <i>flurazepam hcl</i> | 78 | HUMULIN R U-500 KWIKPEN SUBCUTANEOUS SOLUTION PEN-INJECTOR | 86 |
| FORTEO SUBCUTANEOUS SOLUTION PEN- INJECTOR 620 MCG/2.48ML | 174 | <i>hydrocodone bitartrate er oral capsule</i> <i>extended release 12 hour</i> | 4 |
| FOTIVDA | 126 | <i>hydrocodone bitartrate er oral tablet er 24 hour</i> <i>abuse-deterrent</i> | 4, 73 |
| FYAVOLV | 80 | <i>hydromorphone hcl er oral tablet extended</i> <i>release 24 hour</i> | 73 |
| GALAFOLD | 65 | <i>hydromorphone hcl oral tablet 4 mg, 8 mg</i> | 73 |
| GAMMAGARD INJECTION SOLUTION 2.5 GM/25ML | 92 | HYSINGLA ER | 4, 73 |
| GAMMAGARD S/D LESS IGA | 92 | IBRANCE | 126 |
| GAMMAKED INJECTION SOLUTION 1 GM/10ML | 92 | <i>ibuprofen-famotidine</i> | 29 |
| GAMMAPLEX INTRAVENOUS SOLUTION 10 GM/100ML, 10 GM/200ML, 20 GM/200ML, 5 GM/50ML | 92 | <i>icatibant acetate</i> | 8 |
| GAMUNEX-C INJECTION SOLUTION 1 GM/10ML | 92 | ICLUSIG | 126 |
| GATTEX | 66 | IDHIFA | 126 |
| GAVRETO | 126 | ILUMYA | 87 |
| GENOTROPIN | 68 | <i>imatinib mesylate</i> | 126 |
| GENOTROPIN MINIQUICK | 68 | IMBRUVICA | 126 |
| GILOTRIF | 126 | IMVEXXY MAINTENANCE PACK | 140 |
| GLASSIA | 153 | IMVEXXY STARTER PACK | 140 |
| GLEEVEC | 126 | INBRIJA | 139 |
| GLUMETZA | 57 | INCRELEX | 88 |
| GOCOVRI | 13 | INDOCIN ORAL | 78 |
| GRALISE ORAL TABLET | 67 | | |
| GRASTEK | 12 | | |

| | | | |
|---|-----|---|-----|
| INDOCIN RECTAL | 78 | LIBRAX..... | 78 |
| INGREZZA..... | 89 | LICART EXTERNAL..... | 39 |
| INLYTA..... | 126 | <i>lidocaine external patch 5 %</i> | 103 |
| INQOVI..... | 126 | LIDODERM..... | 103 |
| INREBIC..... | 126 | LONSURF..... | 126 |
| INTRAROSA..... | 140 | LORBRENA..... | 126 |
| IRESSA..... | 126 | LORZONE..... | 78 |
| ISTURISA..... | 94 | LUMAKRAS..... | 126 |
| JADENU..... | 36 | LUNESTA ORAL TABLET 3 MG..... | 82 |
| JADENU SPRINKLE..... | 36 | LUPKYNIS..... | 104 |
| JAKAFI..... | 126 | LYLLANA..... | 80 |
| JATENZO..... | 176 | LYNPARZA ORAL TABLET..... | 126 |
| JINTELI..... | 80 | LYRICA CR..... | 105 |
| JUXTAPID ORAL CAPSULE 10 MG, 20 MG, 30 MG, 5 MG..... | 75 | MAVYRET ORAL TABLET..... | 144 |
| JYNARQUE..... | 95 | MEKINIST..... | 126 |
| KALYDECO..... | 96 | MEKTOVI..... | 126 |
| <i>ketorolac tromethamine nasal</i> | 81 | MENOSTAR..... | 80 |
| <i>ketorolac tromethamine oral</i> | 81 | <i>meperidine hcl injection solution 100 mg/ml, 25 mg/ml, 50 mg/ml</i> | 78 |
| KEVEYIS..... | 97 | <i>meperidine hcl oral solution</i> | 78 |
| KEVZARA..... | 98 | <i>meperidine hcl oral tablet 50 mg</i> | 78 |
| KINERET SUBCUTANEOUS SOLUTION PREFILLED SYRINGE..... | 99 | <i>meprobamate</i> | 78 |
| KISQALI (200 MG DOSE)..... | 126 | <i>metaxalone</i> | 78 |
| KISQALI (400 MG DOSE)..... | 126 | <i>metformin hcl er (mod)</i> | 57 |
| KISQALI (600 MG DOSE)..... | 126 | <i>methadone hcl oral solution</i> | 73 |
| KISQALI FEMARA (400 MG DOSE)..... | 126 | <i>methadone hcl oral tablet</i> | 73 |
| KISQALI FEMARA (600 MG DOSE)..... | 126 | <i>methocarbamol oral</i> | 78 |
| KISQALI FEMARA(200 MG DOSE)..... | 126 | <i>miglustat</i> | 195 |
| KLISYRI..... | 100 | MIMVEY..... | 80 |
| KORLYM..... | 101 | MINIVELLE..... | 80 |
| KOSELUGO..... | 126 | <i>modafinil</i> | 16 |
| KYNMOBI..... | 102 | <i>morphine sulfate er beads oral capsule extended release 24 hour 120 mg</i> | 73 |
| <i>lapatinib ditosylate</i> | 126 | <i>morphine sulfate er oral capsule extended release 24 hour 100 mg, 60 mg, 80 mg</i> | 73 |
| LAZANDA NASAL SOLUTION 100 MCG/ACT, 400 MCG/ACT..... | 18 | <i>morphine sulfate er oral tablet extended release 100 mg, 200 mg, 60 mg</i> | 73 |
| <i>ledipasvir-sofosbuvir</i> | 144 | MS CONTIN ORAL TABLET EXTENDED RELEASE 100 MG, 200 MG, 60 MG..... | 73 |
| LENVIMA (10 MG DAILY DOSE)..... | 126 | MULPLETA..... | 106 |
| LENVIMA (12 MG DAILY DOSE)..... | 126 | MYALEPT..... | 107 |
| LENVIMA (14 MG DAILY DOSE)..... | 126 | MYCAPSSA..... | 108 |
| LENVIMA (18 MG DAILY DOSE)..... | 126 | MYFEMBREE..... | 109 |
| LENVIMA (20 MG DAILY DOSE)..... | 126 | MYTESI..... | 110 |
| LENVIMA (24 MG DAILY DOSE)..... | 126 | <i>naproxen-esomeprazole</i> | 29 |
| LENVIMA (4 MG DAILY DOSE)..... | 126 | NATPARA..... | 111 |
| LENVIMA (8 MG DAILY DOSE)..... | 126 | NAYZILAM..... | 9 |
| LETAIRIS..... | 129 | | |
| <i>levorphanol tartrate oral tablet 3 mg</i> | 73 | | |

| | | | |
|--|----------|--|-------|
| NERLYNX | 126 | ORLISSA | 132 |
| NEXAVAR | 126 | ORKAMBI | 133 |
| NEXLETOL | 112 | ORLADEYO | 134 |
| NEXLIZET | 112 | <i>orphenadrine citrate er</i> | 78 |
| NINLARO | 126 | OSMOLEX ER ORAL TABLET ER 24 HOUR | |
| NORDITROPIN FLEXPRO SUBCUTANEOUS | | THERAPY PACK | 13 |
| SOLUTION PEN-INJECTOR | 68 | OSMOLEX ER ORAL TABLET EXTENDED | |
| <i>norethindrone-eth estradiol</i> | 80 | RELEASE 24 HOUR 129 MG, 193 MG | 13 |
| <i>norgesic forte</i> | 78 | OSPHENA | 140 |
| NOURIANZ | 139 | OTEZLA | 135 |
| NOXAFIL ORAL | 118 | OTREXUP SUBCUTANEOUS SOLUTION | |
| NUBEQA | 126 | AUTO-INJECTOR 10 MG/0.4ML, 12.5 | |
| NUCALA | 119 | MG/0.4ML, 15 MG/0.4ML, 17.5 MG/0.4ML, 20 | |
| NUCYNTA ER | 4, 73 | MG/0.4ML, 22.5 MG/0.4ML, 25 MG/0.4ML | 91 |
| NUCYNTA ORAL TABLET 100 MG, 75 MG | 73 | OXBRYTA | 136 |
| NUDEXTA | 121 | OXERVATE | 137 |
| NUPLAZID ORAL CAPSULE | 122 | <i>oxycodone hcl er oral tablet er 12 hour abuse-</i> | |
| NUPLAZID ORAL TABLET 10 MG | 122 | <i>deterrent 30 mg, 60 mg, 80 mg</i> | 73 |
| NUTROPIN AQ NUSPIN 10 SUBCUTANEOUS | | <i>oxycodone hcl er oral tablet er 12 hour abuse-</i> | |
| SOLUTION PEN-INJECTOR | 68 | <i>deterrent 40 mg</i> | 73 |
| NUTROPIN AQ NUSPIN 20 SUBCUTANEOUS | | <i>oxycodone hcl oral tablet 30 mg</i> | 73 |
| SOLUTION PEN-INJECTOR | 68 | OXYCONTIN ORAL TABLET ER 12 HOUR | |
| NUTROPIN AQ NUSPIN 5 SUBCUTANEOUS | | ABUSE-DETERRENT | 4, 73 |
| SOLUTION PEN-INJECTOR | 68 | <i>oxymorphone hcl er oral tablet extended release</i> | |
| NUVIGIL | 16 | <i>12 hour 20 mg, 30 mg</i> | 73 |
| NUZYRA | 115, 125 | <i>oxymorphone hcl er oral tablet extended release</i> | |
| OALIVA | 123 | <i>12 hour 40 mg</i> | 73 |
| OCTAGAM INTRAVENOUS SOLUTION 1 | | <i>oxymorphone hcl oral tablet 10 mg</i> | 73 |
| GM/20ML, 2 GM/20ML | 92 | PALYNZIQ | 138 |
| ODACTRA | 12 | PANZYGA | 92 |
| ODOMZO | 126 | PEMAZYRE | 126 |
| OFEV | 148 | <i>pentazocine-naloxone hcl</i> | 78 |
| OLUMIANT | 124 | PIQRAY (200 MG DAILY DOSE) | 126 |
| OMNITROPE SUBCUTANEOUS SOLUTION | | PIQRAY (250 MG DAILY DOSE) | 126 |
| CARTRIDGE | 68 | PIQRAY (300 MG DAILY DOSE) | 126 |
| OMNITROPE SUBCUTANEOUS SOLUTION | | POMALYST | 126 |
| RECONSTITUTED | 68 | <i>posaconazole</i> | 118 |
| ONGENTYS | 139 | PRALUENT SUBCUTANEOUS SOLUTION | |
| ONUREG | 126 | AUTO-INJECTOR | 142 |
| OPSUMIT | 129 | PREFEST | 80 |
| ORALAIR | 12 | <i>pregabalin er</i> | 105 |
| ORENCIA CLICKJECT | 130 | PREMARIN ORAL | 80 |
| ORENCIA SUBCUTANEOUS SOLUTION | | <i>pretomanid</i> | 145 |
| PREFILLED SYRINGE | 130 | PRIVIGEN INTRAVENOUS SOLUTION 20 | |
| ORENITRAM | 129 | GM/200ML | 92 |
| ORGOVYX | 126 | PROCYSBI ORAL PACKET | 146 |
| ORIAHNN | 131 | | |

| | | | |
|---|-----|--|----------|
| PROLASTIN-C INTRAVENOUS SOLUTION RECONSTITUTED | 153 | <i>sildenafil citrate oral suspension reconstituted.</i> | 159 |
| PROLIA SUBCUTANEOUS SOLUTION | | <i>sildenafil citrate oral tablet 20 mg</i> | 159 |
| PREFILLED SYRINGE | 147 | SILIQ | 160 |
| <i>promethazine hcl oral syrup</i> | 78 | SIMPONI SUBCUTANEOUS SOLUTION AUTO-INJECTOR | 161 |
| <i>promethazine hcl oral tablet</i> | 78 | SIMPONI SUBCUTANEOUS SOLUTION PREFILLED SYRINGE | 161 |
| <i>promethazine hcl rectal suppository 12.5 mg, 25 mg</i> | 78 | SIRTURO | 162 |
| <i>promethazine-phenylephrine</i> | 78 | SIVEXTRO | 115, 125 |
| PROMETHEGAN RECTAL SUPPOSITORY 25 MG, 50 MG | 78 | SKELAXIN | 78 |
| PROVIGIL | 16 | SKYRIZI | 163 |
| QBREXZA | 149 | SKYRIZI (150 MG DOSE) | 163 |
| QINLOCK | 126 | SKYRIZI PEN | 163 |
| QUALAQUIN | 150 | <i>sofosbuvir-velpatasvir</i> | 144 |
| <i>quinine sulfate oral</i> | 150 | SOMA | 83 |
| RASUVO SUBCUTANEOUS SOLUTION AUTO-INJECTOR 10 MG/0.2ML, 12.5 MG/0.25ML, 15 MG/0.3ML, 17.5 MG/0.35ML, 20 MG/0.4ML, 22.5 MG/0.45ML, 25 MG/0.5ML, 30 MG/0.6ML, 7.5 MG/0.15ML | 91 | SOVALDI ORAL PACKET | 117 |
| RAVICTI | 151 | SOVALDI ORAL TABLET 400 MG | 117 |
| REDITREX | 91 | SPRIX | 81 |
| REPATHA | 152 | SPRYCEL | 126 |
| REPATHA PUSHTRONEX SYSTEM | 152 | STELARA SUBCUTANEOUS SOLUTION 45 MG/0.5ML | 164 |
| REPATHA SURECLICK | 152 | STELARA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE | 164 |
| RETEVMO | 126 | STIVARGA | 126 |
| RETIN-A | 178 | SUBSYS | 18 |
| RETIN-A MICRO | 178 | <i>sunitinib malate</i> | 126 |
| RETIN-A MICRO PUMP EXTERNAL GEL 0.06 %, 0.08 % | 178 | SUNOSI | 165 |
| REVATIO ORAL | 141 | SUTENT | 126 |
| REVLIMID | 126 | SYMDEKO | 166 |
| RINVOQ | 154 | SYMLINPEN 120 SUBCUTANEOUS SOLUTION PEN-INJECTOR | 167 |
| ROXICODONE ORAL TABLET 30 MG | 73 | SYMLINPEN 60 SUBCUTANEOUS SOLUTION PEN-INJECTOR | 167 |
| ROZLYTREK | 126 | SYNRIBO | 116 |
| RUBRACA | 126 | TABRECTA | 126 |
| RUCONEST | 8 | <i>tadalafil (pah)</i> | 141 |
| RUZURGI | 155 | <i>tadalafil oral tablet 2.5 mg, 5 mg</i> | 25 |
| RYDAPT | 126 | TAFINLAR | 126 |
| RYVENT | 78 | TAGRISSE | 126 |
| SAIZEN | 68 | TAKHZYRO | 169 |
| SAIZENPREP | 68 | TALTZ | 170 |
| SAMSCA | 156 | TALZENNA | 126 |
| SEROSTIM SUBCUTANEOUS SOLUTION RECONSTITUTED 4 MG, 5 MG, 6 MG | 157 | TARCEVA | 126 |
| SIGNIFOR | 158 | TARGRETIN | 126, 177 |
| | | TASIGNA | 126 |
| | | TAVALISSE | 171 |
| | | TAZVERIK | 126 |

| | | | |
|--|-----|--|-------|
| TEGSEDI..... | 172 | VIMOVO..... | 29 |
| TENCON ORAL TABLET 50-325 MG..... | 78 | VITRAKVI..... | 126 |
| TEPMETKO..... | 126 | VIVELLE-DOT..... | 80 |
| <i>teriparatide (recombinant)</i> | 174 | VIZIMPRO..... | 126 |
| <i>testosterone cypionate intramuscular solution</i> | | VOSEVI..... | 117 |
| <i>100 mg/ml, 200 mg/ml</i> | 176 | VOTRIENT..... | 126 |
| <i>testosterone enanthate intramuscular solution</i> | 176 | VTOL LQ..... | 78 |
| <i>testosterone transdermal gel 10 mg/act (2%),</i> | | VYNDAMAX..... | 168 |
| <i>12.5 mg/act (1%), 20.25 mg/1.25gm (1.62%),</i> | | VYNDAQEL..... | 168 |
| <i>20.25 mg/act (1.62%), 25 mg/2.5gm (1%),</i> | | VYVANSE..... | 186 |
| <i>40.5 mg/2.5gm (1.62%), 50 mg/5gm (1%)</i> | 176 | WAKIX..... | 187 |
| <i>testosterone transdermal solution</i> | 176 | WELIREG..... | 126 |
| <i>tetrabenazine</i> | 189 | XALKORI..... | 126 |
| THALOMID..... | 126 | XELJANZ..... | 188 |
| TIBSOVO..... | 126 | XELJANZ XR..... | 188 |
| TOBI PODHALER..... | 90 | XENAZINE..... | 189 |
| <i>tolvaptan</i> | 156 | XENLETA ORAL..... | 125 |
| TRACLEER..... | 129 | XERMELLO..... | 190 |
| TRELSTAR MIXJECT..... | 116 | XGEVA..... | 191 |
| TREMFYA..... | 179 | XIFAXAN ORAL TABLET 550 MG..... | 192 |
| <i>tretinoin external</i> | 178 | XOLAIR..... | 193 |
| <i>tretinoin microsphere</i> | 178 | XOSPATA..... | 126 |
| TRIKAFTA..... | 180 | XPOVIO (100 MG ONCE WEEKLY) ORAL | |
| TRUSELTIQ (100MG DAILY DOSE)..... | 126 | TABLET THERAPY PACK 50 MG..... | 126 |
| TRUSELTIQ (125MG DAILY DOSE)..... | 126 | XPOVIO (40 MG ONCE WEEKLY) ORAL | |
| TRUSELTIQ (50MG DAILY DOSE)..... | 126 | TABLET THERAPY PACK 40 MG..... | 126 |
| TRUSELTIQ (75MG DAILY DOSE)..... | 126 | XPOVIO (40 MG TWICE WEEKLY) ORAL | |
| TUKYSA..... | 126 | TABLET THERAPY PACK 40 MG..... | 126 |
| TURALIO..... | 126 | XPOVIO (60 MG ONCE WEEKLY) ORAL | |
| TYKERB..... | 126 | TABLET THERAPY PACK 60 MG..... | 126 |
| TYMLOS..... | 181 | XPOVIO (60 MG TWICE WEEKLY)..... | 126 |
| UKONIQ..... | 126 | XPOVIO (80 MG ONCE WEEKLY) ORAL | |
| UPTRAVI ORAL..... | 182 | TABLET THERAPY PACK 40 MG..... | 126 |
| VABOMERE..... | 115 | XPOVIO (80 MG TWICE WEEKLY)..... | 126 |
| VALCHLOR..... | 183 | XTAMPZA ER..... | 4, 73 |
| VALTOCO 10 MG DOSE..... | 9 | XTANDI..... | 126 |
| VALTOCO 15 MG DOSE..... | 9 | XYOSTED..... | 176 |
| VALTOCO 20 MG DOSE..... | 9 | XYREM..... | 194 |
| VALTOCO 5 MG DOSE..... | 9 | XYWAV..... | 194 |
| VECAMYL..... | 184 | YONSA..... | 126 |
| VELTIN..... | 178 | ZAVESCA..... | 195 |
| VENCLEXTA..... | 126 | ZEBUTAL ORAL CAPSULE 50-325-40 MG..... | 78 |
| VENCLEXTA STARTING PACK..... | 126 | ZEJULA..... | 126 |
| VENTAVIS..... | 114 | ZELBORAF..... | 126 |
| VERQUVO..... | 185 | ZEMAIRA..... | 153 |
| VERZENIO..... | 126 | ZEMDRI..... | 115 |
| VIEKIRA PAK..... | 117 | ZEPATIER..... | 117 |

| | |
|---|-----------|
| ZERBAXA | 115 |
| ZIANA | 178 |
| ZOLINZA | 126 |
| <i>zolpidem tartrate er oral tablet extended</i> | |
| <i>release 12.5 mg</i> | <i>82</i> |
| <i>zolpidem tartrate oral tablet 10 mg</i> | <i>82</i> |
| <i>zolpidem tartrate sublingual tablet sublingual</i> | |
| <i>3.5 mg</i> | <i>82</i> |
| ZOMACTON | 68 |
| ZORBTIVE | 196 |
| ZTLIDO | 140 |
| ZYDELIG | 126 |
| ZYKADIA ORAL TABLET | 126 |
| ZYTIGA | 126 |